<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cells</journal-id><journal-id journal-id-type="iso-abbrev">Cells</journal-id><journal-id journal-id-type="pmc-domain-id">2106</journal-id><journal-id journal-id-type="pmc-domain">cells</journal-id><journal-id journal-id-type="publisher-id">cells</journal-id><journal-title-group><journal-title>Cells</journal-title></journal-title-group><issn pub-type="epub">2073-4409</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9220995</article-id><article-id pub-id-type="pmcid-ver">PMC9220995.1</article-id><article-id pub-id-type="pmcaid">9220995</article-id><article-id pub-id-type="pmcaiid">9220995</article-id><article-id pub-id-type="pmid">35740997</article-id><article-id pub-id-type="doi">10.3390/cells11121868</article-id><article-id pub-id-type="publisher-id">cells-11-01868</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0580-0819</contrib-id><name name-style="western"><surname>Ensinck</surname><given-names initials="MM">Marjolein M.</given-names></name><xref rid="af1-cells-11-01868" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8263-0350</contrib-id><name name-style="western"><surname>Carlon</surname><given-names initials="MS">Marianne S.</given-names></name><xref rid="af1-cells-11-01868" ref-type="aff">1</xref><xref rid="af2-cells-11-01868" ref-type="aff">2</xref><xref rid="c1-cells-11-01868" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Conese</surname><given-names initials="M">Massimo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-cells-11-01868"><label>1</label>Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Flanders, Belgium; <email>marjolein.ensinck@kuleuven.be</email></aff><aff id="af2-cells-11-01868"><label>2</label>Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, 3000 Leuven, Flanders, Belgium</aff><author-notes><corresp id="c1-cells-11-01868"><label>*</label>Correspondence: <email>marianne.carlon@kuleuven.be</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>6</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2022</year></pub-date><volume>11</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">410816</issue-id><elocation-id>1868</elocation-id><history><date date-type="received"><day>11</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>06</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>24</day><month>06</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-18 12:25:30.993"><day>18</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cells-11-01868.pdf"/><abstract><p>Cystic fibrosis (CF) is the most common monogenic disorder, caused by mutations in the CF transmembrane conductance regulator (<italic toggle="yes">CFTR</italic>) gene. Over the last 30 years, tremendous progress has been made in understanding the molecular basis of CF and the development of treatments that target the underlying defects in CF. Currently, a highly effective CFTR modulator treatment (Kalydeco&#8482;/Trikafta&#8482;) is available for 90% of people with CF. In this review, we will give an extensive overview of past and ongoing efforts in the development of therapies targeting the molecular defects in CF. We will discuss strategies targeting the CFTR protein (i.e., CFTR modulators such as correctors and potentiators), its cellular environment (i.e., proteostasis modulation, stabilization at the plasma membrane), the <italic toggle="yes">CFTR</italic> mRNA (i.e., amplifiers, nonsense mediated mRNA decay suppressors, translational readthrough inducing drugs) or the <italic toggle="yes">CFTR</italic> gene (gene therapies). Finally, we will focus on how these efforts can be applied to the 15% of people with CF for whom no causal therapy is available yet. </p></abstract><kwd-group><kwd>cystic fibrosis (CF)</kwd><kwd>cystic fibrosis transmembrane conductance regulator (CFTR)</kwd><kwd>personalized medicine</kwd><kwd>CFTR modulators</kwd><kwd>proteostasis modulation</kwd><kwd>stabilizers</kwd><kwd>amplifiers</kwd><kwd>translational readthrough inducing drugs (TRIDs)</kwd><kwd>NMD inhibition</kwd><kwd>gene therapy</kwd></kwd-group><funding-group><award-group><funding-source>FWO-SB (Flemish Research Foundation)</funding-source><award-id>1S29917N</award-id></award-group><award-group><funding-source>FWO Scholarship</funding-source><award-id>12Z5920N</award-id></award-group><award-group><funding-source>Belgian CF Patient Association and Fund Alphonse Jean Forton</funding-source><award-id>2017-J1810150-207746</award-id><award-id>2020-J1810150-E015</award-id></award-group><funding-statement>M.M.E. is supported by an FWO-SB (Flemish Research Foundation) doctoral fellowship 1S29917N, M.S.C. by a senior post-doctoral FWO Scholarship 12Z5920N and KU Leuven BOFZAP professorship. Cystic fibrosis research is funded by the Belgian CF Patient Association and Fund Alphonse Jean Forton from the King Baudouin Foundation (2017-J1810150-207746 and 2020-J1810150-E015).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-cells-11-01868"><title>1. Introduction into Cystic Fibrosis</title><p>Cystic fibrosis (CF) is Europe&#8217;s most common life-threatening autosomal recessive disorder, which affects approximately 50,000 people in Europe and over 85,000 worldwide [<xref rid="B1-cells-11-01868" ref-type="bibr">1</xref>]. While CF in the past has mainly been a pediatric condition, the predicted mean survival of newborns with CF in 2019 was 48 years [<xref rid="B2-cells-11-01868" ref-type="bibr">2</xref>]. Morbidity and mortality in people with CF (PwCF) are mainly caused by progressive obstructive lung disease, with perpetual cycles of airway infection and inflammation, resulting in bronchiectasis, tissue remodeling and a decline in lung function over time [<xref rid="B3-cells-11-01868" ref-type="bibr">3</xref>,<xref rid="B4-cells-11-01868" ref-type="bibr">4</xref>]. Besides the airways, many other organs are affected in CF, including the exocrine pancreas, intestines and sweat glands (reviewed in [<xref rid="B5-cells-11-01868" ref-type="bibr">5</xref>]). Co-morbidities are becoming increasingly important in CF. They can either be congenital, such as congenital bilateral absence of vas deferens (CBAVD), or have a later onset due to progressive damage to organs, such as CF related diabetes (CFRD) and CF related liver disease (CFLD). CF is now, more than ever, a multi-organ disease, requiring therapeutic approaches that cover a wide range of organs.</p><p>CF symptoms are caused by an imbalance in ion and water homeostasis in the secretory epithelia of these organs due to loss of function of the apical chloride and bicarbonate channel CFTR (cystic fibrosis transmembrane conductance regulator, <italic toggle="yes">see <xref rid="sec2dot1-cells-11-01868" ref-type="sec">Section 2.1</xref>. CFTR&#8212;Structure, Folding and Function</italic>). In the pancreas, the absence of CFTR-dependent fluid secretion leads to the destruction of the exocrine pancreatic glands at birth for 85% of PwCF [<xref rid="B6-cells-11-01868" ref-type="bibr">6</xref>]. In the airways, mucus is not readily removed due to a decrease in periciliary liquid height, a watery layer between cells and mucus that depends on CFTR chloride secretion and resulting osmosis and is essential for good mucociliary clearance. In addition, pH changes from lack of bicarbonate secretion prevent the proper unfolding of mucins, compacting the mucus and making it even harder to expel (reviewed in [<xref rid="B7-cells-11-01868" ref-type="bibr">7</xref>]). Combined with altered innate immune responses, such as loss of antimicrobial peptide function [<xref rid="B8-cells-11-01868" ref-type="bibr">8</xref>] and the overactive but ineffective response of infiltrating neutrophils, this creates an environment for opportunistic micro-organisms to thrive in ([<xref rid="B9-cells-11-01868" ref-type="bibr">9</xref>] and reviewed in [<xref rid="B10-cells-11-01868" ref-type="bibr">10</xref>]). Chances of chronic colonization with <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Burkholderia cepacia</italic>, <italic toggle="yes">Staphylococcus aureus</italic> and other common CF pathogens increase throughout the lifespan of PwCF, and by the age of 20, over 80% of PwCF are colonized with at least one micro-organism [<xref rid="B2-cells-11-01868" ref-type="bibr">2</xref>]. Chronic infection is correlated with a more rapid disease progression and worse prognosis [<xref rid="B11-cells-11-01868" ref-type="bibr">11</xref>], stressing the urgency of early treatments in PwCF, preferably before the onset of chronic infections.</p><p>In this review, we will discuss different strategies for the causal treatment of CF, both market-approved and in development. First, we will briefly discuss the CFTR protein and different mutations to stress the need of multiple strategies to cover all PwCF. Next, we will look into strategies to (1) improve CFTR function, (2) increase the amount of CFTR at the plasma membrane (PM), (3) increase the amount of immature CFTR protein or (4) provide a correct <italic toggle="yes">CFTR</italic> template. Finally, we will briefly discuss how to further personalize treatment for PwCF and bring causal therapies to the entire CF population.</p></sec><sec id="sec2-cells-11-01868"><title>2. One Size Does Not Fit All</title><p>A good understanding of the structure and function of the wildtype CFTR protein is essential for (1) grasping the molecular consequences of mutations that result in CF and (2) developing strategies using these models to correct the identified defects. As we will discuss in the next section, the multitude of mutations in <italic toggle="yes">CFTR</italic> identified and characterized to date will evidence the need of therapeutic strategies tailored to individual (classes of) molecular defects.</p><sec id="sec2dot1-cells-11-01868"><title>2.1. CFTR&#8212;Structure, Folding and Function</title><p>CFTR is a 1480 amino acid glycoprotein and member of the ATP-binding cassette (ABC) transporter family. Uniquely for ABC transporters, it functions as an ion channel rather than a transporter (reviewed in [<xref rid="B12-cells-11-01868" ref-type="bibr">12</xref>]). It is comprised of two halves containing a nucleotide binding domain (NBD) and a membrane spanning domain (MSD)&#8212;a common architecture for ABC transporters. The two halves, however, are linked via a regulatory (R) domain that is not found in other members of this protein family. </p><p>Folding of the CFTR protein is a complex process which mainly takes place co-translationally, however inter-domain interactions are completed post-translationally ( [<xref rid="B13-cells-11-01868" ref-type="bibr">13</xref>,<xref rid="B14-cells-11-01868" ref-type="bibr">14</xref>] and reviewed in [<xref rid="B15-cells-11-01868" ref-type="bibr">15</xref>]). The endoplasmic reticulum (ER) quality control (ERQC) evaluates the folding-status of the nascent CFTR protein at several checkpoints [<xref rid="B16-cells-11-01868" ref-type="bibr">16</xref>]. Proteins with a non-native conformation are readily recognized by this machinery. They are primed via ubiquitination for ER associated degradation (ERAD) by the proteasome. It can, however, be argued that all disease-causing mutations lead to a conformational change to some extent, although not all are recognized as faulty by ERQC, e.g., gating mutations (<italic toggle="yes">see <xref rid="sec2dot2-cells-11-01868" ref-type="sec">Section 2.2</xref>. CFTR Mutations</italic>) [<xref rid="B17-cells-11-01868" ref-type="bibr">17</xref>]. Checkpoints include a Hsp40/70/90 chaperone trap, which recognizes and removes the majority of misfolded CFTR protein [<xref rid="B18-cells-11-01868" ref-type="bibr">18</xref>], and a calnexin/calreticulin cycle involving the core N-glycosylated CFTR [<xref rid="B19-cells-11-01868" ref-type="bibr">19</xref>]. Before the newly produced protein can exit the ER and progress to the Golgi, folding is again assessed via arginine-framed tripeptide motifs (which should be hidden on the inside of the 3D protein structure) and di-acidic exit codes (which should be present on the outside) [<xref rid="B20-cells-11-01868" ref-type="bibr">20</xref>,<xref rid="B21-cells-11-01868" ref-type="bibr">21</xref>]. In the Golgi, the high-mannose glycosylation from the ER is modified to a more complex arrangement of sugars, containing galactose and fucose, among others [<xref rid="B22-cells-11-01868" ref-type="bibr">22</xref>]. At this point, CFTR is considered &#8220;mature&#8221; and delivered from the Golgi to the PM. Once at the PM, it is subject to peripheral quality control and repeated cycles of internalization and recycling [<xref rid="B23-cells-11-01868" ref-type="bibr">23</xref>,<xref rid="B24-cells-11-01868" ref-type="bibr">24</xref>]. For an extensive review on CFTR folding and trafficking, we refer to [<xref rid="B16-cells-11-01868" ref-type="bibr">16</xref>]. </p><p>CFTR&#8217;s ion channel function starts with the unique R domain. This unstructured domain contains several important serine residues which, upon phosphorylation by protein kinase A (PKA), induce a conformational change [<xref rid="B25-cells-11-01868" ref-type="bibr">25</xref>]. This allows dimerization of the two NBDs, a first step towards the opening of the channel. Combined, the two NBDs create two ATP binding sites with the Walker A and B motifs from one domain connecting with the Walker C motif from the other [<xref rid="B26-cells-11-01868" ref-type="bibr">26</xref>]. The ATP-bound NBD dimer subsequently opens the channel (reviewed in [<xref rid="B27-cells-11-01868" ref-type="bibr">27</xref>]). The twelve transmembrane spans (TM) from the MSDs combine to form a pore allowing anions like chloride, bicarbonate but also iodide, to cross the PM. Only ATP binding site 2 has retained its ability to hydrolyze ATP, while site 1 was proposed to modulate the stability of CFTR function [<xref rid="B28-cells-11-01868" ref-type="bibr">28</xref>]. Dissociation of ADP in the NBD dimer after ATP hydrolysis at site 2 closes the channel (reviewed in [<xref rid="B29-cells-11-01868" ref-type="bibr">29</xref>]).</p><p>Over the last couple of years, cryo-electron microscopy (cryo-EM) has provided high-resolution structures of various states of both human and zebrafish CFTR, such as closed-open or (de)phosphorylated conformations, and with ATP or CFTR modulating compounds [<xref rid="B30-cells-11-01868" ref-type="bibr">30</xref>,<xref rid="B31-cells-11-01868" ref-type="bibr">31</xref>,<xref rid="B32-cells-11-01868" ref-type="bibr">32</xref>,<xref rid="B33-cells-11-01868" ref-type="bibr">33</xref>,<xref rid="B34-cells-11-01868" ref-type="bibr">34</xref>]. These structures have provided insights into the molecular mechanisms of CFTR channel function, i.e., its anion conductance pathway [<xref rid="B35-cells-11-01868" ref-type="bibr">35</xref>], as well as identified new features not previously described in ABC transporters, such as the N-terminal lasso motif [<xref rid="B32-cells-11-01868" ref-type="bibr">32</xref>]. This motif is of importance for CFTR channel gating as well as for folding of downstream domains and thereby might (partially) explain the molecular mechanism of several missense mutations located within this motif or in its vicinity [<xref rid="B36-cells-11-01868" ref-type="bibr">36</xref>,<xref rid="B37-cells-11-01868" ref-type="bibr">37</xref>,<xref rid="B38-cells-11-01868" ref-type="bibr">38</xref>]. Cryo-EM was further also used to determine the binding site of CFTR corrector VX-809 (<italic toggle="yes">see <xref rid="sec3dot2dot1-cells-11-01868" ref-type="sec">Section 3.2.1</xref>. CFTR Correctors</italic>) [<xref rid="B34-cells-11-01868" ref-type="bibr">34</xref>]. </p></sec><sec id="sec2dot2-cells-11-01868"><title>2.2. CFTR Mutations</title><p>When the <italic toggle="yes">CFTR</italic> gene and the major disease-causing mutation c.1521-1523delCTT (F508del; ~70% of CF alleles and found in ~85% of PwCF) were first described in 1989 [<xref rid="B39-cells-11-01868" ref-type="bibr">39</xref>,<xref rid="B40-cells-11-01868" ref-type="bibr">40</xref>,<xref rid="B41-cells-11-01868" ref-type="bibr">41</xref>], it was proposed that multiple mutations would make up the remaining 30% of CF alleles. To date, over 2100 <italic toggle="yes">CFTR</italic> mutations have been described (Cystic Fibrosis Mutation Database, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.genet.sickkids.on.ca/">https://www.genet.sickkids.on.ca/</uri> (accessed on 10 May 2022)), of which currently 401 are confirmed to cause CF (Clinical and Functional Translation of CFTR (CFTR2), <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.CFTR2.org/">https://www.CFTR2.org/</uri> (accessed on 10 May 2022)). Most mutations, however, are very rare, with only five mutations reaching an allele frequency above 1% and 20 above 0.3%. Compared to F508del, all other mutations are rare. An overview of the mutations discussed in this review can be found in <xref rid="cells-11-01868-t001" ref-type="table">Table 1</xref>.</p><p>Mutations in <italic toggle="yes">CFTR</italic> result in the loss or reduction of CFTR function and are commonly grouped by the mechanism by which this loss is caused, from Class I (most severe) to Class VI (mild) (<xref rid="cells-11-01868-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B42-cells-11-01868" ref-type="bibr">42</xref>,<xref rid="B43-cells-11-01868" ref-type="bibr">43</xref>]. PwCF with two mutations from the first three classes usually present with severe CF and are predominantly pancreatic insufficient. Mutations from Classes IV-VI give rise to a certain level of residual function, and are associated with milder forms of CF.</p><p>Class I contains the most severe mutations where no CFTR protein is produced. On the one hand, these cover mutations were the &#8220;blueprint&#8221; for CFTR is gone due to large insertions and deletions or by frameshift inducing indels. These mutations are unrescuable by means of small molecules (Class Ia, <xref rid="cells-11-01868-f001" ref-type="fig">Figure 1</xref>), such as the 21 kb deletion CFTRdele2,3 (c.54-5940_273+10250del 21 kb; 0.3% of CF alleles) [<xref rid="B44-cells-11-01868" ref-type="bibr">44</xref>]. Canonical splicing mutations, for example 621+1G-&gt;T (c.489+1G&gt;T) and 1717-1G-&gt;A (c.1585-1G&gt;A) (both 0.9% of CF alleles), produce no normal <italic toggle="yes">CFTR</italic> mRNA [<xref rid="B45-cells-11-01868" ref-type="bibr">45</xref>], and are unlikely to be rescued by other means than gene therapy. </p><p>This is in contrast to nonsense mutations (Class 1b) such as G542X (c.1624G&gt;T; 2nd most common <italic toggle="yes">CFTR</italic> mutation, 2.5% of CF alleles) and W1282X (c.3846G&gt;A; 5th most common mutation, 1.2% of CF alleles). Here, the <italic toggle="yes">CFTR</italic> mRNA is mostly degraded by the process of nonsense mediated mRNA decay (NMD) [<xref rid="B46-cells-11-01868" ref-type="bibr">46</xref>], and CFTR protein production is abolished. They are, however, considered rescuable by inhibition of NMD (<italic toggle="yes">see <xref rid="sec3dot3dot3-cells-11-01868" ref-type="sec">Section 3.3.3</xref>. NMD Suppression</italic>) and translational readthrough inducing drugs (TRIDs, <italic toggle="yes">see <xref rid="sec3dot3dot4-cells-11-01868" ref-type="sec">Section 3.3.4</xref>. TRIDs</italic>).</p><p>For Class II mutations, which include the most common F508del mutation as well as the 4th most common mutation N1303K (c.3909C&gt;G; 1.6% of CF alleles), translation takes place but the immature protein does not achieve its native conformation. As a result, most misfolded proteins are recognized by the ERQC as faulty and primed for ER associated degradation (ERAD) by the proteasome. This results in a (near) absence of mutant CFTR channels at the PM [<xref rid="B47-cells-11-01868" ref-type="bibr">47</xref>]. Due to the location of the N1303K mutation near the end of the protein (in the NBD2 domain), folding is arrested at a late stage; indeed, while the N1303K folding intermediate resists ERAD, most of it accumulates instead in autolysosomes, where it is degraded via ER-associated autophagy [<xref rid="B48-cells-11-01868" ref-type="bibr">48</xref>].</p><p>In Class III, the mutant protein reaches the PM but its function is severely impaired. Generally speaking, the ATP-dependent gating of the channel is defective and, as a result, the open probability (P<sub>O</sub>) is strongly reduced, as is the case for G551D (c.1652G&gt;A; 3rd most common mutation, 2.1% of CF alleles) [<xref rid="B49-cells-11-01868" ref-type="bibr">49</xref>].</p><p>Class IV mutations are situated around the channel pore, lowering its conductance of anions and thereby reducing the net transport of anions over the PM. R334W (c.1000C&gt;T; 0.3% of CF alleles) belongs to this class. </p><p>A reduced amount of correctly spliced <italic toggle="yes">CFTR</italic> mRNA is a hallmark of Class V mutations. These mutations cause cryptic splice sites, resulting in alternative splicing in a subset of transcripts, generating both aberrant and correct mRNA copies. One such example is 3849+10kbC&gt;T (c.3717+12191C&gt;T; 9th most common mutation, 0.8% of CF alleles). The remaining correctly spliced mRNA copies will give rise to wild-type (WT) CFTR proteins, but their overall quantity is significantly reduced [<xref rid="B50-cells-11-01868" ref-type="bibr">50</xref>]. </p><p>A reduction in the number of CFTR channels is also found in Class VI [<xref rid="B51-cells-11-01868" ref-type="bibr">51</xref>], albeit by a different mechanism. Here, the protein stability is reduced compared to WT, enhancing its turnover and leaving fewer channels at the PM. Several C-terminal truncations, such as Q1412X (c.4234C&gt;T), destabilize CFTR without interfering with its biogenesis [<xref rid="B52-cells-11-01868" ref-type="bibr">52</xref>]. Temperature rescued F508del, where cells are cultured at 26 &#176;C to promote ERQC escape, is another example of this class [<xref rid="B53-cells-11-01868" ref-type="bibr">53</xref>].</p><p>Insights into the different molecular defect classes provide a starting point for the development of different therapeutic strategies needed to specifically tackle each defect. Not only does the variety and large number of <italic toggle="yes">CFTR</italic> mutations complicate causal treatment of CF, a single mutation can have multiple molecular defects&#8212;all of which need to be overcome to reverse the phenotype [<xref rid="B54-cells-11-01868" ref-type="bibr">54</xref>]. This phenomenon was best studied for F508del, which is usually quickly degraded (Class II) [<xref rid="B55-cells-11-01868" ref-type="bibr">55</xref>]. The small amount that reaches the PM shows defective gating (Class III) as well as reduced stability (Class VI) [<xref rid="B56-cells-11-01868" ref-type="bibr">56</xref>,<xref rid="B57-cells-11-01868" ref-type="bibr">57</xref>]. Multiple defects have since also been described for other mutations, including N1303K and W1282X (the latter, when NMD is suppressed) [<xref rid="B58-cells-11-01868" ref-type="bibr">58</xref>,<xref rid="B59-cells-11-01868" ref-type="bibr">59</xref>].</p></sec></sec><sec id="sec3-cells-11-01868"><title>3. CFTR Causal Therapies</title><p>The need for distinct CFTR-rescuing strategies is underscored by the different <italic toggle="yes">CFTR</italic> mutation classes. In the next paragraph, we will discuss strategies that aim&#8212;alone or in combinations&#8212;to restore CFTR channel activity (<xref rid="cells-11-01868-f002" ref-type="fig">Figure 2</xref>). They can be divided into three groups, based on whether they work on the protein, mRNA or DNA level. CFTR modulators are small molecules that interact directly with the CFTR protein. They either increase CFTR channel function (CFTR potentiators) or promote the folding and trafficking of CFTR to the PM (CFTR correctors). Other therapies target proteins that interact with CFTR to increase the amount of CFTR at the PM (proteostasis modulators and stabilizers) or its function (CFTR activators). mRNA-focused strategies aim to increase the amount of protein that is produced, either mutant or WT, and this treatment can further be supplemented with CFTR modulators where needed. As neither protein nor mRNA modulation provide long lasting effects, both need to be taken lifelong at regular intervals. Only when a correct genetic <italic toggle="yes">CFTR</italic> sequence is introduced into the host genome (by addition of a WT cDNA copy or correction of the mutated <italic toggle="yes">CFTR</italic> gene), the treatment has the potential to provide a cure for CF. </p><p>We will start our discussion with protein targeting therapies and move towards the ultimate goal, i.e., to restore the CFTR &#8220;blueprint&#8221; in the DNA. Not co-incidentally, the CFTR-targeted drug discovery pipeline is following a similar route (<xref rid="cells-11-01868-f002" ref-type="fig">Figure 2</xref>). Currently, CFTR modulator therapy is the only causal treatment for CF that is market-approved. It started in 2012, with the approval of Kalydeco&#8482; for a small percentage of PwCF with the gating mutation G551D [<xref rid="B60-cells-11-01868" ref-type="bibr">60</xref>,<xref rid="B61-cells-11-01868" ref-type="bibr">61</xref>]. Its label was later extended [<xref rid="B62-cells-11-01868" ref-type="bibr">62</xref>,<xref rid="B63-cells-11-01868" ref-type="bibr">63</xref>], and currently Kalydeco&#8482; is FDA approved for 97 <italic toggle="yes">CFTR</italic> mutations [<xref rid="B64-cells-11-01868" ref-type="bibr">64</xref>,<xref rid="B65-cells-11-01868" ref-type="bibr">65</xref>], covering ~8% of PwCF. In 2015 and 2018, CFTR modulator treatments Orkambi&#8482; and Symdeko&#8482; (Symkevi&#8482; in Europe) were approved as the first causal therapies for PwCF homozygous for the F508del mutation [<xref rid="B66-cells-11-01868" ref-type="bibr">66</xref>,<xref rid="B67-cells-11-01868" ref-type="bibr">67</xref>,<xref rid="B68-cells-11-01868" ref-type="bibr">68</xref>,<xref rid="B69-cells-11-01868" ref-type="bibr">69</xref>]. Highly effective modulator therapy for PwCF carrying at least one F508del mutation only became available in 2019, marketed as Trikafta&#8482; (Kaftrio&#8482; in Europe, approved in 2020) [<xref rid="B70-cells-11-01868" ref-type="bibr">70</xref>,<xref rid="B71-cells-11-01868" ref-type="bibr">71</xref>].</p><p>While current CFTR modulator therapies have the potential to treat the majority of PwCF, about 15% of PwCF have mutations not responsive to (current) CFTR modulators [<xref rid="B1-cells-11-01868" ref-type="bibr">1</xref>]. These mainly include premature termination codon, frameshift and deletion mutations as well as certain canonical splice mutations (all in Class I&#8212;no protein) but also several missense mutations from Class II or III/IV that are refractory to the available CFTR modulators. As we will discuss below, several novel treatments are in development for the last 15% of PwCF currently without causal therapy. </p><sec id="sec3dot1-cells-11-01868"><title>3.1. Improving CFTR Function: Activators, Potentiators and Co-Potentiators</title><sec id="sec3dot1dot1-cells-11-01868"><title>3.1.1. CFTR Activators</title><p>One might argue that restoring CFTR activity is most straightforward when CFTR is already present at the PM (<xref rid="cells-11-01868-f003" ref-type="fig">Figure 3</xref>). This can be done by any process that enhances the availability of intracellular cAMP to phosphorylate and hence activate the CFTR channel, or by promoting its open state. Indeed, it was recognized early-on that enhancing the intracellular cAMP concentration by means of forskolin (adenylate cyclase activator) or IBMX (phosphodiesterase inhibitor) could enhance CFTR Cl<sup>&#8722;</sup> currents [<xref rid="B72-cells-11-01868" ref-type="bibr">72</xref>]. Lubiprostone, approved for the treatment of chronic constipation [<xref rid="B73-cells-11-01868" ref-type="bibr">73</xref>], stimulates fluid secretion via activation of the CFTR channel through prostaglandin receptor EP4 mediated modulation of cAMP levels [<xref rid="B74-cells-11-01868" ref-type="bibr">74</xref>]. Recently, Shaughnessy and colleagues reported enhanced F508del rescue in CF airway epithelia when Trikafta&#8482;/Kaftrio&#8482; was combined with lubiprostone [<xref rid="B75-cells-11-01868" ref-type="bibr">75</xref>]. The dual phosphodiesterase 3 and 4 inhibitor RPL554 (ensifentrine), in clinical development for chronic obstructive pulmonary disease (COPD) and asthma [<xref rid="B76-cells-11-01868" ref-type="bibr">76</xref>], was shown to activate CFTR with rare class III and IV mutations [<xref rid="B77-cells-11-01868" ref-type="bibr">77</xref>,<xref rid="B78-cells-11-01868" ref-type="bibr">78</xref>] and was tested in a small phase II trial with promising results ([<xref rid="B79-cells-11-01868" ref-type="bibr">79</xref>] &amp; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02919995">NCT02919995</ext-link>). Similarly, ATP analogues can activate the CFTR channel by locking it in an open state [<xref rid="B80-cells-11-01868" ref-type="bibr">80</xref>]. Several CFTR activators, including CBIQ (4-Chlorobenzo[F]isoquinoline), increased Cl<sup>&#8722;</sup> secretion in heterologous cell models like Calu3 cells by simultaneous activation of CFTR and basolateral K<sup>+</sup> channels [<xref rid="B81-cells-11-01868" ref-type="bibr">81</xref>]. </p><p>A caveat for the use of CFTR activators is the generally unspecific nature of their mechanisms of action (MoA), which include interaction with general cellular functions such as kinase/phosphatase activity and ATP levels. Nevertheless, they have been highly valuable for unraveling CFTR regulation and gating mechanisms [<xref rid="B82-cells-11-01868" ref-type="bibr">82</xref>,<xref rid="B83-cells-11-01868" ref-type="bibr">83</xref>]. Forskolin and IMBX in particular are commonly used to activate CFTR channels in experimental settings, either to evaluate the function of CFTR mutants or to test therapeutic strategies. </p></sec><sec id="sec3dot1dot2-cells-11-01868"><title>3.1.2. CFTR Potentiators</title><p>In contrast to CFTR activators, CFTR potentiators interact directly with CFTR to increase the P<sub>O</sub> of the channel while leaving the native regulation intact (<xref rid="cells-11-01868-f003" ref-type="fig">Figure 3</xref>). The isoflavone genistein was one of the first CFTR potentiators discovered, already in the mid-nineties [<xref rid="B84-cells-11-01868" ref-type="bibr">84</xref>,<xref rid="B85-cells-11-01868" ref-type="bibr">85</xref>]. Although generally described as a tyrosine kinase inhibitor, it was shown to bind CFTR at two distinct sites, with opposite effects, creating a bell-shaped dose response curve [<xref rid="B86-cells-11-01868" ref-type="bibr">86</xref>,<xref rid="B87-cells-11-01868" ref-type="bibr">87</xref>]. A high affinity stimulatory binding site delays closing of the channel, thereby improving the P<sub>O</sub> of CFTR [<xref rid="B86-cells-11-01868" ref-type="bibr">86</xref>]. A second, low affinity inhibitory binding site was proposed around the CFTR ATP binding sites, which could prevent binding of ATP and thus inhibit channel opening [<xref rid="B87-cells-11-01868" ref-type="bibr">87</xref>]. The exact binding sites of genistein have not yet been determined, although the high resolution of cryo-EM would potentially allow doing so [<xref rid="B29-cells-11-01868" ref-type="bibr">29</xref>]. A clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00016744">NCT00016744</ext-link>) testing genistein in combination with the proteostasis modulator sodium 4-phenylbutyrate (4PBA; <italic toggle="yes">see <xref rid="sec3dot2dot2-cells-11-01868" ref-type="sec">Section 3.2.2</xref>. Proteostasis Modulators</italic>) in people homozygous for the F508del mutation was eventually withdrawn as different classes of CFTR modulators with higher potential efficacy were being developed at the same time. </p><p>Several of these novel CFTR potentiators were identified by high throughput screening (HTS). Phenylglycine (PG-01) and sulfonamide (SF-01) were identified as distinct chemical classes with CFTR potentiator activity by screening of 50,000 molecules [<xref rid="B88-cells-11-01868" ref-type="bibr">88</xref>]. As they were screened for their ability to potentiate F508del, mutant CFTR was first rescued by low temperature (27 &#176;C) in order to allow measuring subsequent improved gating by halide sensitive yellow fluorescent protein quenching, indicative of improved CFTR function. As with genistein, there was synergy with cAMP agonists such as forskolin. While only PG-01 could potentiate CFTR mutants other than F508del, it was rapidly metabolized in vivo and therefore not clinically investigated [<xref rid="B88-cells-11-01868" ref-type="bibr">88</xref>]. Van Goor and colleagues screened 228,000 compounds using a fluorescence membrane potential assay on temperature-rescued F508del-overexpressing cells which, after chemical optimization, led to the discovery of VX-770 (ivacaftor) [<xref rid="B89-cells-11-01868" ref-type="bibr">89</xref>,<xref rid="B90-cells-11-01868" ref-type="bibr">90</xref>]. This compound was selected as a good clinical candidate based on its ability to potentiate multiple CFTR mutants, its high selectivity and promising pre-clinical pharmacokinetic profile. When evaluated in a clinical trial setting in PwCF carrying the gating mutation G551D, ivacaftor treatment resulted in rapid and substantial improvements in lung function (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00909532">NCT00909532</ext-link> and [<xref rid="B61-cells-11-01868" ref-type="bibr">61</xref>]). In 2012, ivacaftor monotherapy became the first approved CFTR modulator, marketed as Kalydeco&#8482; [<xref rid="B60-cells-11-01868" ref-type="bibr">60</xref>]. Around the same time, VX-770&#8217;s mode of action was further unraveled, showing that it potentiates both mutant and WT-CFTR in a phosphorylation dependent but ATP independent manner [<xref rid="B91-cells-11-01868" ref-type="bibr">91</xref>], uncoupling the gating from the ATP hydrolysis cycle [<xref rid="B92-cells-11-01868" ref-type="bibr">92</xref>]. The exact binding site from which VX-770 exerts its effect remained elusive, however, and different strategies were employed to identify this site. NBD2 was dismissed, as VX-770 potentiated CFTR lacking this domain [<xref rid="B93-cells-11-01868" ref-type="bibr">93</xref>]. Byrnes and colleagues suggested the binding site at the intracellular loop 4 (ICL4), as this site was protected from hydrogen-deuterium exchange in the presence of VX-770 [<xref rid="B94-cells-11-01868" ref-type="bibr">94</xref>]. Cryo-EM on the other hand identified a binding site in the PM in a cleft created by TM 4, 5 and 8 [<xref rid="B95-cells-11-01868" ref-type="bibr">95</xref>]. Recently, both the ICL4 and TM binding site were confirmed using labeled VX-770 probes, suggesting there are in fact two binding sites [<xref rid="B96-cells-11-01868" ref-type="bibr">96</xref>]. Whether both sites contribute to CFTR potentiation, or one of these sites might contribute to the destabilization of CFTR in the presence of CFTR correctors [<xref rid="B97-cells-11-01868" ref-type="bibr">97</xref>], remains to be investigated further. </p><p>A more stable variant of VX-770, VX-561 (formerly: CPT-561; also known as deutivacaftor), where 9 hydrogens are substituted by deuterium, is currently being tested in two phase 3 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05033080">NCT05033080</ext-link> &amp; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05076149">NCT05076149</ext-link>). Other potentiators, like H-01 and A-04 [<xref rid="B98-cells-11-01868" ref-type="bibr">98</xref>], P1, P2, P7 (from the Cystic Fibrosis Foundation&#8217;s CFTR Compound Program) and most notably ABBV-974 ([<xref rid="B99-cells-11-01868" ref-type="bibr">99</xref>]; formerly GLPG-1837) clustered together in combinatorial profiling, suggesting a similar mode-of-action as VX-770 [<xref rid="B100-cells-11-01868" ref-type="bibr">100</xref>]. In particular, VX-770 and ABBV-974 were shown to compete for the same binding site [<xref rid="B101-cells-11-01868" ref-type="bibr">101</xref>,<xref rid="B102-cells-11-01868" ref-type="bibr">102</xref>]. The efficacy of ABBV-974 on G551D potentiation was three-fold higher compared to VX-770, albeit with a lower potency [<xref rid="B102-cells-11-01868" ref-type="bibr">102</xref>]. In contrast to VX-770, however, ABBV-974 and other potentiators did not reduce the stability of the CFTR protein at the PM [<xref rid="B98-cells-11-01868" ref-type="bibr">98</xref>,<xref rid="B103-cells-11-01868" ref-type="bibr">103</xref>,<xref rid="B104-cells-11-01868" ref-type="bibr">104</xref>]. ABBV-974 was tested in clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02690519">NCT02690519</ext-link> &amp; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02707562">NCT02707562</ext-link>; [<xref rid="B105-cells-11-01868" ref-type="bibr">105</xref>]), but has since been replaced by the novel potentiator ABBV-3067 (navocaftor) in the latest combination trial (with corrector ABBV-2222/GLPG-2222; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03969888">NCT03969888</ext-link>). PTI-808 (also known as dirocaftor, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03500263">NCT03500263</ext-link>, [<xref rid="B106-cells-11-01868" ref-type="bibr">106</xref>]) and QBW251 (icenticaftor; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02190604">NCT02190604</ext-link>) were two other CFTR potentiators evaluated in clinical trials. While further development for CF is not planned, the latter is currently under investigation for the treatment of COPD, where mucociliary clearance is reduced due to smoke-induced acquired CFTR loss-of-function [<xref rid="B107-cells-11-01868" ref-type="bibr">107</xref>]. </p></sec><sec id="sec3dot1dot3-cells-11-01868"><title>3.1.3. CFTR Co-Potentiators</title><p>VX-770, alone or in combination with CFTR correctors, has provided substantial clinical benefit for PwCF. However, long-term follow-up in PwCF on Kalydeco&#8482; has shown that lung function still declines while on the treatment, though at a slower pace [<xref rid="B108-cells-11-01868" ref-type="bibr">108</xref>]. Although many factors might contribute to the continued worsening of lung function, it has been shown for G551D and other (gating) mutations that VX-770 on its own is not able to fully restore the electrophysiological properties of mutant CFTR, such as P<sub>O</sub>, to WT levels [<xref rid="B92-cells-11-01868" ref-type="bibr">92</xref>,<xref rid="B109-cells-11-01868" ref-type="bibr">109</xref>]. This suggested that combinations of CFTR potentiators might further improve CFTR function. Indeed, combining VX-770 with other potentiators, such as genistein, synergistically improved CFTR functional rescue in gating mutants [<xref rid="B100-cells-11-01868" ref-type="bibr">100</xref>,<xref rid="B110-cells-11-01868" ref-type="bibr">110</xref>]. Moreover, it was recognized that potentiator combinations could be beneficial for mutations with a severe gating defect that are not rescued by current modulators, such as N1303K and W1282X [<xref rid="B111-cells-11-01868" ref-type="bibr">111</xref>,<xref rid="B112-cells-11-01868" ref-type="bibr">112</xref>,<xref rid="B113-cells-11-01868" ref-type="bibr">113</xref>]. </p><p>The flavone apigenin, previously identified as a weak CFTR potentiator [<xref rid="B84-cells-11-01868" ref-type="bibr">84</xref>], was found in a synergy screen with ivacaftor and forskolin to effectively improve function of the W1282X truncation product, but only in the presence of VX-770 [<xref rid="B113-cells-11-01868" ref-type="bibr">113</xref>]. As it requires simultaneous VX-770 administration, apigenin was termed a co-potentiator or type II potentiator (in contrast to type I potentiators like VX-770 or ABBV-974) (<xref rid="cells-11-01868-f003" ref-type="fig">Figure 3</xref>). Its MoA of co-potentiation has not been elucidated to date. Similarly, ASP-11 is a co-potentiator from the same class, equally showing great synergy with VX-770 and forskolin, in this case, for example, tested on processing and gating mutant N1303K [<xref rid="B111-cells-11-01868" ref-type="bibr">111</xref>,<xref rid="B114-cells-11-01868" ref-type="bibr">114</xref>]. Co-potentiators were later shown to benefit other NBD2 mutations besides N1303K, such as I1234del (c.3700A&gt;G; the mutation gives rise to missense mutant I1234V as well as an alternatively spliced mutant with a six amino-acid deletion, I1234del), and the truncation products of W1282X and Q1313X (c.3937C&gt;T)&#8212;all of which are currently without approved CFTR modulator therapy [<xref rid="B112-cells-11-01868" ref-type="bibr">112</xref>]. At maximum concentrations of VX-770, however, no additive or synergistic effect of ASP-11 was seen for F508del, suggesting a mutation or domain (NBD2) dependent mechanism [<xref rid="B111-cells-11-01868" ref-type="bibr">111</xref>]. </p><p>VX-445 (elexacaftor), one of the CFTR modulators in Trikafta&#8482;/Kaftrio&#8482;, was recently shown to exert both potentiator and corrector activity (<italic toggle="yes">see <xref rid="sec3dot2dot1-cells-11-01868" ref-type="sec">Section 3.2.1</xref>. CFTR Correctors</italic>), depending on the mutation studied [<xref rid="B114-cells-11-01868" ref-type="bibr">114</xref>,<xref rid="B115-cells-11-01868" ref-type="bibr">115</xref>,<xref rid="B116-cells-11-01868" ref-type="bibr">116</xref>]. To date, the potentiator MoA of VX-445 has not been elucidated yet, although it showed synergy with both type I (e.g., VX-770) and type II (e.g., apigenin) potentiators [<xref rid="B114-cells-11-01868" ref-type="bibr">114</xref>,<xref rid="B116-cells-11-01868" ref-type="bibr">116</xref>]. This suggests the existence of at least three different potentiator MoA which can be targeted simultaneously for maximized CFTR rescue. </p></sec></sec><sec id="sec3dot2-cells-11-01868"><title>3.2. Improving the Amount of CFTR at the Plasma Membrane: Correctors, Proteostasis Modulators and Stabilizers</title><p>Class II <italic toggle="yes">CFTR</italic> mutations present with maturation and trafficking defects, leading to a reduction in the number of channels at the PM. Therefore, folding of the mutant CFTR channel should be restored to levels that allow ERQC escape and trafficking to the PM. Alternatively, the degradation of misfolded CFTR by the ER or peripheral QC should be prevented by other means. Early-on, it was shown that incubation of cells at lower temperatures, e.g., 26 &#176;C, prevented degradation of some class II mutations, most notably F508del [<xref rid="B117-cells-11-01868" ref-type="bibr">117</xref>], but not others, like G85E (c.254G&gt;A) or N1303K [<xref rid="B118-cells-11-01868" ref-type="bibr">118</xref>,<xref rid="B119-cells-11-01868" ref-type="bibr">119</xref>]. F508del degradation is initiated early in the ER by the so-called chaperone trap [<xref rid="B18-cells-11-01868" ref-type="bibr">18</xref>,<xref rid="B19-cells-11-01868" ref-type="bibr">19</xref>], and lowering the temperature results in an accumulation of immature F508del protein by reduced proteasomal degradation, allowing F508del to escape the ERQC and be &#8220;rescued&#8221; to the PM [<xref rid="B120-cells-11-01868" ref-type="bibr">120</xref>]. Temperature sensitive mutants could also be rescued after treatment with 10% glycerol, which appeared to have a stabilizing effect on an early folding intermediate by acting as a chemical chaperone [<xref rid="B121-cells-11-01868" ref-type="bibr">121</xref>]. However, while they are useful tools to study CFTR (mis)processing, neither can serve as a potential therapeutic strategy. CFTR correctors, interacting directly with CFTR, or proteostasis modulators and stabilizers, targeting CFTR interactors, on the other hand, could be translated into therapeutic strategies. As the MoA of most compounds remain incompletely understood and compounds could potentially exert multiple mechanisms, the distinction between CFTR correctors, stabilizers and proteostasis modulators is not always as clear as presented here (<xref rid="cells-11-01868-f004" ref-type="fig">Figure 4</xref>). </p><sec id="sec3dot2dot1-cells-11-01868"><title>3.2.1. CFTR Correctors</title><p>Pharmacological chaperones are small molecules that, like the cellular chaperones present in the ER, assist in the folding of proteins. CFTR correctors can be considered pharmacological chaperones that, by direct interaction with the protein, improve the folding of mutant CFTR to such extent that early degradation is at least partially averted (<xref rid="cells-11-01868-f005" ref-type="fig">Figure 5</xref>) [<xref rid="B122-cells-11-01868" ref-type="bibr">122</xref>,<xref rid="B123-cells-11-01868" ref-type="bibr">123</xref>]. Combinations of correctors can enhance the level of correction by combining different MoA [<xref rid="B123-cells-11-01868" ref-type="bibr">123</xref>,<xref rid="B124-cells-11-01868" ref-type="bibr">124</xref>]. While many CFTR activators and potentiators were rapidly identified, the discovery of CFTR correctors was off to a slower start, as the process of folding and trafficking involves many more components than its gating (reviewed in [<xref rid="B125-cells-11-01868" ref-type="bibr">125</xref>]). In addition, HTS assays have long relied mainly on functional CFTR read-outs that are more readily scaled to allow screening of large libraries [<xref rid="B89-cells-11-01868" ref-type="bibr">89</xref>,<xref rid="B126-cells-11-01868" ref-type="bibr">126</xref>,<xref rid="B127-cells-11-01868" ref-type="bibr">127</xref>]. This strategy assumed that CFTR, once rescued to the PM, is functional. F508del&#8212;and a number of other processing mutations&#8212;however, are known to also suffer from gating defects [<xref rid="B54-cells-11-01868" ref-type="bibr">54</xref>]. To account for this, screening assays looking directly at the trafficking of mutant CFTR proteins have since also been developed [<xref rid="B128-cells-11-01868" ref-type="bibr">128</xref>,<xref rid="B129-cells-11-01868" ref-type="bibr">129</xref>,<xref rid="B130-cells-11-01868" ref-type="bibr">130</xref>,<xref rid="B131-cells-11-01868" ref-type="bibr">131</xref>,<xref rid="B132-cells-11-01868" ref-type="bibr">132</xref>]. Recently, a fluorescence resonance energy transfer (FRET) based HTS platform was developed to evaluate the folding of nascent, ribosome-bound NBD1 mutants to specifically identify compounds able to restore the conformation of NBD1 [<xref rid="B133-cells-11-01868" ref-type="bibr">133</xref>]. </p><p>Screening of 150,000 chemically diverse small molecules by Pedemonte and colleagues identified the bisaminomethylbithiazole corr-4a as a corrector able to improve F508del, but not N1303K, trafficking [<xref rid="B126-cells-11-01868" ref-type="bibr">126</xref>]. In addition, CFTR function was restored to a level similar to that of low temperature rescue in both heterologous and primary epithelial cell models [<xref rid="B126-cells-11-01868" ref-type="bibr">126</xref>]. Corr-4a was found to bind directly to CFTR [<xref rid="B122-cells-11-01868" ref-type="bibr">122</xref>], but the exact binding site and MoA have not been elucidated to date. Although initial studies suggested that corr-4a mainly stabilizes NBD2 [<xref rid="B123-cells-11-01868" ref-type="bibr">123</xref>], it appears that MSD2 is essential for corr-4a mediated rescue [<xref rid="B134-cells-11-01868" ref-type="bibr">134</xref>]. More recent studies also suggest its ability to stabilize MSD2 [<xref rid="B135-cells-11-01868" ref-type="bibr">135</xref>]. Corr-4a remains the archetypical example of type II correctors (i.e., targeting NBD2-MSD2) [<xref rid="B123-cells-11-01868" ref-type="bibr">123</xref>]. Other correctors of this type, such as the aminoarylthiazole derivative, FCG, were recently proposed to bind to NBD2 [<xref rid="B136-cells-11-01868" ref-type="bibr">136</xref>,<xref rid="B137-cells-11-01868" ref-type="bibr">137</xref>]. The MoA of type II correctors is complementary to that of other corrector types and hence allows to be added in conjunction (<xref rid="cells-11-01868-f005" ref-type="fig">Figure 5</xref>) [<xref rid="B120-cells-11-01868" ref-type="bibr">120</xref>,<xref rid="B123-cells-11-01868" ref-type="bibr">123</xref>,<xref rid="B138-cells-11-01868" ref-type="bibr">138</xref>,<xref rid="B139-cells-11-01868" ref-type="bibr">139</xref>].</p><p>Another large screen of 164,000 synthetic compounds by Van Goor and colleagues identified the quinazoline compound VRT-325 as a corrector of F508del [<xref rid="B89-cells-11-01868" ref-type="bibr">89</xref>]. VRT-325 promoted the interaction between NBD1 and both MSD1 and MSD2 [<xref rid="B140-cells-11-01868" ref-type="bibr">140</xref>], and additionally could rescue folding mutants of the P-glycoprotein (a close family member of CFTR) [<xref rid="B141-cells-11-01868" ref-type="bibr">141</xref>]. At high concentrations, however, it was shown to inhibit CFTR function in a similar manner as the CFTR inhibitor Inh172 [<xref rid="B142-cells-11-01868" ref-type="bibr">142</xref>]. Another hit from the same screen, VRT-768, was optimized by extensive medicinal chemistry and structure activity analysis to VX-809 (lumacaftor) [<xref rid="B143-cells-11-01868" ref-type="bibr">143</xref>]. VX-809 was the first CFTR corrector that&#8212;together with potentiator VX-770&#8212;obtained market approval (Orkambi<sup>TM</sup>), as it significantly, though modestly, improved lung function in F508del homozygous PwCF [<xref rid="B66-cells-11-01868" ref-type="bibr">66</xref>]. Insights into VX809&#8217;s MoA were obtained from mutagenesis studies, where the limited additivity of VX-809 and revertant mutant R1070W suggested that both correct F508del folding via a similar mechanism, i.e., by restoring the NBD1:ICL4 interface [<xref rid="B120-cells-11-01868" ref-type="bibr">120</xref>,<xref rid="B123-cells-11-01868" ref-type="bibr">123</xref>]. At around the same time, it was shown that VX-809 is not able to correct the thermodynamic instability of the NBD1 domain [<xref rid="B144-cells-11-01868" ref-type="bibr">144</xref>], but rather seemed to stabilize MSD1 [<xref rid="B38-cells-11-01868" ref-type="bibr">38</xref>,<xref rid="B145-cells-11-01868" ref-type="bibr">145</xref>]. On the one hand, several studies have indeed showed that VX-809 assisted in compacting several transmembrane spans in MSD1 [<xref rid="B146-cells-11-01868" ref-type="bibr">146</xref>,<xref rid="B147-cells-11-01868" ref-type="bibr">147</xref>,<xref rid="B148-cells-11-01868" ref-type="bibr">148</xref>], although other studies have suggested that VX-809 interacts with NBD1 [<xref rid="B149-cells-11-01868" ref-type="bibr">149</xref>], both NBD1 and cytosolic loop 1 [<xref rid="B150-cells-11-01868" ref-type="bibr">150</xref>], or by stabilizing the protein once it is present at the PM [<xref rid="B151-cells-11-01868" ref-type="bibr">151</xref>]. By click-chemistry, VX-809 was shown to directly bind to CFTR [<xref rid="B152-cells-11-01868" ref-type="bibr">152</xref>], although the exact binding site and MoA of VX-809 were only recently elucidated by cryo-EM [<xref rid="B34-cells-11-01868" ref-type="bibr">34</xref>]. This method revealed that VX-809 fills an internal cavity which is intrinsically thermodynamically instable, formed by transmembrane spans 1, 2, 3 and 6 in MSD1. This finding is in line with other recent studies suggesting that VX-809 exerts its effects early in the biogenesis of CFTR [<xref rid="B148-cells-11-01868" ref-type="bibr">148</xref>], and might explain how VX-809 is also able to improve folding and trafficking of the WT-CFTR [<xref rid="B47-cells-11-01868" ref-type="bibr">47</xref>]. </p><p>While VX-809 used to be the prototypical example of type I correctors and is still used in many experiments, it has now mainly been replaced in the clinic with VX-661 (tezacaftor), a molecule related to VX-809 which causes fewer side effects in PwCF and has an improved overall safety profile [<xref rid="B69-cells-11-01868" ref-type="bibr">69</xref>,<xref rid="B70-cells-11-01868" ref-type="bibr">70</xref>,<xref rid="B71-cells-11-01868" ref-type="bibr">71</xref>,<xref rid="B153-cells-11-01868" ref-type="bibr">153</xref>]. It shares its binding site and MoA with VX-809 [<xref rid="B34-cells-11-01868" ref-type="bibr">34</xref>]. Tezacaftor is market-approved in combination with potentiator VX-770 (Symdeko&#8482;/Symkevi&#8482;) or VX-770 and corrector/potentiator VX-445 (Trikafta&#8482;/Kaftrio&#8482;). Other type I correctors, such as C18 (VRT-534; from the Cystic Fibrosis Foundation&#8217;s CFTR Compound Program), ABBV-2222 (formerly GLPG-2222; also known as galicaftor), FDL-169 and trimethylangelicin (derivatives) rescue CFTR through a similar MoA [<xref rid="B123-cells-11-01868" ref-type="bibr">123</xref>,<xref rid="B138-cells-11-01868" ref-type="bibr">138</xref>,<xref rid="B154-cells-11-01868" ref-type="bibr">154</xref>,<xref rid="B155-cells-11-01868" ref-type="bibr">155</xref>]. ABBV-2222 was tested in clinical trials and was shown to be well-tolerated, but no change in lung function was observed ([<xref rid="B156-cells-11-01868" ref-type="bibr">156</xref>] &amp; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03045523">NCT03045523</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03119649">NCT03119649</ext-link>). New trials combining ABBV-2222 with the next generation potentiator ABBV-3067 are currently ongoing (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03969888">NCT03969888</ext-link>). More recently, a novel type I corrector, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="ARN23765">ARN23765</ext-link>, was described with picomolar potency (EC<sub>50</sub>: 38 pM)&#8212;which showed prolonged CFTR rescuing effects in vitro (&gt;36 h) at concentrations 5000 times lower compared to VX-809 [<xref rid="B157-cells-11-01868" ref-type="bibr">157</xref>]. </p><p>As type I and II correctors or combinations were unable to rescue all aspects of the F508del folding defect, in particular the thermodynamic instability of NBD1, the search for novel corrector types continued. Screening of 600,000 compounds identified one of the first type III correctors, 4172, which was proposed to bind and stabilize NBD1 [<xref rid="B138-cells-11-01868" ref-type="bibr">138</xref>,<xref rid="B139-cells-11-01868" ref-type="bibr">139</xref>]. It shares a corrector MoA with the next generation correctors VX-445 (elexacaftor; part of the triple combination Trikafta&#8482;/Kaftrio&#8482;) [<xref rid="B138-cells-11-01868" ref-type="bibr">138</xref>,<xref rid="B158-cells-11-01868" ref-type="bibr">158</xref>] and VX-659 [<xref rid="B159-cells-11-01868" ref-type="bibr">159</xref>]. While the exact binding site and corrector MoA of VX-445 remain unknown, several studies suggest a binding site located at the NBD1 [<xref rid="B138-cells-11-01868" ref-type="bibr">138</xref>,<xref rid="B160-cells-11-01868" ref-type="bibr">160</xref>]. Importantly, VX-445 could at least partially prevent thermal unfolding of NBD1, the hallmark of type III correctors [<xref rid="B138-cells-11-01868" ref-type="bibr">138</xref>]. </p><p>Several other correctors, whose MoA are not covered in corrector types I-II-III or have yet to be elucidated, have also been described. One of the first CFTR correctors to be identified, the benzo(c)quinolizinium compounds (MPBs) were thought to bind NBD1 and promote maturation as well as stimulate function [<xref rid="B161-cells-11-01868" ref-type="bibr">161</xref>,<xref rid="B162-cells-11-01868" ref-type="bibr">162</xref>,<xref rid="B163-cells-11-01868" ref-type="bibr">163</xref>]. Bis-phosphinic acid derivatives c407 and G1, targeting the NBD1, were recently modeled to fill the cavity left by the missing phenylalanine side chain in F508del, thereby restoring the NBD1:ICL4 interface [<xref rid="B164-cells-11-01868" ref-type="bibr">164</xref>,<xref rid="B165-cells-11-01868" ref-type="bibr">165</xref>]. In cell models, additivity of c407 with VX-809 suggests these compounds might represent a complementary MoA with existing CFTR corrector types. Other pharmacological chaperones targeting NBD1 are phenylhydrazones [<xref rid="B166-cells-11-01868" ref-type="bibr">166</xref>], such as RDR-1 [<xref rid="B130-cells-11-01868" ref-type="bibr">130</xref>], which enhanced CFTR currents in differentiated human bronchial epithelial cell (HBE) cultures synergistically with VX-809 and MCG1516A [<xref rid="B167-cells-11-01868" ref-type="bibr">167</xref>], and which, since then, have been proposed to bind at the NBD1:NBD2 interface [<xref rid="B168-cells-11-01868" ref-type="bibr">168</xref>].</p></sec><sec id="sec3dot2dot2-cells-11-01868"><title>3.2.2. Proteostasis Modulators</title><p>Proteostasis modulation has long been considered for the causal treatment of CF as a means of rescuing mutant trafficking to the PM (<xref rid="cells-11-01868-f004" ref-type="fig">Figure 4</xref>). It is an umbrella term for a diverse set of strategies that aim to indirectly rescue mutant CFTR to the PM, by interacting with proteins involved in (mutant) CFTR degradation. One of the first compounds that was found to improve the expression of F508del at the PM was 4PBA [<xref rid="B169-cells-11-01868" ref-type="bibr">169</xref>], shown to increase the expression of pro-folding chaperones like Hsp90 and ERp29 [<xref rid="B170-cells-11-01868" ref-type="bibr">170</xref>,<xref rid="B171-cells-11-01868" ref-type="bibr">171</xref>]. Overexpression of ERp29 rescued F508del to the PM in bronchial epithelial IB3-1 cells, while knockdown decreased levels of PM WT-CFTR [<xref rid="B170-cells-11-01868" ref-type="bibr">170</xref>]. A pilot clinical trial showed partial restoration of nasal epithelial CFTR function, but no reduction in the concentration of sweat chloride [<xref rid="B172-cells-11-01868" ref-type="bibr">172</xref>]. It was later tested in combination with genistein as well (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00016744">NCT00016744</ext-link>, <italic toggle="yes">see <xref rid="sec3dot1dot2-cells-11-01868" ref-type="sec">Section 3.1.2</xref>. CFTR Potentiators</italic>). Currently, an optimized pro-drug variant of 4PBA, glycerol phenylbutyrate (GPBA), is being tested in a phase I/II study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02323100">NCT02323100</ext-link>). Additional ER chaperones were identified whose modulation could rescue F508del trafficking. Proteomics and differential interactomics between WT-CFTR and F508del revealed inhibition of Hsp90 co-chaperones Aha1 [<xref rid="B173-cells-11-01868" ref-type="bibr">173</xref>] or PTPLAD1 [<xref rid="B174-cells-11-01868" ref-type="bibr">174</xref>] as potential novel therapeutic strategies. Another way of altering the expression of ER chaperones is by inhibiting specific histone deacetylases (HDACs). This was studied, for example, by inhibiting HDAC7 using HDAC inhibitors (HDACi), such as suberoylanilide hydroxamic acid (SAHA, vorinostat) or by siRNA knockdown, both of which improved the PM expression and activity of F508del [<xref rid="B175-cells-11-01868" ref-type="bibr">175</xref>]. Other HDACi, such as the fungal metabolite apidicin, showed improved F508del rescuing potential, although they were less potent at HDAC inhibition [<xref rid="B176-cells-11-01868" ref-type="bibr">176</xref>]. Several HDACi have also been shown to rescue a panel of rare CFTR mutants, in particular class II mutations P67L (c.200C&gt;T) and E92K (c.274G&gt;A) [<xref rid="B177-cells-11-01868" ref-type="bibr">177</xref>]. Their biggest caveat, it seems, is that CFTR rescue by HDAC modulation appears highly cell-type-dependent. For example, their rescuing effects in the immortalized CFBE41o- lung cell line, where F508del overexpression is driven by a viral promoter, could not be confirmed in primary airway cells [<xref rid="B178-cells-11-01868" ref-type="bibr">178</xref>,<xref rid="B179-cells-11-01868" ref-type="bibr">179</xref>]. Other primary cell types remain to be investigated though. </p><p>Besides modulating the expression of CFTR chaperones, another strategy consists of disrupting the calnexin/calreticulin ERQC checkpoint. The &#945;-1,2-glucosidase inhibitor miglustat (n-butyldeoxynojirimycin), which is used to treat type I Gaucher and Niemann-Pick type C disease [<xref rid="B180-cells-11-01868" ref-type="bibr">180</xref>], increased F508del trafficking via the inhibition of the deglycosylation of nascent proteins, which usually takes place at this checkpoint [<xref rid="B181-cells-11-01868" ref-type="bibr">181</xref>]. Although F508del function was rescued in airway epithelial cells and CF mice, no clinical benefits were observed in a phase II trial of miglustat in F508del homozygous PwCF [<xref rid="B182-cells-11-01868" ref-type="bibr">182</xref>]. The small molecule thapsigargin has been shown to disrupt the interaction between F508del and calnexin by depleting ER Ca<sup>2+</sup>, which rescued the nasal epithelial potential defect in F508del mice [<xref rid="B183-cells-11-01868" ref-type="bibr">183</xref>]. Roscovitine (seliciclib) increased F508del trafficking by a similar MoA, as well as by inhibiting proteasomal activity, thus preventing ERAD [<xref rid="B184-cells-11-01868" ref-type="bibr">184</xref>]. Moreover, it was shown to have additional favorable properties for PwCF, as it displays anti-inflammatory properties, such as enhanced neutrophil clearance and reduced eosinophil degranulation, through its inhibition of cyclin-dependent kinases (CDKs) ([<xref rid="B185-cells-11-01868" ref-type="bibr">185</xref>]; reviewed in [<xref rid="B186-cells-11-01868" ref-type="bibr">186</xref>]). When tested in a Phase II trial (ROSCO-CF, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02649751">NCT02649751</ext-link>), unfortunately, no significant improvements were found in spirometry, inflammation, infection or sweat chloride [<xref rid="B187-cells-11-01868" ref-type="bibr">187</xref>]. In the meantime, structural roscovitine-analogues have been synthetized, which were recently found to also restore trafficking of other proteins similar to CFTR, such as ABCB4, in cell models [<xref rid="B188-cells-11-01868" ref-type="bibr">188</xref>]. </p><p>Curcumin is a natural product which was first described to correct F508del trafficking via its interaction with the ER-located calcium pump (SERCA) [<xref rid="B189-cells-11-01868" ref-type="bibr">189</xref>]. However, later studies could not confirm this rescue [<xref rid="B190-cells-11-01868" ref-type="bibr">190</xref>,<xref rid="B191-cells-11-01868" ref-type="bibr">191</xref>]. As it is structurally related to CFTR potentiator genistein, it was consequently hypothesized that, like genistein, it could also bind directly to CFTR and increase its P<sub>O</sub> [<xref rid="B192-cells-11-01868" ref-type="bibr">192</xref>]. Recently, a small clinical study investigated the combination of curcumin and genistein in PwCF carrying at least one S1251N (c.3752G&gt;A) gating mutation (NTR4585 &amp; [<xref rid="B193-cells-11-01868" ref-type="bibr">193</xref>]). While some functional rescue was measured in rectal organoids of the respective involved PwCF, it was low compared to VX-770 treatment [<xref rid="B193-cells-11-01868" ref-type="bibr">193</xref>]. Clinically, no clear effect was observed, although it was argued that the plasma concentrations measured for both compounds were much lower than those typically used in in vitro studies. </p><p>Another investigated pathway to rescue trafficking of misfolded CFTR, is to interfere with the unfolded protein response (UPR). As such, latonduine, a sponge alkaloid, and related analogues identified by phenotypic screening, were reported to inhibit the activity of poly-ADP ribose polymerases (PARP) 3 and 16 [<xref rid="B194-cells-11-01868" ref-type="bibr">194</xref>]. These regulate UPR via ADP-ribosylation of IRE-1-&#945; and PERK, two ER stress sensors that initiate UPR. Inhibition of UPR by PARP3 and PARP16 rescued F508del trafficking in cell models [<xref rid="B194-cells-11-01868" ref-type="bibr">194</xref>,<xref rid="B195-cells-11-01868" ref-type="bibr">195</xref>,<xref rid="B196-cells-11-01868" ref-type="bibr">196</xref>]. Misfolded CFTR proteins are &#8220;flagged&#8221; for degradation by ubiquitination. Preventing ubiquitination thus presents another means for enhancing ER escape and trafficking. In that light, the E1 ubiquitin-activating enzyme could be inhibited by PYR-41, a small molecule which synergistically with corrector C18 rescued F508del trafficking and function, as by itself it only increased the amount of immature, ER-localized protein [<xref rid="B197-cells-11-01868" ref-type="bibr">197</xref>]. This compound was further chemically optimized into &#8220;7134&#8221; in order to reduce toxicity while maintaining its ability to augment F508del function when co-treated with VX-809 [<xref rid="B198-cells-11-01868" ref-type="bibr">198</xref>]. Recently, Borgo and colleagues used the small molecule inhibitor TAK-243 (also known as mln7243) of the ubiquitin-activating enzyme UBA1 to enhance the efficacy of Trikafta&#8482;/Kaftrio&#8482; treatment in primary airway epithelial cells [<xref rid="B199-cells-11-01868" ref-type="bibr">199</xref>]. This effect was not limited to F508del, but also translated towards other processing mutations, including the difficult to rescue mutation N1303K. Alternatively, preventing ubiquitination by inhibiting the ubiquitin ligase RNF5, rescued F508del in a primary airway epithelial cell model [<xref rid="B200-cells-11-01868" ref-type="bibr">200</xref>]. As another approach, de-ubiquitination targeting chimeras (DUBTAC) can be used to recruit de-ubiquitinases and reverse ubiquitination of misfolded proteins [<xref rid="B201-cells-11-01868" ref-type="bibr">201</xref>]. For CF it was shown that F508del could be stabilized in epithelial cells by linking the OTUB1 de-ubiquitinase recruiter EN523 to VX-809&#8212;which conferred specificity to CFTR&#8212;and allowed trafficking to the PM and subsequent potentiation by VX-770 [<xref rid="B201-cells-11-01868" ref-type="bibr">201</xref>]. Small Ubiquitin Like Modifier (SUMO) conjugation, SUMOylation, is a post-translational modification which can regulate a vast number of cell processes, including protein degradation [<xref rid="B202-cells-11-01868" ref-type="bibr">202</xref>]. Prevention of SUMOylation through SUMO2/3 by overexpression of activated STAT isoform 4 (PIAS4), slowed down the degradation of immature F508del-CFTR as well as several other processing mutants [<xref rid="B203-cells-11-01868" ref-type="bibr">203</xref>,<xref rid="B204-cells-11-01868" ref-type="bibr">204</xref>]. Improved folding (i.e., increased mature/immature CFTR ratio on Western blot analysis) was also obtained for a panel of rare mutations, including N1303K, when PIAS4 overexpression was combined with the type I corrector C18 [<xref rid="B203-cells-11-01868" ref-type="bibr">203</xref>]. For a more extensive discussion of ubiquitination as a target for CFTR rescue, we refer to [<xref rid="B205-cells-11-01868" ref-type="bibr">205</xref>], but in summary, any strategy interfering with this process is able to promote the escape of misfolded CFTR, though predominantly in conjunction with correctors does this lead to improved CFTR function. </p><p>Moving further in the biogenesis cycle of CFTR, enhancing autophagy is another strategy proposed to enhance expression of mutant CFTR at the PM [<xref rid="B206-cells-11-01868" ref-type="bibr">206</xref>]. In that context, cysteamine, approved for the treatment of cystinosis [<xref rid="B207-cells-11-01868" ref-type="bibr">207</xref>], was tested in CF mice, followed by a small open-label clinical trial in PwCF, where it was shown to reduce sweat chloride levels in F508del carrying PwCF, but not in a cohort which contained PwCF carrying two non-F508del mutations not responsive to current CFTR modulators [<xref rid="B208-cells-11-01868" ref-type="bibr">208</xref>,<xref rid="B209-cells-11-01868" ref-type="bibr">209</xref>]. More recently, however, functional rescue by cysteamine and thymosin &#945;1&#8212;the rescue by the latter also reported to occur through promoting autophagy [<xref rid="B210-cells-11-01868" ref-type="bibr">210</xref>]&#8212;could not be confirmed by several other labs [<xref rid="B211-cells-11-01868" ref-type="bibr">211</xref>,<xref rid="B212-cells-11-01868" ref-type="bibr">212</xref>,<xref rid="B213-cells-11-01868" ref-type="bibr">213</xref>], dampening the enthusiasm to stimulate autophagy as a way of reversing the CF phenotype. </p><p>Phosphodiesterase type 5 (PDE5) inhibitors cause vasodilation via smooth muscle relaxation by inhibiting cGMP degradation [<xref rid="B214-cells-11-01868" ref-type="bibr">214</xref>]. PDE5 inhibitor sildenafil and structural analogues, such as vardenafil and KM11060, were reported to enhance CFTR maturation, i.e., the fully glycosylated &#8220;band C&#8221; on Western blot, PM expression and function [<xref rid="B215-cells-11-01868" ref-type="bibr">215</xref>,<xref rid="B216-cells-11-01868" ref-type="bibr">216</xref>,<xref rid="B217-cells-11-01868" ref-type="bibr">217</xref>]. Although the MoA by which maturation and PM expression are rescued by these compounds remains unclear, it is possible that its phosphodiesterase modulation also activates CFTR channels [<xref rid="B216-cells-11-01868" ref-type="bibr">216</xref>,<xref rid="B218-cells-11-01868" ref-type="bibr">218</xref>]. Since sildenafil was already FDA approved for erectile dysfunction and pulmonary arterial hypertension [<xref rid="B214-cells-11-01868" ref-type="bibr">214</xref>], it could relatively easily be repurposed to PwCF. Although the therapy was safe and well-tolerated, no clear clinical benefit was observed (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00659529">NCT00659529</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01132482">NCT01132482</ext-link>, [<xref rid="B219-cells-11-01868" ref-type="bibr">219</xref>]). Similarly, the soluble guanylate cyclase stimulator riociguat, which is also approved (as Adempas&#8482;) for the treatment of pulmonary hypertension [<xref rid="B220-cells-11-01868" ref-type="bibr">220</xref>], modulates the same pathway as the above phosphodiesterase inhibitors [<xref rid="B221-cells-11-01868" ref-type="bibr">221</xref>]. However, while CFTR processing and function was increased in vitro and in vivo in F508del mice, it did not improve CFTR activity or lung function in the Rio-CF study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02170025">NCT02170025</ext-link>), a small clinical trial in F508del PwCF [<xref rid="B221-cells-11-01868" ref-type="bibr">221</xref>,<xref rid="B222-cells-11-01868" ref-type="bibr">222</xref>]. </p><p>A final example of proteostasis modulators is the non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and glafenine. These block the production of prostaglandins and thromboxanes by inhibiting the cyclooxygenase (COX) enzymes that convert arachidonic acid to prostaglandins [<xref rid="B223-cells-11-01868" ref-type="bibr">223</xref>]. They were also reported to rescue CFTR expression [<xref rid="B132-cells-11-01868" ref-type="bibr">132</xref>,<xref rid="B224-cells-11-01868" ref-type="bibr">224</xref>]. Recently, Carlile and colleagues showed that glafenine and analogues corrected misfolded class II CFTR by preventing the stimulation of the prostaglandin E2 receptor PE4, which was confirmed by siRNA mediated knockdown of PE4 [<xref rid="B225-cells-11-01868" ref-type="bibr">225</xref>]. It was further proposed that targeting this metabolic pathway, rather than specific protein production/QC pathways, could potentially rescue misfolded proteins other than CFTR as well [<xref rid="B225-cells-11-01868" ref-type="bibr">225</xref>].</p><p>In summary, the search for proteostasis modulators able to promote mutant CFTR trafficking to the PM has been extensive. As evidenced by the numerous examples discussed in this section, many different strategies have been investigated. However, none of them have translated so far into a therapy for PwCF. The main reasons for this are the occurrence of cell-type specific rescue, often not translating to rescue in primary cells, and the lack of clinical benefit in PwCF in clinical trials. This highlights how the choice of cell model greatly influences the degree of CFTR rescue, in particular when rescued via non-direct mechanisms such as proteostasis modulation. Any potential strategy (including, but not limited to, proteostasis modulation) should thus be tested in primary cell models with good translational value as soon as possible, to prevent attrition at later stages.</p></sec><sec id="sec3dot2dot3-cells-11-01868"><title>3.2.3. Stabilizers</title><p>As CFTR has now reached the PM, with or without the help of CFTR correctors and proteostasis modulators, the next important step is to make sure it stays there. Once at the PM, CFTR is continuously endocytosed and recycled back to the PM [<xref rid="B16-cells-11-01868" ref-type="bibr">16</xref>]. During this process, misfolded proteins, however, are recognized by the peripheral quality control (PQC) and, rather than recycled, are instead ubiquitinated to prime them for lysosomal degradation, reducing the number of available CFTR channels [<xref rid="B16-cells-11-01868" ref-type="bibr">16</xref>,<xref rid="B23-cells-11-01868" ref-type="bibr">23</xref>]. Stabilizers thus aim to improve the amount of CFTR channels at the PM by stabilizing the CFTR protein and slowing down its turn-over, a strategy which is complementary to CFTR correctors or proteostasis modulation (<xref rid="cells-11-01868-f004" ref-type="fig">Figure 4</xref>). As discussed earlier, it is not always possible to discriminate between CFTR correctors, proteostasis modulators and stabilizers, especially as not all the mechanisms of these compounds have been elucidated in detail yet. Compared to correctors and proteostasis modulators, only a few compounds have been developed to specifically target peripheral stability of the CFTR protein. The only CFTR stabilizer tested in clinical trials to date is cavosonstat (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="N91115">N91115</ext-link>), an inhibitor of the S-nitrosoglutathione reductase (SNGOR) ([<xref rid="B226-cells-11-01868" ref-type="bibr">226</xref>], <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02275936">NCT02275936</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02013388">NCT02013388</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02500667">NCT02500667</ext-link>). This compound exerts its CFTR stabilizing function by decreasing the internalization rates of CFTR and thus extending its half-life at the PM [<xref rid="B227-cells-11-01868" ref-type="bibr">227</xref>,<xref rid="B228-cells-11-01868" ref-type="bibr">228</xref>]. Specifically, this is achieved through interfering with the PQC. Cavosonstat preserves S-nitrosothiols by inhibiting SNGOR, which results in the nitrosylation of Hsp70/Hsp90 organizing protein (HOP). This, in turn, lowers the interaction of CFTR with CHIP (C-terminus of Hsp70 interacting protein), thereby preventing its degradation. Although the Phase I trial was not powered to evaluate efficacy, no effects were observed with mono-therapy of cavosonstat in F508del homozygous PwCF, besides a small reduction in sweat chloride [<xref rid="B226-cells-11-01868" ref-type="bibr">226</xref>]. In a Phase II follow-up study where cavosonstat was administered together with ivacaftor and lumacaftor, no clinical benefits were observed [<xref rid="B229-cells-11-01868" ref-type="bibr">229</xref>]. </p><p>In addition, CFTR modulators have been found to influence CFTR stability. As such, the corrector VX-809 and other type I correctors were shown to not only correct folding in the ER, but also improve stability once at the PM [<xref rid="B151-cells-11-01868" ref-type="bibr">151</xref>]. In contrast, potentiator VX-770 destabilizes corrector type I-rescued CFTR [<xref rid="B97-cells-11-01868" ref-type="bibr">97</xref>], even in the presence of VX-445 [<xref rid="B230-cells-11-01868" ref-type="bibr">230</xref>]. Other potentiators with similar mechanisms as VX-770 do not destabilize the protein, so the choice of combination of small molecules can affect protein stability [<xref rid="B98-cells-11-01868" ref-type="bibr">98</xref>,<xref rid="B230-cells-11-01868" ref-type="bibr">230</xref>]. Alternatively, the destabilization could be prevented by co-treatment with the hepatocyte growth factor (HGF) [<xref rid="B231-cells-11-01868" ref-type="bibr">231</xref>,<xref rid="B232-cells-11-01868" ref-type="bibr">232</xref>], which stabilizes CFTR by promoting its anchoring to the actin cytoskeleton via the Rac1 GTPase [<xref rid="B232-cells-11-01868" ref-type="bibr">232</xref>,<xref rid="B233-cells-11-01868" ref-type="bibr">233</xref>]. The vaso-active intestinal peptide (VIP) has been shown to increase the membrane localization by promoting interaction between CFTR and the N<sup>+</sup>/H<sup>+</sup> exchanger regulatory factor 1 (NHERF1) and ezrin/radixin/moesin (ERM) complex, while at the same time inhibiting interaction with the CFTR associated ligand (CAL) [<xref rid="B234-cells-11-01868" ref-type="bibr">234</xref>]. Activation of the cAMP sensor EPAC1 also promoted the interaction between CFTR and NHERF1, stabilizing CFTR at the PM [<xref rid="B235-cells-11-01868" ref-type="bibr">235</xref>,<xref rid="B236-cells-11-01868" ref-type="bibr">236</xref>]. Inhibition of the protease calpain 1, on the other hand, stabilized CFTR through promoting its interaction with ezrin [<xref rid="B237-cells-11-01868" ref-type="bibr">237</xref>]. Other strategies have also focused on these interaction partners, by overexpressing NHERF1 [<xref rid="B238-cells-11-01868" ref-type="bibr">238</xref>], inhibiting CAL [<xref rid="B239-cells-11-01868" ref-type="bibr">239</xref>], or by preventing endocytosis [<xref rid="B240-cells-11-01868" ref-type="bibr">240</xref>,<xref rid="B241-cells-11-01868" ref-type="bibr">241</xref>] and promoting recycling (reviewed in [<xref rid="B242-cells-11-01868" ref-type="bibr">242</xref>]). CFTR PM levels have furthermore been shown to be regulated through phosphorylation of Y512 by the spleen tyrosine kinase SYK [<xref rid="B243-cells-11-01868" ref-type="bibr">243</xref>]. Consequently, inhibition of SYK or the adaptor SHC1, which recognizes phosphorylated Y512-CFTR, increased the amount of PM CFTR [<xref rid="B244-cells-11-01868" ref-type="bibr">244</xref>]. </p><p>In conclusion, stabilizing CFTR at the PM is, in theory, an attractive way to increase CFTR PM density. However, all specific stabilizing strategies are still in early pre-clinical development. Therefore, on the short term, stabilization of CFTR is most likely to occur from optimizing CFTR modulator combinations to avoid destabilization.</p></sec></sec><sec id="sec3dot3-cells-11-01868"><title>3.3. Improving the Amount of Immature CFTR Protein</title><p>So far, all strategies discussed have focused on modulating the mutated CFTR protein to, at least, a certain level of CFTR function. However, these strategies assume there is sufficient immature protein available to correct. In the next section, we will focus on strategies that aim to enhance the amount of immature protein by interacting with the <italic toggle="yes">CFTR</italic> mRNA and the process of translation rather than to modulate the mutant protein itself. The new pool of available immature protein can then be rescued further by combining it with CFTR correctors and potentiators as needed. In certain cases, however, it might suffice to modulate the translation process in the ER to overcome CFTR defects. By reducing ribosome velocity during translation for example through suppression of the ribosomal protein L12 (RPL12), mutant CFTR trafficking and function has been shown to be partially restored [<xref rid="B245-cells-11-01868" ref-type="bibr">245</xref>,<xref rid="B246-cells-11-01868" ref-type="bibr">246</xref>]. </p><p>In the next paragraphs, we will discuss other means of increasing the amount of immature protein. First, we will detail the development of amplifiers and miRNA modulation, which could be of use to rescue <italic toggle="yes">CFTR</italic> mutations where protein is still produced, i.e., class II-VI. Second, we will focus on NMD suppression and TRIDs, potential therapies for PwCF with pre-termination codon (PTC) mutations.</p><sec id="sec3dot3dot1-cells-11-01868"><title>3.3.1. Amplifiers</title><p>An HTS of 54,000 compounds performed by Giuliano and colleagues identified a novel CFTR modulator, which was neither a potentiator nor a corrector but showed synergism with both [<xref rid="B247-cells-11-01868" ref-type="bibr">247</xref>,<xref rid="B248-cells-11-01868" ref-type="bibr">248</xref>]. This modulator, PTI-CH, termed an amplifier, increased the amount of immature CFTR by stabilizing the mRNA, which resulted in a 1.5-2-fold increase in available <italic toggle="yes">CFTR</italic> mRNA transcripts [<xref rid="B248-cells-11-01868" ref-type="bibr">248</xref>]. This strategy could be of particular interest for Class II mutations, as it would increase the pool of immature protein available for corrector rescue, as well as for Class V mutations, where, due to cryptic splice sites only a fraction of the <italic toggle="yes">CFTR</italic> mRNA is correctly spliced (<xref rid="cells-11-01868-f006" ref-type="fig">Figure 6</xref>). PTI-CH was, furthermore, found to act co-translationally by promoting translation and insertion of the first transmembrane spans into the ER, a process which is inherently inefficient [<xref rid="B249-cells-11-01868" ref-type="bibr">249</xref>]. PTI-CH was shown to bind directly to the poly(RC) binding protein 1 (PCBP1), whose interaction increased <italic toggle="yes">CFTR</italic> mRNA in the ER. This interaction appeared specific for the <italic toggle="yes">CFTR</italic> mRNA [<xref rid="B249-cells-11-01868" ref-type="bibr">249</xref>], though in a mutation-agnostic manner, as it was shown to stabilize both F508del, I1234V and WT mRNA [<xref rid="B248-cells-11-01868" ref-type="bibr">248</xref>,<xref rid="B250-cells-11-01868" ref-type="bibr">250</xref>]. Based on these promising results, the optimized amplifier PTI-428 (nesolicaftor), was tested together with potentiator PTI-808 and corrector PTI-801, in a phase 1/2 clinical trial in PwCF carrying F508del alleles (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03500263">NCT03500263</ext-link>). On average, an improvement in lung function of 8% was observed [<xref rid="B251-cells-11-01868" ref-type="bibr">251</xref>]. While the absolute improvement was lower compared to that of Trikafta&#8482;/Kaftrio&#8482;, rescue was highest in subgroups with the highest disease burden (+10&#8211;12%) or with poor response to previous CFTR modulators (+12%). Recently, these compounds (including the amplifier) were licensed so that development may continue [<xref rid="B252-cells-11-01868" ref-type="bibr">252</xref>].</p></sec><sec id="sec3dot3dot2-cells-11-01868"><title>3.3.2. miRNA Modulation</title><p>Post-transcriptional regulation of <italic toggle="yes">CFTR</italic> mRNA by microRNAs (miRNAs) may affect the number of available transcripts, as exemplified in the CF airway epithelium (reviewed in [<xref rid="B253-cells-11-01868" ref-type="bibr">253</xref>,<xref rid="B254-cells-11-01868" ref-type="bibr">254</xref>]). Among the miRNAs upregulated in PwCF, several were found to negatively regulate <italic toggle="yes">CFTR</italic> expression by interacting with the 3&#8242; untranslated region (UTR) of the <italic toggle="yes">CFTR</italic> mRNA, including miR-145-5p and miR-509-3p [<xref rid="B255-cells-11-01868" ref-type="bibr">255</xref>,<xref rid="B256-cells-11-01868" ref-type="bibr">256</xref>]. Inhibition of these miRNAs with peptide nucleic acids (PNA) directed against them resulted in increased expression of WT or F508del CFTR [<xref rid="B257-cells-11-01868" ref-type="bibr">257</xref>,<xref rid="B258-cells-11-01868" ref-type="bibr">258</xref>,<xref rid="B259-cells-11-01868" ref-type="bibr">259</xref>]. However, these strategies do not only inhibit the interaction between the miRNA and <italic toggle="yes">CFTR</italic> template, but also its interaction with other targets, potentially causing unwanted side-effects. To overcome this issue, De Santi and colleagues focused on the development of a <italic toggle="yes">CFTR-</italic>specific approach by blocking specific miRNA binding sites in the <italic toggle="yes">CFTR</italic> 3&#8242;UTR, the so-called target site blockers (TSBs) [<xref rid="B260-cells-11-01868" ref-type="bibr">260</xref>]. They showed that treatment with TSBs significantly enhanced rescue of F508del by VX-770 and VX-809/VX-661 in a CF bronchial epithelial cell line. </p></sec><sec id="sec3dot3dot3-cells-11-01868"><title>3.3.3. Nonsense Mediated mRNA Decay (NMD) Suppression</title><p>The majority of PwCF who are currently not eligible for causal CF therapies have one or two nonsense <italic toggle="yes">CFTR</italic> mutations. Approximately 5% of all CF alleles in the CFTR2 database are nonsense mutations, which create PTCs, giving rise to truncated proteins but also, in many cases, which prime the <italic toggle="yes">CFTR</italic> mRNA for NMD (<xref rid="cells-11-01868-f007" ref-type="fig">Figure 7</xref>; left panel). For a review on NMD in health and disease, we refer to [<xref rid="B261-cells-11-01868" ref-type="bibr">261</xref>]. A PTC can trigger NMD when it generates long 3&#8242;UTRs or when exon junction complexes (EJC) are formed downstream of the PTC. NMD reduces the amount of mutant <italic toggle="yes">CFTR</italic> mRNA and hampers subsequent rescue of the CFTR protein by other means, such as by TRIDs (<italic toggle="yes">discussed next</italic>) and by CFTR modulators [<xref rid="B262-cells-11-01868" ref-type="bibr">262</xref>,<xref rid="B263-cells-11-01868" ref-type="bibr">263</xref>]. The level of NMD differs not only between cell-types, but also depends on the specific PTC mutation. In addition to this, individual variation is at play, as seen between PwCF with the same genotype [<xref rid="B46-cells-11-01868" ref-type="bibr">46</xref>,<xref rid="B262-cells-11-01868" ref-type="bibr">262</xref>,<xref rid="B264-cells-11-01868" ref-type="bibr">264</xref>,<xref rid="B265-cells-11-01868" ref-type="bibr">265</xref>]. Clarke and colleagues reported that in primary nasal epithelial cells from 10 PwCF carrying the G542X/F508del genotype, mRNA expression of the G542X alleles was reduced by ~60% [<xref rid="B264-cells-11-01868" ref-type="bibr">264</xref>]. Differences in the abundance of the 3&#8242; and 5&#8242; of the <italic toggle="yes">CFTR</italic> mRNA suggest that some of the mRNA is partially degraded and not a suitable substrate for full-length protein translation [<xref rid="B46-cells-11-01868" ref-type="bibr">46</xref>]. Making sure that a sufficient amount of suitable <italic toggle="yes">CFTR</italic> mRNA is available is therefore the first important step towards effective treatments for PTC-induced CF (<xref rid="cells-11-01868-f007" ref-type="fig">Figure 7</xref>; right panel). Several strategies have been proposed in pre-clinical models to prevent NMD and enhance mRNA expression of PTC <italic toggle="yes">CFTR</italic> (reviewed in [<xref rid="B266-cells-11-01868" ref-type="bibr">266</xref>,<xref rid="B267-cells-11-01868" ref-type="bibr">267</xref>]). Inhibition of the NMD activator serine/threonine-protein kinase SMG1, via the small molecule inhibitor SMG1i, resulted in increased levels of G542X, W1282X and other PTC containing mRNAs in various models, including airway epithelial cells, primary rectal organoids and several CF animal models [<xref rid="B58-cells-11-01868" ref-type="bibr">58</xref>,<xref rid="B268-cells-11-01868" ref-type="bibr">268</xref>,<xref rid="B269-cells-11-01868" ref-type="bibr">269</xref>,<xref rid="B270-cells-11-01868" ref-type="bibr">270</xref>,<xref rid="B271-cells-11-01868" ref-type="bibr">271</xref>,<xref rid="B272-cells-11-01868" ref-type="bibr">272</xref>,<xref rid="B273-cells-11-01868" ref-type="bibr">273</xref>,<xref rid="B274-cells-11-01868" ref-type="bibr">274</xref>]. As SMG1 is active in other cellular processes besides NMD, its inhibition causes considerable toxicity, which likely precludes it from translation into a therapy [<xref rid="B272-cells-11-01868" ref-type="bibr">272</xref>,<xref rid="B275-cells-11-01868" ref-type="bibr">275</xref>]. Similarly, siRNA mediated knockdown of the regulator of nonsense transcripts, UPF1&#8212;which gets phosphorylated by SMG1 [<xref rid="B276-cells-11-01868" ref-type="bibr">276</xref>]&#8212;increased mRNA levels of exon 22 PTC mutations, increasing their overall response to other therapies [<xref rid="B277-cells-11-01868" ref-type="bibr">277</xref>]. In addition, inhibition of the interaction between UPF1 and SMG7 by small molecule NMDI-14, suppressed NMD and stabilized W1282X mRNA [<xref rid="B263-cells-11-01868" ref-type="bibr">263</xref>]. Some compounds, like the clinically approved drugs amlexanox and escin were suggested to provide dual NMD and PTC suppression [<xref rid="B272-cells-11-01868" ref-type="bibr">272</xref>,<xref rid="B278-cells-11-01868" ref-type="bibr">278</xref>,<xref rid="B279-cells-11-01868" ref-type="bibr">279</xref>]. All of these treatments, however, inhibit the NMD machinery in a non-<italic toggle="yes">CFTR</italic> specific manner, thereby posing potential unwanted side-effects related to unspecific NMD suppression. </p><p>A more targeted approach can therefore be achieved by designing antisense oligonucleotides (ASO) that bind the <italic toggle="yes">CFTR</italic> mRNA and prevent EJC deposition downstream of the PTC [<xref rid="B280-cells-11-01868" ref-type="bibr">280</xref>]. Alternatively, removal of the PTC from the mRNA allows the prevention of NMD. Both strategies were shown to rescue the W1282X mutation either by removing the gene downstream of the W1282X mutation (and thus removing the remaining EJCs) by means of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing [<xref rid="B281-cells-11-01868" ref-type="bibr">281</xref>] or by inducing skipping of exon 23 (CFTRex23del), in which W1282X is located, using ASOs [<xref rid="B282-cells-11-01868" ref-type="bibr">282</xref>,<xref rid="B283-cells-11-01868" ref-type="bibr">283</xref>,<xref rid="B284-cells-11-01868" ref-type="bibr">284</xref>]. Exon 23 is an in-frame exon [<xref rid="B284-cells-11-01868" ref-type="bibr">284</xref>], meaning that no additional mutations or frameshifts are introduced by the deletion of this exon. While CFTRex23del is hardly functional on its own, it can be rescued by CFTR modulators [<xref rid="B282-cells-11-01868" ref-type="bibr">282</xref>,<xref rid="B283-cells-11-01868" ref-type="bibr">283</xref>,<xref rid="B284-cells-11-01868" ref-type="bibr">284</xref>]. Whether this exon skipping strategy can also be applied to other PTC mutations outside of exon 23, remains to be investigated. In general, suppression of NMD will need to be paired with other strategies, such as TRIDs (<italic toggle="yes">see next section</italic>) and CFTR modulators, to reach sufficient levels of CFTR function (<xref rid="cells-11-01868-f007" ref-type="fig">Figure 7</xref>, right panel).</p></sec><sec id="sec3dot3dot4-cells-11-01868"><title>3.3.4. Translational Readthrough Inducing Drugs (TRIDs)</title><p>Saving the PTC mRNA molecules from degradation, however, is only the first hurdle to restoring the function of most PTC CFTR mutants. The PTC will still give rise to a truncated protein, which, in most cases, is not functional or responsive to CFTR modulators. Suppressing this premature translation termination would therefore be highly favorable. Aminoglycoside antibiotics such as gentamicin and G418 (geneticin) have been shown to promote translational read-through via near-cognate mispairing of an aminoacyl-tRNA with the PTC for several <italic toggle="yes">CFTR</italic> mutations in cell models and a G542X mouse model [<xref rid="B285-cells-11-01868" ref-type="bibr">285</xref>,<xref rid="B286-cells-11-01868" ref-type="bibr">286</xref>,<xref rid="B287-cells-11-01868" ref-type="bibr">287</xref>]. Trials in PwCF showed variable responses to treatment with aminoglycosides without prolonged clinical benefit [<xref rid="B288-cells-11-01868" ref-type="bibr">288</xref>,<xref rid="B289-cells-11-01868" ref-type="bibr">289</xref>,<xref rid="B290-cells-11-01868" ref-type="bibr">290</xref>]. In G542X mice, the aminoglycoside amikacin was more effective at suppressing premature translation termination compared to gentamicin [<xref rid="B291-cells-11-01868" ref-type="bibr">291</xref>]. However, rescue by tobramycin, another aminoglycoside antibiotic commonly prescribed in CF, was much more modest [<xref rid="B287-cells-11-01868" ref-type="bibr">287</xref>,<xref rid="B292-cells-11-01868" ref-type="bibr">292</xref>]. </p><p>The oxadiazole PTC124 (ataluren) was developed as a non-aminoglycoside alternative with TRID properties that promotes ribosomal readthrough of PTCs, but not normal termination codons [<xref rid="B293-cells-11-01868" ref-type="bibr">293</xref>]. This molecule was discovered in a generic HTS using a PTC-containing luciferase reporter. Currently, it is EMA approved to treat nonsense forms of Duchenne muscular dystrophy [<xref rid="B294-cells-11-01868" ref-type="bibr">294</xref>], but it was quickly also tested for treatment of PTC mutations causing CF [<xref rid="B295-cells-11-01868" ref-type="bibr">295</xref>]. While early clinical studies suggested a beneficial effect of PTC124 ([<xref rid="B296-cells-11-01868" ref-type="bibr">296</xref>,<xref rid="B297-cells-11-01868" ref-type="bibr">297</xref>,<xref rid="B298-cells-11-01868" ref-type="bibr">298</xref>] and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00237380">NCT00237380</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00351078">NCT00351078</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00458341">NCT00458341</ext-link>), ultimately no significant effect on lung function was observed in a Phase III trial ([<xref rid="B299-cells-11-01868" ref-type="bibr">299</xref>] and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00803205">NCT00803205</ext-link>). Interestingly, in rectal organoids of human or mouse origin, PTC124 also failed to rescue CFTR function [<xref rid="B300-cells-11-01868" ref-type="bibr">300</xref>,<xref rid="B301-cells-11-01868" ref-type="bibr">301</xref>]. Other oxadiazoles were shown to be more efficient than PTC124 in a Fisher rat thyroid (FRT) cell model [<xref rid="B302-cells-11-01868" ref-type="bibr">302</xref>,<xref rid="B303-cells-11-01868" ref-type="bibr">303</xref>], but for now, none have yet reached clinical testing.</p><p>Novel, synthetic aminoglycosides, such as NB54 and NB124 (ELX-02), had a more favorable toxicity and bio-availability profile compared to first generation aminoglycoside TRIDs [<xref rid="B304-cells-11-01868" ref-type="bibr">304</xref>,<xref rid="B305-cells-11-01868" ref-type="bibr">305</xref>,<xref rid="B306-cells-11-01868" ref-type="bibr">306</xref>]. The most promising TRID currently in clinical evaluation is ELX-02 [<xref rid="B307-cells-11-01868" ref-type="bibr">307</xref>]. Phase I trials have shown its safety ([<xref rid="B308-cells-11-01868" ref-type="bibr">308</xref>] and NCT0280796, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03292302">NCT03292302</ext-link>), and currently, Phase II trials are ongoing to evaluate its efficacy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04126473">NCT04126473</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04135495">NCT04135495</ext-link>). In contrast to PTC124, ELX-02 has been shown to restore CFTR function in G542X human rectal organoids [<xref rid="B309-cells-11-01868" ref-type="bibr">309</xref>]. Moreover, it was able to rescue several other PTC mutations in isogenic human bronchial cell lines (16HBEge) [<xref rid="B268-cells-11-01868" ref-type="bibr">268</xref>]. Here, ELX-02 was combined with several other treatments, including NMD suppressors, amplifiers, correctors and potentiators, to reach maximum functional rescue. </p><p>Indeed, preventing premature translation termination does not necessarily fix the resulting protein. Instead, it will often alter the nonsense mutation into a missense mutation, in the case that a non-native amino-acid is incorporated [<xref rid="B310-cells-11-01868" ref-type="bibr">310</xref>]. Which amino-acid is incorporated depends not only on the identity of the PTC, but also on the sequence context in which it resides. For example, while G542X and W1282X are both UGA PTCs, different amino-acids were found to be incorporated after treatment with TRIDs [<xref rid="B310-cells-11-01868" ref-type="bibr">310</xref>]. Similarly, G542X appears to be more responsive to TRIDS than W1282X due to differences in the respective sequence contexts [<xref rid="B311-cells-11-01868" ref-type="bibr">311</xref>]. To rescue the resulting missense mutations, many pre-clinical studies now focus on combining TRIDs with other classes of compounds, which in most cases synergistically improves functional rescue [<xref rid="B58-cells-11-01868" ref-type="bibr">58</xref>,<xref rid="B263-cells-11-01868" ref-type="bibr">263</xref>,<xref rid="B268-cells-11-01868" ref-type="bibr">268</xref>,<xref rid="B269-cells-11-01868" ref-type="bibr">269</xref>,<xref rid="B270-cells-11-01868" ref-type="bibr">270</xref>,<xref rid="B271-cells-11-01868" ref-type="bibr">271</xref>,<xref rid="B272-cells-11-01868" ref-type="bibr">272</xref>,<xref rid="B273-cells-11-01868" ref-type="bibr">273</xref>,<xref rid="B274-cells-11-01868" ref-type="bibr">274</xref>,<xref rid="B277-cells-11-01868" ref-type="bibr">277</xref>].</p><p>Recently, a HTS of &gt;750,000 compounds identified SRI-37240 and its more potent derivative SRI-4131 as novel TRIDs with a mechanism that is complementary to that of aminoglycosides and oxadiazoles [<xref rid="B312-cells-11-01868" ref-type="bibr">312</xref>]. These compounds prolong the translational pause at the PTC position in the transcript by reducing the abundance of translation termination factor eRF1, thereby promoting readthrough. Additionally, another HTS 1536-well platform to phenotypically screen specifically for G542X readthrough and subsequent rescue by CFTR modulators was recently published [<xref rid="B313-cells-11-01868" ref-type="bibr">313</xref>]. Other novel strategies have focused in particular on restoring native amino-acid incorporation. Using anticodon engineered (ACE)-tRNAs, this could indeed be achieved for G542X, R1162X (c.3484C&gt;T) and W1282X without disrupting physiological termination codons [<xref rid="B314-cells-11-01868" ref-type="bibr">314</xref>,<xref rid="B315-cells-11-01868" ref-type="bibr">315</xref>].</p></sec></sec><sec id="sec3dot4-cells-11-01868"><title>3.4. Producing Correct CFTR</title><p>The previously discussed strategies have focused on enhancing CFTR production, trafficking, function and stabilization. Alternatively, rather than repairing an &#8220;impaired&#8221; CFTR protein, one might circumvent this by providing either a new &#8220;blueprint&#8221; to generate WT-CFTR or by repairing the mutation on the mRNA or DNA level (<xref rid="cells-11-01868-f008" ref-type="fig">Figure 8</xref>). The final strategies we will discuss in this review will focus on restoring the production of WT-CFTR as a causal treatment for CF. </p></sec><sec id="sec3dot4dot1-cells-11-01868"><title>3.4.1. mRNA Repair</title><p>Two decades ago, it was shown in a minigene model and in F508del bronchial epithelial cells that the <italic toggle="yes">CFTR</italic> pre-mRNA could be repaired by the use of spliceosome-mediated RNA <italic toggle="yes">trans-</italic>splicing (SMaRT) with a super-exon for exons 11&#8211;27 (10&#8211;24 in the old nomenclature) [<xref rid="B316-cells-11-01868" ref-type="bibr">316</xref>,<xref rid="B317-cells-11-01868" ref-type="bibr">317</xref>]. The super-exon contains multiple exons and replaces the sequence downstream of the <italic toggle="yes">trans-</italic>splice site on the mRNA, inserting the CUU that is missing in F508del. While this repair was aimed at F508del, it could be extrapolated to other mutations located in exons 11&#8211;27. A duplex of two short single complementary-strand oligonucleotides that were constructed to repair the F508del mutation also led to phenotypic recovery of channel currents in F508del overexpressing cells [<xref rid="B318-cells-11-01868" ref-type="bibr">318</xref>]. One of these oligos was further developed into eluforsen (QR-010), a 33 nt ASO, which restored F508del-CFTR function in a differentiated airway epithelium and in F508del mice [<xref rid="B319-cells-11-01868" ref-type="bibr">319</xref>]. The mechanism by which the antisense oligo corrected the F508del mRNA remains unknown. Eluforsen was administered via inhalation in two small trials to F508del homozygous PwCF (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02532764">NCT02532764</ext-link> &amp; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02564354">NCT02564354</ext-link>). While treatment was well tolerated and the respiratory symptom score (CFQ-R RSS) and CFTR currents, as measured by nasal potential difference (NPD), improved, no significant change in lung function was obtained four weeks after treatment [<xref rid="B320-cells-11-01868" ref-type="bibr">320</xref>,<xref rid="B321-cells-11-01868" ref-type="bibr">321</xref>], leading to a halt in further clinical development to date. </p><p>mRNA repair strategies have not solely focused on F508del, though. Using an engineered site-directed RNA editase, the W496X (c.1487G&gt;A) mRNA expressed in <italic toggle="yes">Xenopus</italic> oocytes, could be corrected [<xref rid="B322-cells-11-01868" ref-type="bibr">322</xref>]. More recently, Melfi and colleagues edited the W1282X mRNA in cell lines using &#8220;REPAIRv2&#8221; (RNA Editing for Programmable A to I Replacement, version 2), a CRISPR/dCas13b-based molecular tool which allows mRNA editing of adenosines to inosines, which are read as guanosines [<xref rid="B323-cells-11-01868" ref-type="bibr">323</xref>]. However, the editing efficiency would need to be further optimized in order to reach sufficient rescue. </p><p>Class V <italic toggle="yes">CFTR</italic> mutations cause cryptic splice sites, which lead to the insertion of additional nucleotides into the mRNA. Although a fraction of the <italic toggle="yes">CFTR</italic> mRNA is correctly spliced and creates WT-CFTR channels, this is usually not enough to ameliorate CF symptoms. Restoring the correct splicing of these mutations would therefore be a promising therapeutic approach as well. Splice altering ASOs are already used in the clinic, for example to treat spinal muscle atrophy (nusinersen/Spinraza&#8482;) [<xref rid="B324-cells-11-01868" ref-type="bibr">324</xref>]. In CF, splice altering ASOs were shown to correct the 2789+5G&gt;A (c.2657+5G&gt;A) [<xref rid="B325-cells-11-01868" ref-type="bibr">325</xref>] and 3849+10kbC&gt;T [<xref rid="B326-cells-11-01868" ref-type="bibr">326</xref>,<xref rid="B327-cells-11-01868" ref-type="bibr">327</xref>,<xref rid="B328-cells-11-01868" ref-type="bibr">328</xref>] mutations. The clinical candidate ASO SPL84-23 was able to rescue CFTR expression and function in primary bronchial and nasal epithelial cells to ~40% of WT [<xref rid="B328-cells-11-01868" ref-type="bibr">328</xref>], received orphan drug designation recently by both the FDA and EMA, and a first clinical trial is planned for the end of 2022 [<xref rid="B329-cells-11-01868" ref-type="bibr">329</xref>].</p></sec><sec id="sec3dot4dot2-cells-11-01868"><title>3.4.2. mRNA Therapy</title><p>One alternative to mRNA editing is to bypass the mutated mRNA altogether and provide a WT-transcript instead. In this way, by producing WT-CFTR, the CF phenotype can be reversed. As this approach is mutation agnostic, e.g., not dependent on the <italic toggle="yes">CFTR</italic> genotype, it can potentially be used for all PwCF. Delivery of the mRNA molecules to the right cells, however, is one of the major challenges for mRNA replacement therapy in CF and in general [<xref rid="B330-cells-11-01868" ref-type="bibr">330</xref>]. Besides the need to be safe, reliable and efficient, the mRNA should be stable enough to allow sufficient translation [<xref rid="B331-cells-11-01868" ref-type="bibr">331</xref>]. For an in-depth discussion on mRNA delivery we refer to [<xref rid="B330-cells-11-01868" ref-type="bibr">330</xref>,<xref rid="B331-cells-11-01868" ref-type="bibr">331</xref>]. The use of mRNA in medicine has taken a tremendous flight with the implementation of mRNA vaccines against SARS-CoV-2 (reviewed in [<xref rid="B332-cells-11-01868" ref-type="bibr">332</xref>]). For CF, the first-in-man therapeutic mRNA trial (RESTORE-CF) is currently underway (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03375047">NCT03375047</ext-link>). MRT5005 is a WT, modified <italic toggle="yes">CFTR</italic> mRNA that is provided to airway cells via nebulization [<xref rid="B333-cells-11-01868" ref-type="bibr">333</xref>,<xref rid="B334-cells-11-01868" ref-type="bibr">334</xref>]. The most recent interim results suggest that multiple doses of the mRNA treatment are safe and well tolerated, although at this stage no change in lung function was observed [<xref rid="B333-cells-11-01868" ref-type="bibr">333</xref>]. The mRNA sequence and lipid nanoparticle delivery vehicle have received further optimization and are planned to be tested in a clinical trial in the near future as a next generation mRNA therapeutic [<xref rid="B333-cells-11-01868" ref-type="bibr">333</xref>]. ARCT-032 (LUNAR-CF), another nebulized mRNA replacement therapy, is also in preparation for clinical testing [<xref rid="B335-cells-11-01868" ref-type="bibr">335</xref>]. Recent preclinical work showed that chitosan nanoparticles, loaded with both the <italic toggle="yes">WT</italic>-<italic toggle="yes">CFTR</italic> mRNA and capsaicin, the latter blocking the epithelial sodium channel ENaC that is hyperactive in CF, could normalize both CFTR and ENaC function [<xref rid="B336-cells-11-01868" ref-type="bibr">336</xref>]. The novelty of this strategy lies in its ability to target two CF-related defects simultaneously. </p></sec><sec id="sec3dot4dot3-cells-11-01868"><title>3.4.3. Targeting the DNA&#8212;Towards a Cure for CF</title><p>Up to now, we have discussed strategies targeting either the CFTR protein or its mRNA. However, none of these therapies will be able to cure CF. As long as the underlying defect, e.g., the mutation within the <italic toggle="yes">CFTR</italic> gene, remains present, so will the disease. If protein or mRNA therapies are suspended, the disease will return in full force. In fact, VX-770 withdrawal syndrome has been described in PwCF with the G551D mutation after cessation of Kalydeco&#8482; treatment [<xref rid="B337-cells-11-01868" ref-type="bibr">337</xref>]. In addition, the currently available CFTR modulator treatments have not been able to fully halt disease progression. Long term follow-up studies of Kalydeco&#8482;&#8212;which has been on the market the longest, since 2012&#8212;have shown that lung function continues to decline, although at a slower pace compared to the control group [<xref rid="B108-cells-11-01868" ref-type="bibr">108</xref>]. Gene therapy thus holds potential to cure PwCF. Ever since the discovery of the <italic toggle="yes">CFTR</italic> gene in 1989, this has somewhat been the holy grail of causal CF therapies. Recently, the Cystic Fibrosis Foundation announced its &#8220;Path to a Cure&#8221;, which aims to find a curative treatment for all PwCF [<xref rid="B338-cells-11-01868" ref-type="bibr">338</xref>]. </p><p>Early DNA targeting efforts focused on the delivery of a <italic toggle="yes">WT</italic>-<italic toggle="yes">CFTR</italic> cDNA to airway cells. Unfortunately, clinical trials with these gene addition therapies were not able to substantially improve lung function in PwCF (reviewed in [<xref rid="B339-cells-11-01868" ref-type="bibr">339</xref>,<xref rid="B340-cells-11-01868" ref-type="bibr">340</xref>,<xref rid="B341-cells-11-01868" ref-type="bibr">341</xref>]). This disappointment resulted in a shift away from gene therapy approaches for a while, but more recently, interest has been revived. Using optimized constructs and delivery methods, effective gene therapy has been shown in a number of CF models [<xref rid="B342-cells-11-01868" ref-type="bibr">342</xref>,<xref rid="B343-cells-11-01868" ref-type="bibr">343</xref>,<xref rid="B344-cells-11-01868" ref-type="bibr">344</xref>,<xref rid="B345-cells-11-01868" ref-type="bibr">345</xref>]. The most recent gene therapy clinical trial by Alton et al. demonstrated that liposome delivery of <italic toggle="yes">CFTR</italic> cDNA stabilized lung function in treated patients, whereas a further decline was observed in the placebo group [<xref rid="B346-cells-11-01868" ref-type="bibr">346</xref>]. As the clinical effect was considered modest, current efforts are focused on a F/HN-pseudotyped lentiviral vector to deliver <italic toggle="yes">CFTR</italic> cDNA to patients&#8217; airways (BI 3720931, [<xref rid="B344-cells-11-01868" ref-type="bibr">344</xref>]). The first clinical trial for this viral vector-based gene addition therapy as well as several more developed by other groups are currently being planned [<xref rid="B347-cells-11-01868" ref-type="bibr">347</xref>,<xref rid="B348-cells-11-01868" ref-type="bibr">348</xref>,<xref rid="B349-cells-11-01868" ref-type="bibr">349</xref>]. </p><p>Besides gene addition, gene editing, e.g., &#8220;rewriting&#8221; the mutation in the genome to the WT sequence, has gained a lot of traction over the last couple of years. The Nobel Prize for Chemistry in 2020 was awarded to Jennifer Doudna and Emmanuelle Charpentier for their discovery of the CRISPR/Cas9 system&#8212;the most versatile and commonly used gene editing technique [<xref rid="B350-cells-11-01868" ref-type="bibr">350</xref>,<xref rid="B351-cells-11-01868" ref-type="bibr">351</xref>]. It has been successfully employed in correcting <italic toggle="yes">CFTR</italic> mutations in translational cell models, such as rectal organoids [<xref rid="B352-cells-11-01868" ref-type="bibr">352</xref>,<xref rid="B353-cells-11-01868" ref-type="bibr">353</xref>,<xref rid="B354-cells-11-01868" ref-type="bibr">354</xref>] and airway epithelial progenitor (basal) cells [<xref rid="B355-cells-11-01868" ref-type="bibr">355</xref>,<xref rid="B356-cells-11-01868" ref-type="bibr">356</xref>]. We recently reviewed gene editing in CF and its potential for therapeutic approaches and model generation in detail. Therefore, we refer to [<xref rid="B267-cells-11-01868" ref-type="bibr">267</xref>,<xref rid="B357-cells-11-01868" ref-type="bibr">357</xref>] for an extensive discussion on the subject. </p></sec></sec><sec id="sec4-cells-11-01868"><title>4. Towards the Future: Personalizing Therapies for PwCF</title><p>In the previous section, we have provided an overview on the past and ongoing efforts in the development of novel causal therapies for CF. The majority of these efforts has focused on providing an effective therapy for F508del. This is not surprising, as such a therapy is able to treat ~85% of all PwCF. On top of that, the first market approval of a highly effective therapeutic strategy only became available as recent as 2019 (2020 in Europe) with the FDA and EMA approval of Trikafta&#8482;/Kaftrio&#8482; for PwCF with one F508del allele. Previously, Orkambi&#8482; and Symdeko&#8482;/Symkevi&#8482; had already been approved for F508del homozygous PwCF, but with modest effects compared to Trikafta&#8482;/Kaftrio&#8482;. While the main focus for causal treatments has mostly been directed towards F508del, G551D became the first <italic toggle="yes">CFTR</italic> mutation for which a causal treatment (Kalydeco&#8482;) was market approved [<xref rid="B61-cells-11-01868" ref-type="bibr">61</xref>]. After additional clinical trials, treatment was extended for 9 more mutations both in the USA and Europe: R117H (c.350G&gt;A; 3rd most common mutation in the United States), G1244E (c.3731G&gt;A), G1349D (c.4046G&gt;A), G178R (c.532G&gt;A), G551S (c.1651G&gt;A), S1251N (c.3752G&gt;A), S1255P (c.3763T&gt;C), S549N (c.1646G&gt;A) and S549R (c.1645A&gt;C) [<xref rid="B63-cells-11-01868" ref-type="bibr">63</xref>,<xref rid="B358-cells-11-01868" ref-type="bibr">358</xref>]. G970R (c.2908G&gt;C) was also evaluated, but no improvements were observed for this mutation [<xref rid="B63-cells-11-01868" ref-type="bibr">63</xref>]. It was later shown that this particular mutant causes a previously undetected splicing defect rather than a gating defect, which precludes efficient rescue by CFTR potentiators [<xref rid="B359-cells-11-01868" ref-type="bibr">359</xref>]. Nevertheless, of importance was the fact that pre-clinical models, and more particularly, Fischer rat thyroid (FRT) cells overexpressing the respective mutations from a cDNA copy, were able to predict the outcomes for eight out of nine gating <italic toggle="yes">CFTR</italic> mutations tested [<xref rid="B63-cells-11-01868" ref-type="bibr">63</xref>,<xref rid="B109-cells-11-01868" ref-type="bibr">109</xref>]. These first label extensions were limited to <italic toggle="yes">CFTR</italic> mutations that were still (relatively) frequent in the sense that they allowed at least two PwCF per genotype to be included in the clinical study, and that their defects&#8212;at least to some extent&#8212;had been studied preclinically first. </p><sec id="sec4dot1-cells-11-01868"><title>4.1. Theratyping &amp; Expanding the Label for Existing Therapies</title><p>There are hundreds of <italic toggle="yes">CFTR</italic> mutations which are present only in a handful of PwCF and which have not or minimally been characterized. This poses two problems. First, as these mutations remain uncharacterized, how can the right therapeutic strategy be selected? On the one hand, the CFTR2 project aims to confirm and determine which of the &gt;2100 mutations described to date in the <italic toggle="yes">CFTR</italic> gene are disease-causing or rather, polymorphisms or disease modifiers [<xref rid="B360-cells-11-01868" ref-type="bibr">360</xref>]. Full characterization via in-depth study of the folding, trafficking, function and stability of each mutation (a summary of these efforts is provided in [<xref rid="B54-cells-11-01868" ref-type="bibr">54</xref>]), would of course provide the best understanding of each mutation&#8217;s molecular defect, but might not be feasible to perform on thousands of mutations. Moreover, in order to be able to treat PwCF, it is more important to know whether particular mutations respond to certain treatments. Therefore, CFTR modulator therapy is now often tested directly on patient-derived material, a strategy called theratyping [<xref rid="B361-cells-11-01868" ref-type="bibr">361</xref>]. It allows us to (1) predict individual responsiveness to treatment (personalized medicine) and (2) gain insight into molecular mechanisms of rare mutations based on modulator responses [<xref rid="B361-cells-11-01868" ref-type="bibr">361</xref>]. One example of the use of theratyping is the ongoing European H2020 HIT-CF project (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hitcf.org/">https://www.hitcf.org/</uri> (accessed on 10 May 2022)), in which novel CFTR modulators are tested in human rectal organoids with rare genotypes and in vitro responders are selected for specific clinical trials, with hopes of bringing causal therapies to small, specific PwCF populations with rare mutations [<xref rid="B362-cells-11-01868" ref-type="bibr">362</xref>]. CFTR modulator responses are measured in the so-called forskolin induced swelling (FIS) assay [<xref rid="B363-cells-11-01868" ref-type="bibr">363</xref>]. Application of forskolin to these 3D, self-organizing organoid structures results in the rapid increase in organoid area, in the case that CFTR is functional. This process is dependent solely on CFTR, which is located at the apical membrane facing the organoid lumen and regulates paracellular water transport that causes the swelling of organoids. FIS responses have been shown to correlate well with clinical parameters such as the FEV<sub>1</sub> (forced expiratory volume in one second, a measure for lung function) [<xref rid="B364-cells-11-01868" ref-type="bibr">364</xref>,<xref rid="B365-cells-11-01868" ref-type="bibr">365</xref>]. FIS can also be performed on organoids of airway origin, but due to the presence of other ion channels in the airways, the swelling is less CFTR specific and thus less straightforward to interpret [<xref rid="B366-cells-11-01868" ref-type="bibr">366</xref>]. Rectal organoids can be obtained via minimally invasive rectum biopsies and can be expanded rapidly and near infinitely, as such providing an advantage over other state of the art cell models, such as HBE (from explant lungs) or human nasal epithelial cells (HNE; from nasal brushings). The former are, when grown at air liquid interface (ALI), considered the golden standard for pre-clinical evaluation of CFTR function via short circuit current (I<sub>SC</sub>) measurements in Ussing chambers before moving towards clinical trials (for example [<xref rid="B90-cells-11-01868" ref-type="bibr">90</xref>]). Clancy and colleagues remarked that HBE analysis was missing for therapies that ultimately failed in clinical trials such as PTC124 and cavosonstat (<italic toggle="yes">see <xref rid="sec3dot3dot4-cells-11-01868" ref-type="sec">Section 3.3.4</xref>. TRIDs &amp; <xref rid="sec3dot2dot3-cells-11-01868" ref-type="sec">Section 3.2.3</xref>. Stabilizers</italic> [<xref rid="B361-cells-11-01868" ref-type="bibr">361</xref>]). HBE, however, typically originate from end-stage disease tissue and are therefore not easily available for rarer genotypes [<xref rid="B367-cells-11-01868" ref-type="bibr">367</xref>]. HNE, on the other hand, do not have the above limitations and also have been shown to predict CFTR modulator responses [<xref rid="B368-cells-11-01868" ref-type="bibr">368</xref>], although the culturing is technically more challenging, requiring an important expansion step prior to testing [<xref rid="B361-cells-11-01868" ref-type="bibr">361</xref>]. The RARE project is an ongoing clinical trial which aims to collect intestinal and nasal cells of PwCF with rare mutations for future theratyping efforts (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03161808">NCT03161808</ext-link>). Finally, also iPSC-derived airway models can be applied for theratyping [<xref rid="B369-cells-11-01868" ref-type="bibr">369</xref>]. </p><p>The second question is: how can the efficacy of a treatment for rare genotypes be proven? The many rare to ultra-rare CF-causing mutations do not allow for classical clinical trial designs due to the small number of PwCF for each mutation. Alternative strategies are thus needed for label extension or novel therapies targeted towards the rare <italic toggle="yes">CFTR</italic> genotypes. For Kalydeco&#8482;, Symdeko&#8482;, and Trikafta&#8482; label extension, the FDA therefore based itself on pre-clinical data from FRT cells overexpressing <italic toggle="yes">CFTR</italic> variants to guide its decision [<xref rid="B62-cells-11-01868" ref-type="bibr">62</xref>,<xref rid="B64-cells-11-01868" ref-type="bibr">64</xref>]. As a result, 97 mutations are now eligible for Kalydeco&#8482; [<xref rid="B65-cells-11-01868" ref-type="bibr">65</xref>], 155 for Symdeko&#8482; [<xref rid="B370-cells-11-01868" ref-type="bibr">370</xref>] and 178 for Trikafta&#8482; [<xref rid="B371-cells-11-01868" ref-type="bibr">371</xref>]. In total, 184 <italic toggle="yes">CFTR</italic> mutations thus have modulator therapy approved (there is overlap between the mutations approved for each treatment), but it is important to note that not all the mutations listed are considered CF-causing according to the CFTR2 database. To date, label extension based on pre-clinical data has not yet been followed by the EMA.</p></sec><sec id="sec4dot2-cells-11-01868"><title>4.2. What Is in the Pipeline for the Last 15% of PwCF without Causal Treatment?</title><p>Now that highly effective CFTR modulator therapy is available for the majority of PwCF, the focus has shifted towards the ~15% of PwCF who carry two alleles still without causal treatments, e.g., non-F508del, non-gating, non-residual function and non-rescuable by Trikafta&#8482;/Kaftrio&#8482;. While this group encompasses many, many rare and ultra-rare mutations, it is noticeable that of the top five most common <italic toggle="yes">CFTR</italic> mutations, only F508del (1st) and G551D (3rd) have an approved causal therapy to date. </p><p>N1303K (4th) and I507del (c.1519-1521delATC; 11th) are two processing mutations with allele frequencies &gt;0.5% that are not yet approved for modulator therapy [<xref rid="B59-cells-11-01868" ref-type="bibr">59</xref>,<xref rid="B119-cells-11-01868" ref-type="bibr">119</xref>,<xref rid="B371-cells-11-01868" ref-type="bibr">371</xref>,<xref rid="B372-cells-11-01868" ref-type="bibr">372</xref>]. In particular, N1303K has been investigated extensively [<xref rid="B373-cells-11-01868" ref-type="bibr">373</xref>]. In recent years, modest rescue was observed by modulator combinations in multiple cell models [<xref rid="B114-cells-11-01868" ref-type="bibr">114</xref>,<xref rid="B119-cells-11-01868" ref-type="bibr">119</xref>,<xref rid="B138-cells-11-01868" ref-type="bibr">138</xref>,<xref rid="B374-cells-11-01868" ref-type="bibr">374</xref>,<xref rid="B375-cells-11-01868" ref-type="bibr">375</xref>]. A case study reported a clinical benefit in one N1303K carrying PwCF with Trikafta&#8482;/Kaftrio&#8482; treatment after 10 months, without a clear reduction in sweat chloride [<xref rid="B375-cells-11-01868" ref-type="bibr">375</xref>]. A clinical trial is currently ongoing to test its efficacy in 20 PwCF with the N1303K mutation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03506061">NCT03506061</ext-link>). R334W is a Class IV conductance mutation that is associated with some residual function and a milder form of CF. Nevertheless, it is currently not approved for modulator therapy as its in vitro rescue by Kalydeco&#8482; was below the set threshold of &gt;10% of WT in order to allow label extension [<xref rid="B65-cells-11-01868" ref-type="bibr">65</xref>,<xref rid="B109-cells-11-01868" ref-type="bibr">109</xref>]. Based on positive results in rectal organoids, a small clinical trial will test CFTR modulator therapy for this mutation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04254705">NCT04254705</ext-link>). </p><p>PTC mutations G542X (2nd) and W1282X (5th) have become major targets for the development of CF causal strategies. Novel therapies are currently in pre-clinical and clinical development to tackle the specific defects associated with PTCs, i.e., NMD inhibition and TRIDs (<italic toggle="yes">see <xref rid="sec3dot3dot3-cells-11-01868" ref-type="sec">Section 3.3.3</xref>. NMD Inhibition &amp; <xref rid="sec3dot3dot4-cells-11-01868" ref-type="sec">Section 3.3.4</xref>. TRIDs</italic>). As it is unlikely that NMD inhibition and TRIDs will fully be able to rescue nonsense CFTR, they will likely be combined with modulator therapy already on the market, such as Trikafta&#8482;/Kaftrio&#8482;. Pre-clinical studies so far suggest that TRIDs are also able to rescue rarer mutations such as Y122X (c.336T&gt;A), R553X (c.1657C&gt;T) and R1162X [<xref rid="B268-cells-11-01868" ref-type="bibr">268</xref>].</p><p>What remains are the &#8220;unrescuable&#8221; mutations. On the one hand, this comprises canonical splice mutations such as 621+1G-&gt;T and 1717-1G-&gt;A, the 7th and 8th most common <italic toggle="yes">CFTR</italic> mutations, respectively. In contrast to cryptic splice mutations with various degrees of alternative splicing, thereby retaining a proportion of correctly spliced mRNA, this fraction is almost non-existent with canonical splice mutations. Exons get alternatively spliced or skipped altogether, and the &#8220;blueprint&#8221; for the CFTR protein is gone [<xref rid="B376-cells-11-01868" ref-type="bibr">376</xref>]. In addition, in contrast to cryptic splice mutations, which are located further away from exon boundaries and therefore allow splice site modulation more easily, little progress has been made in repairing canonical splice mutations. As discussed above, splice-altering ASOs are expected to enter clinical trials soon [<xref rid="B329-cells-11-01868" ref-type="bibr">329</xref>,<xref rid="B377-cells-11-01868" ref-type="bibr">377</xref>], but for canonical splice mutations, it is more likely that precision gene editing will be needed to re-write the mutation to its WT sequence. To date, cryptic splice sites have been removed by knocking-out the mutation and surrounding sequence using CRISPR/Cas9 and Cas12a approaches [<xref rid="B352-cells-11-01868" ref-type="bibr">352</xref>,<xref rid="B378-cells-11-01868" ref-type="bibr">378</xref>]. These Cas-induced targeted, double stranded DNA breaks and subsequent DNA repair by non-homologous end-joining lead to effective knockout (KO) of the cryptic splice site by indel (insertion-deletion) formation, which is possible due to their location sufficiently deep inside an intron. Since canonical splice mutations reside right at exon-intron boundaries, KO by indel formation is not precise enough and hence not an option. Base or prime editing, both CRISPR-derived gene editing technologies (reviewed in [<xref rid="B267-cells-11-01868" ref-type="bibr">267</xref>,<xref rid="B357-cells-11-01868" ref-type="bibr">357</xref>]), allow to make precise, targeted edits in the genome, and are more likely able to correct these mutations. In that regard, successful adenine base editing has already been already reported for correcting nonsense mutations in <italic toggle="yes">CFTR</italic> [<xref rid="B354-cells-11-01868" ref-type="bibr">354</xref>,<xref rid="B379-cells-11-01868" ref-type="bibr">379</xref>]. In addition, frameshift mutations caused by small indels might be rescued by base or prime editing approaches in the future. Collectively, these CRISPR/Cas technologies have, to date, mainly focused on the repair of F508del, PTC mutations and 3849+10kbC&gt;T [<xref rid="B353-cells-11-01868" ref-type="bibr">353</xref>,<xref rid="B354-cells-11-01868" ref-type="bibr">354</xref>,<xref rid="B379-cells-11-01868" ref-type="bibr">379</xref>], and can be further expanded to study the repair of most <italic toggle="yes">CFTR</italic> mutations (reviewed in [<xref rid="B267-cells-11-01868" ref-type="bibr">267</xref>]). Larger deletions, however, such as the 21kb deletion mutation CFTRdele2,3 cannot be targeted by this type of strategy and will require other corrective means such as gene addition (reviewed in [<xref rid="B339-cells-11-01868" ref-type="bibr">339</xref>]), super-exon insertion (see [<xref rid="B356-cells-11-01868" ref-type="bibr">356</xref>,<xref rid="B380-cells-11-01868" ref-type="bibr">380</xref>] for examples, although neither super-exon designs include the region deleted in CFTRdele2,3), stimulation of alternative chloride channels or ENaC inhibition (reviewed in [<xref rid="B381-cells-11-01868" ref-type="bibr">381</xref>,<xref rid="B382-cells-11-01868" ref-type="bibr">382</xref>]). While gene editing has reached the clinic for several diseases (for an overview of its clinical development we refer to [<xref rid="B383-cells-11-01868" ref-type="bibr">383</xref>,<xref rid="B384-cells-11-01868" ref-type="bibr">384</xref>]), this is not yet the case for CF. </p></sec></sec><sec sec-type="conclusions" id="sec5-cells-11-01868"><title>5. Conclusions</title><p>In this review, we have aimed to cover the diversity of <italic toggle="yes">CFTR</italic> mutations and the different therapeutic approaches that have been, and are currently being, developed to rescue all mutations. The driving force behind the dedicated CF community is to find a treatment and eventually a cure for all PwCF. Tremendous progress has been made since the first description of the <italic toggle="yes">CFTR</italic> gene in 1989, which has led to the approval of four CFTR modulator therapies in the last decade. With these, PwCF carrying one F508del allele, or one of the additional 183 approved mutations can be treated. The focus has now shifted to providing causal treatment for the remaining 15% of PwCF. For PwCF carrying PTC mutations, a novel TRID is currently being clinically evaluated. NMD inhibition strategies have taken flight, although they have not yet reached the clinical stage yet. Rapid advances in the field of gene editing might, for the first time, provide a way to treat the underlying gene defect in mutations previously considered unrescuable. New gene and mRNA replacement clinical trials are planned that could provide a mutation agnostic approach for all PwCF. Novel CFTR modulators are being developed to improve CFTR rescue and reduce side effects, as well as proteostasis modulators, stabilizers and amplifiers. All in all, exciting times remain ahead for the causal treatment of CF.</p></sec></body><back><ack><title>Acknowledgments</title><p>Biorender was used to generate figures.</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.S.C. and M.M.E. conceptualized the review; M.M.E. wrote the first draft of the manuscript and made the figures; M.S.C. revised the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-cells-11-01868"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Zolin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orenti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naerlich</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Rens</surname><given-names>J.</given-names></name></person-group><source>ECFSPR Annual Report 2018</source><publisher-name>European Cystic Fibrosis Society</publisher-name><publisher-loc>Karup, Denmark</publisher-loc><year>2020</year></element-citation></ref><ref id="B2-cells-11-01868"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>CFF</collab></person-group><source>Cystic Fibrosis Foundation Patient Registry</source><comment>2019 Annual Data Report</comment><publisher-name>Bethesda</publisher-name><publisher-loc>Rockville, MD, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B3-cells-11-01868"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name></person-group><article-title>Cystic fibrosis in the year 2020: A disease with a new face</article-title><source>Acta Paediatr.</source><year>2020</year><volume>109</volume><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1111/apa.15155</pub-id><pub-id pub-id-type="pmid">31899933</pub-id></element-citation></ref><ref id="B4-cells-11-01868"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verleden</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lammertyn</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>McDonough</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Verschakelen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kemner-van de Corput</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tiddens</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Proesmans</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Morphometric Analysis of Explant Lungs in Cystic Fibrosis</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2016</year><volume>193</volume><fpage>516</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1164/rccm.201507-1281OC</pub-id><pub-id pub-id-type="pmid">26551917</pub-id></element-citation></ref><ref id="B5-cells-11-01868"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ronan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Elborn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Plant</surname><given-names>B.J.</given-names></name></person-group><article-title>Current and emerging comorbidities in cystic fibrosis</article-title><source>La Presse M&#233;dicale</source><year>2017</year><volume>46</volume><fpage>e125</fpage><lpage>e138</lpage><pub-id pub-id-type="doi">10.1016/j.lpm.2017.05.011</pub-id><pub-id pub-id-type="pmid">28554721</pub-id></element-citation></ref><ref id="B6-cells-11-01868"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saint-Criq</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>M.A.</given-names></name></person-group><article-title>Role of CFTR in epithelial physiology</article-title><source>Cell. Mol. Life Sci.</source><year>2017</year><volume>74</volume><fpage>93</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2391-y</pub-id><pub-id pub-id-type="pmid">27714410</pub-id><pub-id pub-id-type="pmcid">PMC5209439</pub-id></element-citation></ref><ref id="B7-cells-11-01868"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borowitz</surname><given-names>D.</given-names></name></person-group><article-title>CFTR, bicarbonate, and the pathophysiology of cystic fibrosis</article-title><source>Pediatric Pulmonol.</source><year>2015</year><volume>50</volume><issue>(Suppl. 40)</issue><fpage>S24</fpage><lpage>S30</lpage><pub-id pub-id-type="doi">10.1002/ppul.23247</pub-id><pub-id pub-id-type="pmid">26335950</pub-id></element-citation></ref><ref id="B8-cells-11-01868"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abou Alaiwa</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Reznikov</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Gansemer</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Sheets</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Horswill</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Stoltz</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Zabner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>M.J.</given-names></name></person-group><article-title>pH modulates the activity and synergism of the airway surface liquid antimicrobials &#946;-defensin-3 and LL-37</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>18703</fpage><lpage>18708</lpage><pub-id pub-id-type="doi">10.1073/pnas.1422091112</pub-id><pub-id pub-id-type="pmid">25512526</pub-id><pub-id pub-id-type="pmcid">PMC4284593</pub-id></element-citation></ref><ref id="B9-cells-11-01868"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simonin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bille</surname><given-names>E.</given-names></name><name name-style="western"><surname>Crambert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Noel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dreano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hatton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pranke</surname><given-names>I.</given-names></name><name name-style="western"><surname>Villeret</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cottart</surname><given-names>C.-H.</given-names></name><etal/></person-group><article-title>Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>6516</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-42751-4</pub-id><pub-id pub-id-type="pmid">31019198</pub-id><pub-id pub-id-type="pmcid">PMC6482305</pub-id></element-citation></ref><ref id="B10-cells-11-01868"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Law</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>R.D.</given-names></name></person-group><article-title>Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: A review</article-title><source>J. Inflamm.</source><year>2017</year><volume>14</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s12950-017-0176-1</pub-id><pub-id pub-id-type="pmcid">PMC5745605</pub-id><pub-id pub-id-type="pmid">29299029</pub-id></element-citation></ref><ref id="B11-cells-11-01868"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyczak</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Pier</surname><given-names>G.B.</given-names></name></person-group><article-title>Lung Infections Associated with Cystic Fibrosis</article-title><source>Clin. Microbiol. Rev.</source><year>2002</year><volume>15</volume><fpage>194</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1128/CMR.15.2.194-222.2002</pub-id><pub-id pub-id-type="pmid">11932230</pub-id><pub-id pub-id-type="pmcid">PMC118069</pub-id></element-citation></ref><ref id="B12-cells-11-01868"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Csan&#225;dy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vergani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gadsby</surname><given-names>D.C.</given-names></name></person-group><article-title>Structure, Gating, and Regulation of the CFTR Anion Channel</article-title><source>Physiol. Rev.</source><year>2019</year><volume>99</volume><fpage>707</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1152/physrev.00007.2018</pub-id><pub-id pub-id-type="pmid">30516439</pub-id></element-citation></ref><ref id="B13-cells-11-01868"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleizen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Van Vlijmen</surname><given-names>T.</given-names></name><name name-style="western"><surname>De Jonge</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Braakman</surname><given-names>I.</given-names></name></person-group><article-title>Folding of CFTR Is Predominantly Cotranslational</article-title><source>Mol. Cell</source><year>2005</year><volume>20</volume><fpage>277</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.09.007</pub-id><pub-id pub-id-type="pmid">16246729</pub-id></element-citation></ref><ref id="B14-cells-11-01868"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name></person-group><article-title>The &#916;F508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR</article-title><source>Nat. Struct. Mol. Biol.</source><year>2005</year><volume>12</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/nsmb882</pub-id><pub-id pub-id-type="pmid">15619635</pub-id></element-citation></ref><ref id="B15-cells-11-01868"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Skach</surname><given-names>W.R.</given-names></name></person-group><article-title>Mechanisms of CFTR Folding at the Endoplasmic Reticulum</article-title><source>Front. Pharmacol.</source><year>2012</year><volume>3</volume><fpage>201</fpage><pub-id pub-id-type="doi">10.3389/fphar.2012.00201</pub-id><pub-id pub-id-type="pmid">23248597</pub-id><pub-id pub-id-type="pmcid">PMC3521238</pub-id></element-citation></ref><ref id="B16-cells-11-01868"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Canato</surname><given-names>S.</given-names></name></person-group><article-title>From the endoplasmic reticulum to the plasma membrane: Mechanisms of CFTR folding and trafficking</article-title><source>Cell. Mol. Life Sci.</source><year>2017</year><volume>74</volume><fpage>39</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2387-7</pub-id><pub-id pub-id-type="pmid">27699454</pub-id><pub-id pub-id-type="pmcid">PMC11107782</pub-id></element-citation></ref><ref id="B17-cells-11-01868"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mijnders</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleizen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Braakman</surname><given-names>I.</given-names></name></person-group><article-title>Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis</article-title><source>Curr. Opin. Pharmacol.</source><year>2017</year><volume>34</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2017.09.014</pub-id><pub-id pub-id-type="pmid">29055231</pub-id></element-citation></ref><ref id="B18-cells-11-01868"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coppinger</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hutt</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Razvi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koulov</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Pankow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Balch</surname><given-names>W.E.</given-names></name></person-group><article-title>A Chaperone Trap Contributes to the Onset of Cystic Fibrosis</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e37682</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0037682</pub-id><pub-id pub-id-type="pmid">22701530</pub-id><pub-id pub-id-type="pmcid">PMC3365120</pub-id></element-citation></ref><ref id="B19-cells-11-01868"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name></person-group><article-title>Most F508del-CFTR Is Targeted to Degradation at an Early Folding Checkpoint and Independently of Calnexin</article-title><source>Mol. Cell. Biol.</source><year>2005</year><volume>25</volume><fpage>5242</fpage><lpage>5252</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.12.5242-5252.2005</pub-id><pub-id pub-id-type="pmid">15923638</pub-id><pub-id pub-id-type="pmcid">PMC1140594</pub-id></element-citation></ref><ref id="B20-cells-11-01868"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>J.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moyer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Bannykh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Riordan</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Balch</surname><given-names>W.E.</given-names></name></person-group><article-title>COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code</article-title><source>J. Cell Biol.</source><year>2004</year><volume>167</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1083/jcb.200401035</pub-id><pub-id pub-id-type="pmid">15479737</pub-id><pub-id pub-id-type="pmcid">PMC2172508</pub-id></element-citation></ref><ref id="B21-cells-11-01868"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michelsen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schwappach</surname><given-names>B.</given-names></name></person-group><article-title>Hide and run</article-title><source>EMBO Rep.</source><year>2005</year><volume>6</volume><fpage>717</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400480</pub-id><pub-id pub-id-type="pmid">16065065</pub-id><pub-id pub-id-type="pmcid">PMC1369147</pub-id></element-citation></ref><ref id="B22-cells-11-01868"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McClure</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Sorscher</surname><given-names>E.J.</given-names></name></person-group><article-title>Trafficking and function of the cystic fibrosis transmembrane conductance regulator: A complex network of posttranslational modifications</article-title><source>Am. J. Physiol.-Lung Cell. Mol. Physiol.</source><year>2016</year><volume>311</volume><fpage>L719</fpage><lpage>L733</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00431.2015</pub-id><pub-id pub-id-type="pmid">27474090</pub-id><pub-id pub-id-type="pmcid">PMC5142128</pub-id></element-citation></ref><ref id="B23-cells-11-01868"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okiyoneda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barri&#232;re</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bagd&#225;ny</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rabeh</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Du</surname><given-names>K.</given-names></name><name name-style="western"><surname>H&#246;hfeld</surname><given-names>J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name></person-group><article-title>Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane</article-title><source>Science</source><year>2010</year><volume>329</volume><fpage>805</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1126/science.1191542</pub-id><pub-id pub-id-type="pmid">20595578</pub-id><pub-id pub-id-type="pmcid">PMC5026491</pub-id></element-citation></ref><ref id="B24-cells-11-01868"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pampinella</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nemes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Benharouga</surname><given-names>M.</given-names></name><name name-style="western"><surname>So</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bache</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Papsin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zerangue</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stenmark</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Misfolding diverts CFTR from recycling to degradation</article-title><source>J. Cell Biol.</source><year>2004</year><volume>164</volume><fpage>923</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1083/jcb.200312018</pub-id><pub-id pub-id-type="pmid">15007060</pub-id><pub-id pub-id-type="pmcid">PMC2172283</pub-id></element-citation></ref><ref id="B25-cells-11-01868"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heged&#369;s</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aleksandrov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mengos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Riordan</surname><given-names>J.R.</given-names></name></person-group><article-title>Role of individual R domain phosphorylation sites in CFTR regulation by protein kinase A</article-title><source>Biochim. Et Biophys. Acta (BBA)-Biomembr.</source><year>2009</year><volume>1788</volume><fpage>1341</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2009.03.015</pub-id><pub-id pub-id-type="pmid">19328185</pub-id></element-citation></ref><ref id="B26-cells-11-01868"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>D.N.</given-names></name></person-group><article-title>Gating of the CFTR Cl<sup>&#8722;</sup> channel by ATP-driven nucleotide-binding domain dimerisation</article-title><source>J. Physiol.</source><year>2009</year><volume>587</volume><fpage>2151</fpage><lpage>2161</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2009.171595</pub-id><pub-id pub-id-type="pmid">19332488</pub-id><pub-id pub-id-type="pmcid">PMC2697289</pub-id></element-citation></ref><ref id="B27-cells-11-01868"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>K.L.</given-names></name></person-group><article-title>The CFTR Ion Channel: Gating, Regulation, and Anion Permeation</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2013</year><volume>3</volume><fpage>a009498</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a009498</pub-id><pub-id pub-id-type="pmid">23284076</pub-id><pub-id pub-id-type="pmcid">PMC3530039</pub-id></element-citation></ref><ref id="B28-cells-11-01868"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.C.</given-names></name></person-group><article-title>Functional stability of CFTR depends on tight binding of ATP at its degenerate ATP-binding site</article-title><source>J. Physiol.</source><year>2021</year><volume>599</volume><fpage>4625</fpage><lpage>4642</lpage><pub-id pub-id-type="doi">10.1113/JP281933</pub-id><pub-id pub-id-type="pmid">34411298</pub-id><pub-id pub-id-type="pmcid">PMC8527797</pub-id></element-citation></ref><ref id="B29-cells-11-01868"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>J.-T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>H.-I.</given-names></name><name name-style="western"><surname>Destefano</surname><given-names>S.</given-names></name></person-group><article-title>Structural mechanisms of CFTR function and dysfunction</article-title><source>J. Gen. Physiol.</source><year>2018</year><volume>150</volume><fpage>539</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1085/jgp.201711946</pub-id><pub-id pub-id-type="pmid">29581173</pub-id><pub-id pub-id-type="pmcid">PMC5881446</pub-id></element-citation></ref><ref id="B30-cells-11-01868"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Molecular structure of the ATP-bound, phosphorylated human CFTR</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>12757</fpage><lpage>12762</lpage><pub-id pub-id-type="doi">10.1073/pnas.1815287115</pub-id><pub-id pub-id-type="pmid">30459277</pub-id><pub-id pub-id-type="pmcid">PMC6294961</pub-id></element-citation></ref><ref id="B31-cells-11-01868"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Csan&#225;dy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gadsby</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Molecular Structure of the Human CFTR Ion Channel</article-title><source>Cell</source><year>2017</year><volume>169</volume><fpage>85</fpage><lpage>95.e88</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.02.024</pub-id><pub-id pub-id-type="pmid">28340353</pub-id></element-citation></ref><ref id="B32-cells-11-01868"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Atomic Structure of the Cystic Fibrosis Transmembrane Conductance Regulator</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>1586</fpage><lpage>1597.e9</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.11.014</pub-id><pub-id pub-id-type="pmid">27912062</pub-id></element-citation></ref><ref id="B33-cells-11-01868"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fay</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Aleksandrov</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Kousouros</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aleksandrov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Gingerich</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Riordan</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.Z.</given-names></name></person-group><article-title>Cryo-EM Visualization of an Active High Open Probability CFTR Anion Channel</article-title><source>Biochemistry</source><year>2018</year><volume>57</volume><fpage>6234</fpage><lpage>6246</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.8b00763</pub-id><pub-id pub-id-type="pmid">30281975</pub-id></element-citation></ref><ref id="B34-cells-11-01868"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiedorczuk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Mechanism of CFTR correction by type I folding correctors</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>158</fpage><lpage>168.e11</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.12.009</pub-id><pub-id pub-id-type="pmid">34995514</pub-id></element-citation></ref><ref id="B35-cells-11-01868"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farkas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tordai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pad&#225;nyi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tordai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paragi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heged&#369;s</surname><given-names>T.</given-names></name></person-group><article-title>Discovering the chloride pathway in the CFTR channel</article-title><source>Cell. Mol. Life Sci.</source><year>2020</year><volume>77</volume><fpage>765</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03211-4</pub-id><pub-id pub-id-type="pmid">31327045</pub-id><pub-id pub-id-type="pmcid">PMC7039865</pub-id></element-citation></ref><ref id="B36-cells-11-01868"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gen&#233;</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Llobet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larriba</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Semir</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Escalada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Solsona</surname><given-names>C.</given-names></name><name name-style="western"><surname>Casals</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aran</surname><given-names>J.M.</given-names></name></person-group><article-title>N-terminal CFTR missense variants severely affect the behavior of the CFTR chloride channel</article-title><source>Hum. Mutat.</source><year>2008</year><volume>29</volume><fpage>738</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1002/humu.20721</pub-id><pub-id pub-id-type="pmid">18306312</pub-id></element-citation></ref><ref id="B37-cells-11-01868"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabusap</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Simhaev</surname><given-names>L.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Senderowitz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Van Willigen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Braakman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sorscher</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.S.</given-names></name></person-group><article-title>The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue</article-title><source>J. Biol. Chem.</source><year>2021</year><volume>296</volume><fpage>100598</fpage><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100598</pub-id><pub-id pub-id-type="pmid">33781744</pub-id><pub-id pub-id-type="pmcid">PMC8102917</pub-id></element-citation></ref><ref id="B38-cells-11-01868"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Grove</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>De La Rosa</surname><given-names>O.</given-names></name><name name-style="western"><surname>Houck</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sopha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Goor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Cyr</surname><given-names>D.M.</given-names></name></person-group><article-title>VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1</article-title><source>Mol. Biol. Cell</source><year>2013</year><volume>24</volume><fpage>3016</fpage><lpage>3024</lpage><pub-id pub-id-type="doi">10.1091/mbc.e13-05-0240</pub-id><pub-id pub-id-type="pmid">23924900</pub-id><pub-id pub-id-type="pmcid">PMC3784376</pub-id></element-citation></ref><ref id="B39-cells-11-01868"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riordan</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Rommens</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kerem</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rozmahel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grzelczak</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zielenski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lok</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plavsic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA</article-title><source>Science</source><year>1989</year><volume>245</volume><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1126/science.2475911</pub-id><pub-id pub-id-type="pmid">2475911</pub-id></element-citation></ref><ref id="B40-cells-11-01868"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rommens</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Iannuzzi</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Kerem</surname><given-names>B.</given-names></name><name name-style="western"><surname>Drumm</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Melmer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rozmahel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hidaka</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Identification of the cystic fibrosis gene: Chromosome walking and jumping</article-title><source>Science</source><year>1989</year><volume>245</volume><fpage>1059</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1126/science.2772657</pub-id><pub-id pub-id-type="pmid">2772657</pub-id></element-citation></ref><ref id="B41-cells-11-01868"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerem</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rommens</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Markiewicz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Chakravarti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buchwald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsui</surname><given-names>L.C.</given-names></name></person-group><article-title>Identification of the cystic fibrosis gene: Genetic analysis</article-title><source>Science</source><year>1989</year><volume>245</volume><fpage>1073</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1126/science.2570460</pub-id><pub-id pub-id-type="pmid">2570460</pub-id></element-citation></ref><ref id="B42-cells-11-01868"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name></person-group><article-title>Progress in therapies for cystic fibrosis</article-title><source>Lancet Respir. Med.</source><year>2016</year><volume>4</volume><fpage>662</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(16)00023-0</pub-id><pub-id pub-id-type="pmid">27053340</pub-id></element-citation></ref><ref id="B43-cells-11-01868"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marson</surname><given-names>F.A.L.</given-names></name><name name-style="western"><surname>Bertuzzo</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>J.D.</given-names></name></person-group><article-title>Classification of CFTR mutation classes</article-title><source>Lancet Respir. Med.</source><year>2016</year><volume>4</volume><fpage>e37</fpage><lpage>e38</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(16)30188-6</pub-id><pub-id pub-id-type="pmid">27377414</pub-id></element-citation></ref><ref id="B44-cells-11-01868"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;rk</surname><given-names>T.</given-names></name><name name-style="western"><surname>Macek</surname><given-names>M.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Mekus</surname><given-names>F.</given-names></name><name name-style="western"><surname>T&#252;mmler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tzountzouris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casals</surname><given-names>T.</given-names></name><name name-style="western"><surname>Krebsov&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koudov&#225;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sakmaryov&#225;</surname><given-names>I.</given-names></name><name name-style="western"><surname>Macek Sr</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Characterization of a novel 21-kb deletion, CFTRdele2,3(21 kb), in the CFTR gene: A cystic fibrosis mutation of Slavic origin common in Central and East Europe</article-title><source>Hum. Genet.</source><year>2000</year><volume>106</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1007/s004390000246</pub-id><pub-id pub-id-type="pmid">10798353</pub-id></element-citation></ref><ref id="B45-cells-11-01868"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sosnay</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Ramalho</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Douville</surname><given-names>C.</given-names></name><name name-style="western"><surname>Franca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vecchio-Pagan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Raraigh</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Experimental Assessment of Splicing Variants Using Expression Minigenes and Comparison with In Silico Predictions</article-title><source>Hum. Mutat.</source><year>2014</year><volume>35</volume><fpage>1249</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1002/humu.22624</pub-id><pub-id pub-id-type="pmid">25066652</pub-id><pub-id pub-id-type="pmcid">PMC4425124</pub-id></element-citation></ref><ref id="B46-cells-11-01868"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Luz</surname><given-names>V.C.C.</given-names></name><name name-style="western"><surname>Targowski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramalho</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name></person-group><article-title>Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis</article-title><source>Genes</source><year>2021</year><volume>12</volume><elocation-id>1810</elocation-id><pub-id pub-id-type="doi">10.3390/genes12111810</pub-id><pub-id pub-id-type="pmid">34828417</pub-id><pub-id pub-id-type="pmcid">PMC8621375</pub-id></element-citation></ref><ref id="B47-cells-11-01868"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensinck</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Keersmaecker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heylen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ramalho</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gijsbers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Farr&#233;</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Christ</surname><given-names>F.</given-names></name><name name-style="western"><surname>Debyser</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Carlon</surname><given-names>M.S.</given-names></name></person-group><article-title>Phenotyping of Rare CFTR Mutations Reveals Distinct Trafficking and Functional Defects</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>754</elocation-id><pub-id pub-id-type="doi">10.3390/cells9030754</pub-id><pub-id pub-id-type="pmcid">PMC7140603</pub-id><pub-id pub-id-type="pmid">32204475</pub-id></element-citation></ref><ref id="B48-cells-11-01868"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Houck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aleksandrov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Quinney</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Cyr-Scully</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cholon</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Gentzsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Randell</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H.Y.</given-names></name><etal/></person-group><article-title>DNAJB12 and Hsp70 triage arrested intermediates of N1303K-CFTR for endoplasmic reticulum-associated autophagy</article-title><source>Mol. Biol. Cell</source><year>2021</year><volume>32</volume><fpage>538</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1091/mbc.E20-11-0688</pub-id><pub-id pub-id-type="pmid">33534640</pub-id><pub-id pub-id-type="pmcid">PMC8101465</pub-id></element-citation></ref><ref id="B49-cells-11-01868"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bompadre</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name></person-group><article-title>Mechanism of G551D-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Potentiation by a High Affinity ATP Analog</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>5364</fpage><lpage>5369</lpage><pub-id pub-id-type="doi">10.1074/jbc.M709417200</pub-id><pub-id pub-id-type="pmid">18167357</pub-id></element-citation></ref><ref id="B50-cells-11-01868"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiba-Falek</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kerem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shoshani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aviram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Augarten</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bentur</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rahat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kerem</surname><given-names>B.</given-names></name></person-group><article-title>The Molecular Basis of Disease Variability among Cystic Fibrosis Patients Carrying the 3849+10 kb C&#8594;T Mutation</article-title><source>Genomics</source><year>1998</year><volume>53</volume><fpage>276</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1006/geno.1998.5517</pub-id><pub-id pub-id-type="pmid">9799593</pub-id></element-citation></ref><ref id="B51-cells-11-01868"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Okiyoneda</surname><given-names>T.</given-names></name></person-group><article-title>Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>1100</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01100</pub-id><pub-id pub-id-type="pmid">30319426</pub-id><pub-id pub-id-type="pmcid">PMC6170605</pub-id></element-citation></ref><ref id="B52-cells-11-01868"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haardt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benharouga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lechardeur</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kartner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name></person-group><article-title>C-terminal Truncations Destabilize the Cystic Fibrosis Transmembrane Conductance Regulator without Impairing Its Biogenesis</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>21873</fpage><lpage>21877</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.31.21873</pub-id><pub-id pub-id-type="pmid">10419506</pub-id></element-citation></ref><ref id="B53-cells-11-01868"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benharouga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name></person-group><article-title>Conformational and Temperature-sensitive Stability Defects of the &#916;F508 Cystic Fibrosis Transmembrane Conductance Regulator in Post-endoplasmic Reticulum Compartments</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>8942</fpage><lpage>8950</lpage><pub-id pub-id-type="doi">10.1074/jbc.M009172200</pub-id><pub-id pub-id-type="pmid">11124952</pub-id></element-citation></ref><ref id="B54-cells-11-01868"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Avramescu</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Houck</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Guggino</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Balch</surname><given-names>W.E.</given-names></name><etal/></person-group><article-title>From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations</article-title><source>Mol. Biol. Cell</source><year>2016</year><volume>27</volume><fpage>424</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1091/mbc.e14-04-0935</pub-id><pub-id pub-id-type="pmid">26823392</pub-id><pub-id pub-id-type="pmcid">PMC4751594</pub-id></element-citation></ref><ref id="B55-cells-11-01868"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>White</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>O'Riordan</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.E.</given-names></name></person-group><article-title>Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis</article-title><source>Cell</source><year>1990</year><volume>63</volume><fpage>827</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90148-8</pub-id><pub-id pub-id-type="pmid">1699669</pub-id></element-citation></ref><ref id="B56-cells-11-01868"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X.B.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kartner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riordan</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Grinstein</surname><given-names>S.</given-names></name></person-group><article-title>The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells</article-title><source>J. Biol. Chem.</source><year>1993</year><volume>268</volume><fpage>21592</fpage><lpage>21598</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(20)80582-1</pub-id><pub-id pub-id-type="pmid">7691813</pub-id></element-citation></ref><ref id="B57-cells-11-01868"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalemans</surname><given-names>W.</given-names></name><name name-style="western"><surname>Barbry</surname><given-names>P.</given-names></name><name name-style="western"><surname>Champigny</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jallat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jallat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dott</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dreyer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Pavirani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lecocq</surname><given-names>J.-P.</given-names></name><etal/></person-group><article-title>Altered chloride ion channel kinetics associated with the &#916;F508 cystic fibrosis mutation</article-title><source>Nature</source><year>1991</year><volume>354</volume><fpage>526</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/354526a0</pub-id><pub-id pub-id-type="pmid">1722027</pub-id></element-citation></ref><ref id="B58-cells-11-01868"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laselva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Eckford</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gunawardena</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Gonska</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.E.</given-names></name></person-group><article-title>Functional rescue of c.3846G&gt;A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>19</volume><fpage>717</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2019.12.001</pub-id><pub-id pub-id-type="pmid">31831337</pub-id></element-citation></ref><ref id="B59-cells-11-01868"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Destefano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gees</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name></person-group><article-title>Physiological and pharmacological characterization of the N1303K mutant CFTR</article-title><source>J. Cyst. Fibros.</source><year>2018</year><volume>17</volume><fpage>573</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2018.05.011</pub-id><pub-id pub-id-type="pmid">29887518</pub-id><pub-id pub-id-type="pmcid">PMC7008954</pub-id></element-citation></ref><ref id="B60-cells-11-01868"><label>60.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>FDA</collab></person-group><source>Press Announcements&#8212;FDA Approves Kalydeco to Treat Rare form of Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2012</year></element-citation></ref><ref id="B61-cells-11-01868"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramsey</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.</given-names></name><name name-style="western"><surname>McElvaney</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Drevinek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Griese</surname><given-names>M.</given-names></name><name name-style="western"><surname>McKone</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Wainwright</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Konstan</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>A CFTR potentiator in patients with cystic fibrosis and the G551D mutation</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>365</volume><fpage>1663</fpage><lpage>1672</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1105185</pub-id><pub-id pub-id-type="pmid">22047557</pub-id><pub-id pub-id-type="pmcid">PMC3230303</pub-id></element-citation></ref><ref id="B62-cells-11-01868"><label>62.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>FDA</collab></person-group><source>FDA Expands Approved Use of Kalydeco to Treat Additional Mutations of Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B63-cells-11-01868"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Munck</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Faro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hiatt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gilmartin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation</article-title><source>J. Cyst. Fibros.</source><year>2014</year><volume>13</volume><fpage>674</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2014.09.005</pub-id><pub-id pub-id-type="pmid">25266159</pub-id></element-citation></ref><ref id="B64-cells-11-01868"><label>64.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Vertex</collab></person-group><source>Vertex Announces FDA Approvals of TRIKAFTA&#174; (Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor),SYMDEKO&#174; (Tezacaftor/Ivacaftor and Ivacaftor) and KALYDECO&#174; (Ivacaftor) for Use in People WithCF with Certain Rare Mutations</source><publisher-name>Vertex</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B65-cells-11-01868"><label>65.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Vertex</collab></person-group><article-title>Who KALYDECO Is for</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.kalydeco.com/who-kalydeco" ext-link-type="uri">https://www.kalydeco.com/who-kalydeco</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-10">(accessed on 10 May 2022)</date-in-citation></element-citation></ref><ref id="B66-cells-11-01868"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wainwright</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Elborn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Marigowda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cipolli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Flume</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>220</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1409547</pub-id><pub-id pub-id-type="pmid">25981758</pub-id><pub-id pub-id-type="pmcid">PMC4764353</pub-id></element-citation></ref><ref id="B67-cells-11-01868"><label>67.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>FDA</collab></person-group><source>Press Announcements&#8212;FDA Approves New Treatment for Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2015</year></element-citation></ref><ref id="B68-cells-11-01868"><label>68.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Drug Trials Snapshots: SYMDEKO|FDA</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-symdeko" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-symdeko</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-10">(accessed on 10 May 2022)</date-in-citation></element-citation></ref><ref id="B69-cells-11-01868"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor-Cousar</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Munck</surname><given-names>A.</given-names></name><name name-style="western"><surname>McKone</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>van der Ent</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Ingenito</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>McKee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2013</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1709846</pub-id><pub-id pub-id-type="pmid">29099344</pub-id></element-citation></ref><ref id="B70-cells-11-01868"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heijerman</surname><given-names>H.G.M.</given-names></name><name name-style="western"><surname>McKone</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Van Braeckel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Welter</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>McKee</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial</article-title><source>Lancet</source><year>2019</year><volume>394</volume><fpage>1940</fpage><lpage>1948</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)32597-8</pub-id><pub-id pub-id-type="pmid">31679946</pub-id><pub-id pub-id-type="pmcid">PMC7571408</pub-id></element-citation></ref><ref id="B71-cells-11-01868"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Mall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Drevinek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lands</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>McKone</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Polineni</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Taylor-Cousar</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>1809</fpage><lpage>1819</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1908639</pub-id><pub-id pub-id-type="pmid">31697873</pub-id><pub-id pub-id-type="pmcid">PMC7282384</pub-id></element-citation></ref><ref id="B72-cells-11-01868"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drumm</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Worrell</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Frizzell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>F.S.</given-names></name></person-group><article-title>Chloride Conductance Expressed by (F508) and Other Mutant CFTRs in Xenopus Oocytes</article-title><source>Science</source><year>1991</year><volume>254</volume><fpage>1797</fpage><pub-id pub-id-type="doi">10.1126/science.1722350</pub-id><pub-id pub-id-type="pmid">1722350</pub-id></element-citation></ref><ref id="B73-cells-11-01868"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schey</surname><given-names>R.</given-names></name></person-group><article-title>Lubiprostone in constipation: Clinical evidence and place in therapy</article-title><source>Ther. Adv. Chronic Dis.</source><year>2015</year><volume>6</volume><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1177/2040622314567678</pub-id><pub-id pub-id-type="pmid">25729555</pub-id><pub-id pub-id-type="pmcid">PMC4331234</pub-id></element-citation></ref><ref id="B74-cells-11-01868"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bijvelds</surname><given-names>M.J.C.</given-names></name><name name-style="western"><surname>Bot</surname><given-names>A.G.M.</given-names></name><name name-style="western"><surname>Escher</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>De Jonge</surname><given-names>H.R.</given-names></name></person-group><article-title>Activation of Intestinal Cl<sup>&#8722;</sup> Secretion by Lubiprostone Requires the Cystic Fibrosis Transmembrane Conductance Regulator</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>976</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.05.037</pub-id><pub-id pub-id-type="pmid">19454284</pub-id></element-citation></ref><ref id="B75-cells-11-01868"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaughnessy</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bratcher</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Zeitlin</surname><given-names>P.L.</given-names></name></person-group><article-title>Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway</article-title><source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source><year>2022</year><volume>322</volume><fpage>L305</fpage><lpage>L314</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00388.2021</pub-id><pub-id pub-id-type="pmid">35020527</pub-id><pub-id pub-id-type="pmcid">PMC8858663</pub-id></element-citation></ref><ref id="B76-cells-11-01868"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cazzola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Page</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calzetta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Matera</surname><given-names>M.G.</given-names></name></person-group><article-title>Ensifentrine (RPL554): An inhaled &#8216;bifunctional&#8217; dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease</article-title><source>Pharm. Pat. Anal.</source><year>2018</year><volume>7</volume><fpage>249</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.4155/ppa-2018-0030</pub-id><pub-id pub-id-type="pmid">30657422</pub-id></element-citation></ref><ref id="B77-cells-11-01868"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Matthes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Billet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Randell</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ostrowski</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Abbott-Banner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name></person-group><article-title>The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia</article-title><source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source><year>2016</year><volume>310</volume><fpage>L59</fpage><lpage>L70</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00324.2015</pub-id><pub-id pub-id-type="pmid">26545902</pub-id></element-citation></ref><ref id="B78-cells-11-01868"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name></person-group><article-title>The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants</article-title><source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source><year>2020</year><volume>318</volume><fpage>L908</fpage><lpage>L920</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00285.2019</pub-id><pub-id pub-id-type="pmid">32159371</pub-id></element-citation></ref><ref id="B79-cells-11-01868"><label>79.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Verona Pharma</collab></person-group><source>Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2018</year></element-citation></ref><ref id="B80-cells-11-01868"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunderson</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Kopito</surname><given-names>R.R.</given-names></name></person-group><article-title>Effects of pyrophosphate and nucleotide analogs suggest a role for ATP hydrolysis in cystic fibrosis transmembrane regulator channel gating</article-title><source>J. Biol. Chem.</source><year>1994</year><volume>269</volume><fpage>19349</fpage><lpage>19353</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(17)32174-9</pub-id><pub-id pub-id-type="pmid">7518455</pub-id></element-citation></ref><ref id="B81-cells-11-01868"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murthy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><name name-style="western"><surname>MacVinish</surname><given-names>L.</given-names></name><name name-style="western"><surname>Galietta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cuthbert</surname><given-names>A.</given-names></name></person-group><article-title>4-Chlorobenzo[F]isoquinoline (CBIQ), a novel activator of CFTR and &#916;F508 CFTR</article-title><source>Eur. J. Pharmacol.</source><year>2005</year><volume>516</volume><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2005.04.037</pub-id><pub-id pub-id-type="pmid">15921678</pub-id></element-citation></ref><ref id="B82-cells-11-01868"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sohma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.C.</given-names></name></person-group><article-title>High affinity ATP/ADP analogues as new tools for studying CFTR gating</article-title><source>J. Physiol.</source><year>2005</year><volume>569</volume><fpage>447</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2005.095083</pub-id><pub-id pub-id-type="pmid">16223764</pub-id><pub-id pub-id-type="pmcid">PMC1464241</pub-id></element-citation></ref><ref id="B83-cells-11-01868"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Travis</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>M.J.</given-names></name></person-group><article-title>Regulation of the cystic fibrosis transmembrane conductance regulator Cl<sup>&#8722;</sup> channel by specific protein kinases and protein phosphatases</article-title><source>J. Biol. Chem.</source><year>1993</year><volume>268</volume><fpage>2037</fpage><lpage>2047</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)53959-4</pub-id><pub-id pub-id-type="pmid">7678414</pub-id></element-citation></ref><ref id="B84-cells-11-01868"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>H.</given-names></name></person-group><article-title>Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo</article-title><source>Am. J. Physiol.</source><year>1998</year><volume>275</volume><fpage>L902</fpage><lpage>L910</lpage><pub-id pub-id-type="doi">10.1152/ajplung.1998.275.5.L902</pub-id><pub-id pub-id-type="pmid">9815107</pub-id></element-citation></ref><ref id="B85-cells-11-01868"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Illek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Widdicombe</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Machen</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Reenstra</surname><given-names>W.W.</given-names></name></person-group><article-title>cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein</article-title><source>Am. J. Physiol.</source><year>1995</year><volume>268</volume><fpage>C886</fpage><lpage>C893</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.1995.268.4.C886</pub-id><pub-id pub-id-type="pmid">7537452</pub-id></element-citation></ref><ref id="B86-cells-11-01868"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zeltwanger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>I.C.H.</given-names></name><name name-style="western"><surname>Nairn</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name></person-group><article-title>Actions of Genistein on Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating</article-title><source>J. Gen. Physiol.</source><year>1998</year><volume>111</volume><fpage>477</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1085/jgp.111.3.477</pub-id><pub-id pub-id-type="pmid">9482713</pub-id><pub-id pub-id-type="pmcid">PMC2217116</pub-id></element-citation></ref><ref id="B87-cells-11-01868"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lansdell</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>D.N.</given-names></name></person-group><article-title>Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl<sup>&#8722;</sup> channels expressed in murine cell line</article-title><source>J. Physiol.</source><year>2000</year><volume>524</volume><fpage>317</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7793.2000.t01-1-00317.x</pub-id><pub-id pub-id-type="pmid">10766914</pub-id><pub-id pub-id-type="pmcid">PMC2269882</pub-id></element-citation></ref><ref id="B88-cells-11-01868"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sonawane</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Taddei</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zegarra-Moran</surname><given-names>O.</given-names></name><name name-style="western"><surname>Suen</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Robins</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Dicus</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Willenbring</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nantz</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Phenylglycine and Sulfonamide Correctors of Defective &#916;F508 and G551D Cystic Fibrosis Transmembrane Conductance Regulator Chloride-Channel Gating</article-title><source>Mol. Pharmacol.</source><year>2005</year><volume>67</volume><fpage>1797</fpage><lpage>1807</lpage><pub-id pub-id-type="doi">10.1124/mol.105.010959</pub-id><pub-id pub-id-type="pmid">15722457</pub-id></element-citation></ref><ref id="B89-cells-11-01868"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Goor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Straley</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hadida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hazlewood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joubran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>T.</given-names></name><name name-style="western"><surname>Makings</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Rescue of &#916;F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules</article-title><source>Am. J. Physiol.-Lung Cell. Mol. Physiol.</source><year>2006</year><volume>290</volume><fpage>L1117</fpage><lpage>L1130</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00169.2005</pub-id><pub-id pub-id-type="pmid">16443646</pub-id></element-citation></ref><ref id="B90-cells-11-01868"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Goor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hadida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grootenhuis</surname><given-names>P.D.J.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neuberger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Turnbull</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joubran</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hazlewood</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>18825</fpage><lpage>18830</lpage><pub-id pub-id-type="doi">10.1073/pnas.0904709106</pub-id><pub-id pub-id-type="pmid">19846789</pub-id><pub-id pub-id-type="pmcid">PMC2773991</pub-id></element-citation></ref><ref id="B91-cells-11-01868"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckford</surname><given-names>P.D.W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramjeesingh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.E.</given-names></name></person-group><article-title>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>36639</fpage><lpage>36649</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.393637</pub-id><pub-id pub-id-type="pmid">22942289</pub-id><pub-id pub-id-type="pmcid">PMC3481266</pub-id></element-citation></ref><ref id="B92-cells-11-01868"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jih</surname><given-names>K.-Y.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name></person-group><article-title>Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>4404</fpage><lpage>4409</lpage><pub-id pub-id-type="doi">10.1073/pnas.1215982110</pub-id><pub-id pub-id-type="pmid">23440202</pub-id><pub-id pub-id-type="pmcid">PMC3600496</pub-id></element-citation></ref><ref id="B93-cells-11-01868"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>H.-I.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>J.-T.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name></person-group><article-title>Modulation of CFTR gating by permeant ions</article-title><source>J. Gen. Physiol.</source><year>2015</year><volume>145</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1085/jgp.201411272</pub-id><pub-id pub-id-type="pmid">25512598</pub-id><pub-id pub-id-type="pmcid">PMC4278182</pub-id></element-citation></ref><ref id="B94-cells-11-01868"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrnes</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>West</surname><given-names>G.M.</given-names></name></person-group><article-title>Sites associated with Kalydeco binding on human Cystic Fibrosis Transmembrane Conductance Regulator revealed by Hydrogen/Deuterium Exchange</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>4664</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-22959-6</pub-id><pub-id pub-id-type="pmid">29549268</pub-id><pub-id pub-id-type="pmcid">PMC5856801</pub-id></element-citation></ref><ref id="B95-cells-11-01868"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Levit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Levring</surname><given-names>J.</given-names></name><name name-style="western"><surname>Touhara</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Shoichet</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Structural identification of a hotspot on CFTR for potentiation</article-title><source>Science</source><year>2019</year><volume>364</volume><fpage>1184</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1126/science.aaw7611</pub-id><pub-id pub-id-type="pmid">31221859</pub-id><pub-id pub-id-type="pmcid">PMC7184887</pub-id></element-citation></ref><ref id="B96-cells-11-01868"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laselva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Z.-W.</given-names></name><name name-style="western"><surname>Petrotchenko</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Ramjeesingh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Huan</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Borchers</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Pom&#232;s</surname><given-names>R.</given-names></name><name name-style="western"><surname>Young</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator</article-title><source>iScience</source><year>2021</year><volume>24</volume><fpage>102542</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.102542</pub-id><pub-id pub-id-type="pmid">34142049</pub-id><pub-id pub-id-type="pmcid">PMC8184517</pub-id></element-citation></ref><ref id="B97-cells-11-01868"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cholon</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Quinney</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Fulcher</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Esther</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Das</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dokholyan</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Randell</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Gentzsch</surname><given-names>M.</given-names></name></person-group><article-title>Potentiator ivacaftor abrogates pharmacological correction of F508 CFTR in cystic fibrosis</article-title><source>Sci. Transl. Med.</source><year>2014</year><volume>6</volume><fpage>246ra96</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3008680</pub-id><pub-id pub-id-type="pmcid">PMC4272825</pub-id><pub-id pub-id-type="pmid">25101886</pub-id></element-citation></ref><ref id="B98-cells-11-01868"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phuan</surname><given-names>P.-W.</given-names></name><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Finkbeiner</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Verkman</surname><given-names>A.S.</given-names></name></person-group><article-title>Potentiators of Defective &#916;F508&#8211;CFTR Gating that Do Not Interfere with Corrector Action</article-title><source>Mol. Pharmacol.</source><year>2015</year><volume>88</volume><fpage>791</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1124/mol.115.099689</pub-id><pub-id pub-id-type="pmid">26245207</pub-id><pub-id pub-id-type="pmcid">PMC4576684</pub-id></element-citation></ref><ref id="B99-cells-11-01868"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Plas</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Kelgtermans</surname><given-names>H.</given-names></name><name name-style="western"><surname>De Munck</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martina</surname><given-names>S.L.X.</given-names></name><name name-style="western"><surname>Dropsit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quinton</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Blieck</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joannesse</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tomaskovic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jans</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Discovery of <italic toggle="yes">N</italic>-(3-Carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-lH-pyrazole-5-carboxamide (GLPG1837), a Novel Potentiator Which Can Open Class III Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channels to a High Extent</article-title><source>J. Med. Chem.</source><year>2018</year><volume>61</volume><fpage>1425</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01288</pub-id><pub-id pub-id-type="pmid">29148763</pub-id></element-citation></ref><ref id="B100-cells-11-01868"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Da Fonte</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Avramescu</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Premchandar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bagdany</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bensinger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stubba</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Matouk</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Mutation-specific dual potentiators maximize rescue of CFTR gating mutants</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>19</volume><fpage>236</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2019.10.011</pub-id><pub-id pub-id-type="pmid">31678009</pub-id><pub-id pub-id-type="pmcid">PMC7190413</pub-id></element-citation></ref><ref id="B101-cells-11-01868"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sohma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Conrath</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.C.</given-names></name></person-group><article-title>Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770</article-title><source>J. Gen. Physiol.</source><year>2019</year><volume>151</volume><fpage>912</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1085/jgp.201912360</pub-id><pub-id pub-id-type="pmid">31164398</pub-id><pub-id pub-id-type="pmcid">PMC6605684</pub-id></element-citation></ref><ref id="B102-cells-11-01868"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeh</surname><given-names>H.-I.</given-names></name><name name-style="western"><surname>Sohma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Conrath</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name></person-group><article-title>A common mechanism for CFTR potentiators</article-title><source>J. Gen. Physiol.</source><year>2017</year><volume>149</volume><fpage>1105</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1085/jgp.201711886</pub-id><pub-id pub-id-type="pmid">29079713</pub-id><pub-id pub-id-type="pmcid">PMC5715911</pub-id></element-citation></ref><ref id="B103-cells-11-01868"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khloya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Namkung</surname><given-names>W.</given-names></name></person-group><article-title>Potentiation of &#916;F508- and G551D-CFTR-Mediated Cl<sup>&#8722;</sup> Current by Novel Hydroxypyrazolines</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0149131</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0149131</pub-id><pub-id pub-id-type="pmid">26863533</pub-id><pub-id pub-id-type="pmcid">PMC4749168</pub-id></element-citation></ref><ref id="B104-cells-11-01868"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gees</surname><given-names>M.</given-names></name><name name-style="western"><surname>Musch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van der Plas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wesse</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Vandevelde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verdonck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mammoliti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.-C.</given-names></name><name name-style="western"><surname>Sonck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stouten</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Identification and Characterization of Novel CFTR Potentiators</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>1221</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01221</pub-id><pub-id pub-id-type="pmid">30416447</pub-id><pub-id pub-id-type="pmcid">PMC6212544</pub-id></element-citation></ref><ref id="B105-cells-11-01868"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Van de Steen</surname><given-names>O.</given-names></name><name name-style="western"><surname>van Koningsbruggen-Rietschel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Drevinek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Derichs</surname><given-names>N.</given-names></name><name name-style="western"><surname>McKone</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Kanters</surname><given-names>D.</given-names></name><name name-style="western"><surname>Allamassey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Namour</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Kock</surname><given-names>H.</given-names></name><etal/></person-group><article-title>GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)</article-title><source>J. Cyst. Fibros.</source><year>2019</year><volume>18</volume><fpage>693</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2019.05.006</pub-id><pub-id pub-id-type="pmid">31147302</pub-id></element-citation></ref><ref id="B106-cells-11-01868"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Downey</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Fajac</surname><given-names>I.</given-names></name><name name-style="western"><surname>Flume</surname><given-names>P.</given-names></name><name name-style="western"><surname>O&#8217;Carroll</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pressler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Proesmans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sutharsan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>WS11.5 Evaluation of combinations of the CFTR potentiator dirocaftor, corrector posenacaftor and amplifier nesolicaftor in cystic fibrosis subjects with two copies of the F508del mutation</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>19</volume><fpage>S19</fpage><pub-id pub-id-type="doi">10.1016/S1569-1993(20)30226-5</pub-id></element-citation></ref><ref id="B107-cells-11-01868"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dransfield</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Haque</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gleason</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Kulmatycki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Danahay</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gosling</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial</article-title><source>Int. J. Chronic Obstr. Pulm. Dis.</source><year>2020</year><volume>15</volume><fpage>2399</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.2147/COPD.S257474</pub-id><pub-id pub-id-type="pmcid">PMC7547289</pub-id><pub-id pub-id-type="pmid">33116455</pub-id></element-citation></ref><ref id="B108-cells-11-01868"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volkova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Moy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Konstan</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Sawicki</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Elbert</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>19</volume><fpage>68</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2019.05.015</pub-id><pub-id pub-id-type="pmid">31196670</pub-id></element-citation></ref><ref id="B109-cells-11-01868"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Goor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>B.J.</given-names></name></person-group><article-title>Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function</article-title><source>J. Cyst. Fibros.</source><year>2014</year><volume>13</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2013.06.008</pub-id><pub-id pub-id-type="pmid">23891399</pub-id></element-citation></ref><ref id="B110-cells-11-01868"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dekkers</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Van Mourik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vonk</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kruisselbrink</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berkers</surname><given-names>G.</given-names></name><name name-style="western"><surname>de Winter-de Groot</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Bronsveld</surname><given-names>I.</given-names></name><name name-style="western"><surname>van der Ent</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>H.R.</given-names></name><etal/></person-group><article-title>Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations</article-title><source>J. Cyst. Fibros.</source><year>2016</year><volume>15</volume><fpage>568</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2016.04.007</pub-id><pub-id pub-id-type="pmid">27160424</pub-id></element-citation></ref><ref id="B111-cells-11-01868"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phuan</surname><given-names>P.-W.</given-names></name><name name-style="western"><surname>Son</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.-A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Musante</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zlock</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nielson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Finkbeiner</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Kurth</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Galietta</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Combination potentiator (&#8216;co-potentiator&#8217;) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators</article-title><source>J. Cyst. Fibros.</source><year>2018</year><volume>17</volume><fpage>595</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2018.05.010</pub-id><pub-id pub-id-type="pmid">29903467</pub-id><pub-id pub-id-type="pmcid">PMC6436558</pub-id></element-citation></ref><ref id="B112-cells-11-01868"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phuan</surname><given-names>P.-W.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.-A.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Zlock</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nielson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Finkbeiner</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Haggie</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Verkman</surname><given-names>A.S.</given-names></name></person-group><article-title>Nanomolar-potency &#8216;co-potentiator&#8217; therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>17640</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-54158-2</pub-id><pub-id pub-id-type="pmid">31776420</pub-id><pub-id pub-id-type="pmcid">PMC6881293</pub-id></element-citation></ref><ref id="B113-cells-11-01868"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haggie</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Phuan</surname><given-names>P.-W.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.-A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Avramescu</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Perdomo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zlock</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nielson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Finkbeiner</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name><etal/></person-group><article-title>Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product</article-title><source>J. Biol. Chem.</source><year>2017</year><volume>292</volume><fpage>771</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.764720</pub-id><pub-id pub-id-type="pmid">27895116</pub-id><pub-id pub-id-type="pmcid">PMC5247652</pub-id></element-citation></ref><ref id="B114-cells-11-01868"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensinck</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>De Keersmaecker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ramalho</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Cuyx</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Biervliet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>L.</given-names></name><name name-style="western"><surname>Christ</surname><given-names>F.</given-names></name><name name-style="western"><surname>Debyser</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carlon</surname><given-names>M.S.</given-names></name></person-group><article-title>Novel CFTR modulator combinations maximize rescue of G85E and N1303K in rectal organoids</article-title><source>ERJ Open Res.</source><year>2022</year><volume>8</volume><fpage>00716</fpage><lpage>02021</lpage><pub-id pub-id-type="doi">10.1183/23120541.00716-2021</pub-id><pub-id pub-id-type="pmid">35449760</pub-id><pub-id pub-id-type="pmcid">PMC9016267</pub-id></element-citation></ref><ref id="B115-cells-11-01868"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laselva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gunawardena</surname><given-names>T.N.A.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Eckford</surname><given-names>P.D.W.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Gonska</surname><given-names>T.</given-names></name></person-group><article-title>Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator</article-title><source>Eur. Respir. J.</source><year>2021</year><volume>57</volume><fpage>2002774</fpage><pub-id pub-id-type="doi">10.1183/13993003.02774-2020</pub-id><pub-id pub-id-type="pmid">33303536</pub-id><pub-id pub-id-type="pmcid">PMC8209484</pub-id></element-citation></ref><ref id="B116-cells-11-01868"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vaccarin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name></person-group><article-title>Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR</article-title><source>J. Cyst. Fibros.</source><year>2021</year><volume>20</volume><fpage>895</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2021.03.011</pub-id><pub-id pub-id-type="pmid">33775603</pub-id><pub-id pub-id-type="pmcid">PMC8463622</pub-id></element-citation></ref><ref id="B117-cells-11-01868"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denning</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Amara</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>M.J.</given-names></name></person-group><article-title>Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive</article-title><source>Nature</source><year>1992</year><volume>358</volume><fpage>761</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/358761a0</pub-id><pub-id pub-id-type="pmid">1380673</pub-id></element-citation></ref><ref id="B118-cells-11-01868"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patrick</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Karamyshev</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Millen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.J.</given-names></name></person-group><article-title>Alteration of CFTR transmembrane span integration by disease-causing mutations</article-title><source>Mol. Biol. Cell</source><year>2011</year><volume>22</volume><fpage>4461</fpage><lpage>4471</lpage><pub-id pub-id-type="doi">10.1091/mbc.e11-05-0396</pub-id><pub-id pub-id-type="pmid">21998193</pub-id><pub-id pub-id-type="pmcid">PMC3226467</pub-id></element-citation></ref><ref id="B119-cells-11-01868"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rapino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sabirzhanova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lopes-Pacheco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grover</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guggino</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Cebotaru</surname><given-names>L.</given-names></name></person-group><article-title>Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0119796</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0119796</pub-id><pub-id pub-id-type="pmid">25799511</pub-id><pub-id pub-id-type="pmcid">PMC4370480</pub-id></element-citation></ref><ref id="B120-cells-11-01868"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>King-Underwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Henriques</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Roxo-Rosa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Da Paula</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hirst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction</article-title><source>Chem. Biol.</source><year>2013</year><volume>20</volume><fpage>943</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2013.06.004</pub-id><pub-id pub-id-type="pmid">23890012</pub-id></element-citation></ref><ref id="B121-cells-11-01868"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Krouse</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wine</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kopito</surname><given-names>R.R.</given-names></name></person-group><article-title>Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation</article-title><source>J. Biol. Chem.</source><year>1996</year><volume>271</volume><fpage>635</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.2.635</pub-id><pub-id pub-id-type="pmid">8557666</pub-id></element-citation></ref><ref id="B122-cells-11-01868"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Loo</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>D.M.</given-names></name></person-group><article-title>Correctors Promote Maturation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-processing Mutants by Binding to the Protein</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>33247</fpage><lpage>33251</lpage><pub-id pub-id-type="doi">10.1074/jbc.C700175200</pub-id><pub-id pub-id-type="pmid">17911111</pub-id></element-citation></ref><ref id="B123-cells-11-01868"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okiyoneda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Bagdany</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roldan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verkman</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kurth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mechanism-based corrector combination restores &#916;F508-CFTR folding and function</article-title><source>Nat. Chem. Biol.</source><year>2013</year><volume>9</volume><fpage>444</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1253</pub-id><pub-id pub-id-type="pmid">23666117</pub-id><pub-id pub-id-type="pmcid">PMC3840170</pub-id></element-citation></ref><ref id="B124-cells-11-01868"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Loo</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>D.M.</given-names></name></person-group><article-title>Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants</article-title><source>Biochem. J.</source><year>2007</year><volume>406</volume><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1042/BJ20070478</pub-id><pub-id pub-id-type="pmid">17535157</pub-id><pub-id pub-id-type="pmcid">PMC1948964</pub-id></element-citation></ref><ref id="B125-cells-11-01868"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Verkman</surname><given-names>A.S.</given-names></name></person-group><article-title>Cystic fibrosis transmembrane regulator correctors and potentiators</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2013</year><volume>3</volume><fpage>a009761</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a009761</pub-id><pub-id pub-id-type="pmid">23818513</pub-id><pub-id pub-id-type="pmcid">PMC3685879</pub-id></element-citation></ref><ref id="B126-cells-11-01868"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name></person-group><article-title>Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening</article-title><source>J. Clin. Investig.</source><year>2005</year><volume>115</volume><fpage>2564</fpage><lpage>2571</lpage><pub-id pub-id-type="doi">10.1172/JCI24898</pub-id><pub-id pub-id-type="pmid">16127463</pub-id><pub-id pub-id-type="pmcid">PMC1190372</pub-id></element-citation></ref><ref id="B127-cells-11-01868"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirth</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cuff</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Cochran</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Pregel</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Sneddon</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>J.L.</given-names></name></person-group><article-title>Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2005</year><volume>15</volume><fpage>2087</fpage><lpage>2091</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2005.02.041</pub-id><pub-id pub-id-type="pmid">15808474</pub-id></element-citation></ref><ref id="B128-cells-11-01868"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botelho</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Uliyakina</surname><given-names>I.</given-names></name><name name-style="western"><surname>Awatade</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Proen&#231;a</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Tischer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sirianant</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kunzelmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pepperkok</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name></person-group><article-title>Protein Traffic Disorders: An Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>9038</fpage><pub-id pub-id-type="doi">10.1038/srep09038</pub-id><pub-id pub-id-type="pmid">25762484</pub-id><pub-id pub-id-type="pmcid">PMC4356983</pub-id></element-citation></ref><ref id="B129-cells-11-01868"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Teske</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name></person-group><article-title>Correctors of protein trafficking defects identified by a novel high-throughput screening assay</article-title><source>Chembiochem</source><year>2007</year><volume>8</volume><fpage>1012</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1002/cbic.200700027</pub-id><pub-id pub-id-type="pmid">17497613</pub-id></element-citation></ref><ref id="B130-cells-11-01868"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sampson</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matthes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name></person-group><article-title>Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR</article-title><source>Chem. Biol.</source><year>2011</year><volume>18</volume><fpage>231</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2010.11.016</pub-id><pub-id pub-id-type="pmid">21338920</pub-id></element-citation></ref><ref id="B131-cells-11-01868"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phuan</surname><given-names>P.-W.</given-names></name><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.-A.</given-names></name><name name-style="western"><surname>Roldan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Finkbeiner</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Haggie</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Verkman</surname><given-names>A.S.</given-names></name></person-group><article-title>&#916;F508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter</article-title><source>SLAS DISCOVERY Adv. Sci. Drug Discov.</source><year>2018</year><volume>23</volume><fpage>823</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1177/2472555218763310</pub-id><pub-id pub-id-type="pmcid">PMC6133293</pub-id><pub-id pub-id-type="pmid">29533733</pub-id></element-citation></ref><ref id="B132-cells-11-01868"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Balghi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lesimple</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rotin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wilke</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Jonge</surname><given-names>H.R.</given-names></name><etal/></person-group><article-title>Correction of the &#916;Phe508 Cystic Fibrosis Transmembrane Conductance Regulator Trafficking Defect by the Bioavailable Compound Glafenine</article-title><source>Mol. Pharmacol.</source><year>2010</year><volume>77</volume><fpage>922</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1124/mol.109.062679</pub-id><pub-id pub-id-type="pmid">20200141</pub-id></element-citation></ref><ref id="B133-cells-11-01868"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shishido</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Skach</surname><given-names>W.R.</given-names></name></person-group><article-title>A small molecule high throughput screening platform to profile conformational properties of nascent, ribosome-bound proteins</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>2509</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-06456-5</pub-id><pub-id pub-id-type="pmid">35169219</pub-id><pub-id pub-id-type="pmcid">PMC8847357</pub-id></element-citation></ref><ref id="B134-cells-11-01868"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grove</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Rosser</surname><given-names>M.F.N.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Naren</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Cyr</surname><given-names>D.M.</given-names></name></person-group><article-title>Mechanisms for Rescue of Correctable Folding Defects in CFTR&#916;F508</article-title><source>Mol. Biol. Cell</source><year>2009</year><volume>20</volume><fpage>4059</fpage><lpage>4069</lpage><pub-id pub-id-type="doi">10.1091/mbc.e08-09-0929</pub-id><pub-id pub-id-type="pmid">19625452</pub-id><pub-id pub-id-type="pmcid">PMC2743624</pub-id></element-citation></ref><ref id="B135-cells-11-01868"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laselva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Molinski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casavola</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.E.</given-names></name></person-group><article-title>Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains</article-title><source>Mol. Pharmacol.</source><year>2018</year><volume>93</volume><fpage>612</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1124/mol.118.111799</pub-id><pub-id pub-id-type="pmid">29618585</pub-id></element-citation></ref><ref id="B136-cells-11-01868"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pesce</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bellotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liessi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Guariento</surname><given-names>S.</given-names></name><name name-style="western"><surname>Damonte</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cichero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Galatini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gianotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Synthesis and structure&#8211;activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis</article-title><source>Eur. J. Med. Chem.</source><year>2015</year><volume>99</volume><fpage>14</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2015.05.030</pub-id><pub-id pub-id-type="pmid">26041577</pub-id></element-citation></ref><ref id="B137-cells-11-01868"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ludovico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parodi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>O.</given-names></name><name name-style="western"><surname>Millo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cichero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Baroni</surname><given-names>D.</given-names></name></person-group><article-title>NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>1417</elocation-id><pub-id pub-id-type="doi">10.3390/biom11101417</pub-id><pub-id pub-id-type="pmid">34680050</pub-id><pub-id pub-id-type="pmcid">PMC8533355</pub-id></element-citation></ref><ref id="B138-cells-11-01868"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Roldan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Da Fonte</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frenkiel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matouk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Velkov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name></person-group><article-title>Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination</article-title><source>JCI Insight</source><year>2020</year><volume>5</volume><fpage>e139983</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.139983</pub-id><pub-id pub-id-type="pmid">32853178</pub-id><pub-id pub-id-type="pmcid">PMC7526550</pub-id></element-citation></ref><ref id="B139-cells-11-01868"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dreano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Avramescu</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Bagdany</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beitel</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Roldan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Structure-guided combination therapy to potently improve the function of mutant CFTRs</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>1732</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0200-x</pub-id><pub-id pub-id-type="pmid">30297908</pub-id><pub-id pub-id-type="pmcid">PMC6301090</pub-id></element-citation></ref><ref id="B140-cells-11-01868"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loo</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>D.M.</given-names></name></person-group><article-title>Correctors Enhance Maturation of &#916;F508 CFTR by Promoting Interactions between the Two Halves of the Molecule</article-title><source>Biochemistry</source><year>2009</year><volume>48</volume><fpage>9882</fpage><lpage>9890</lpage><pub-id pub-id-type="doi">10.1021/bi9004842</pub-id><pub-id pub-id-type="pmid">19761259</pub-id></element-citation></ref><ref id="B141-cells-11-01868"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loo</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>D.M.</given-names></name></person-group><article-title>Rescue of &#916;F508 and Other Misprocessed CFTR Mutants by a Novel Quinazoline Compound</article-title><source>Mol. Pharm.</source><year>2005</year><volume>2</volume><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1021/mp0500521</pub-id><pub-id pub-id-type="pmid">16196493</pub-id></element-citation></ref><ref id="B142-cells-11-01868"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiaw</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Wellhauser</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huan</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Ramjeesingh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.E.</given-names></name></person-group><article-title>A Chemical Corrector Modifies the Channel Function of F508del-CFTR</article-title><source>Mol. Pharmacol.</source><year>2010</year><volume>78</volume><fpage>411</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1124/mol.110.065862</pub-id><pub-id pub-id-type="pmid">20501743</pub-id></element-citation></ref><ref id="B143-cells-11-01868"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Goor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hadida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grootenhuis</surname><given-names>P.D.J.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stack</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Straley</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Decker</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCartney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>E.R.</given-names></name><etal/></person-group><article-title>Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>18843</fpage><lpage>18848</lpage><pub-id pub-id-type="doi">10.1073/pnas.1105787108</pub-id><pub-id pub-id-type="pmid">21976485</pub-id><pub-id pub-id-type="pmcid">PMC3219147</pub-id></element-citation></ref><ref id="B144-cells-11-01868"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kota</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aleksandrov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dokholyan</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Riordan</surname><given-names>J.R.</given-names></name></person-group><article-title>Correctors of &#916;F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein</article-title><source>FASEB J.</source><year>2013</year><volume>27</volume><fpage>536</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1096/fj.12-216119</pub-id><pub-id pub-id-type="pmid">23104983</pub-id><pub-id pub-id-type="pmcid">PMC3545534</pub-id></element-citation></ref><ref id="B145-cells-11-01868"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loo</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>D.M.</given-names></name></person-group><article-title>Corrector VX-809 stabilizes the first transmembrane domain of CFTR</article-title><source>Biochem. Pharmacol.</source><year>2013</year><volume>86</volume><fpage>612</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2013.06.028</pub-id><pub-id pub-id-type="pmid">23835419</pub-id></element-citation></ref><ref id="B146-cells-11-01868"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krainer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Treff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deber</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Schlierf</surname><given-names>M.</given-names></name></person-group><article-title>A minimal helical-hairpin motif provides molecular-level insights into misfolding and pharmacological rescue of CFTR</article-title><source>Commun. Biol.</source><year>2018</year><volume>1</volume><fpage>154</fpage><pub-id pub-id-type="doi">10.1038/s42003-018-0153-0</pub-id><pub-id pub-id-type="pmid">30302398</pub-id><pub-id pub-id-type="pmcid">PMC6162264</pub-id></element-citation></ref><ref id="B147-cells-11-01868"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krainer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ravamehr-Lake</surname><given-names>D.</given-names></name><name name-style="western"><surname>Deber</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Schlierf</surname><given-names>M.</given-names></name></person-group><article-title>CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>1985</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.1074/jbc.AC119.011360</pub-id><pub-id pub-id-type="pmid">31882543</pub-id><pub-id pub-id-type="pmcid">PMC7029128</pub-id></element-citation></ref><ref id="B148-cells-11-01868"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleizen</surname><given-names>B.</given-names></name><name name-style="western"><surname>van Willigen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mijnders</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>F.</given-names></name><name name-style="western"><surname>Grudniewska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hillenaar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kooijman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Frizzell</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Co-Translational Folding of the First Transmembrane Domain of ABC-Transporter CFTR is Supported by Assembly with the First Cytosolic Domain</article-title><source>J. Mol. Biol.</source><year>2021</year><volume>433</volume><fpage>166955</fpage><pub-id pub-id-type="doi">10.1016/j.jmb.2021.166955</pub-id><pub-id pub-id-type="pmid">33771570</pub-id></element-citation></ref><ref id="B149-cells-11-01868"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hudson</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Millen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Brouillette</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Forman-Kay</surname><given-names>J.D.</given-names></name></person-group><article-title>Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface</article-title><source>Mol. Pharmacol.</source><year>2017</year><volume>92</volume><fpage>124</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1124/mol.117.108373</pub-id><pub-id pub-id-type="pmid">28546419</pub-id></element-citation></ref><ref id="B150-cells-11-01868"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loo</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>D.M.</given-names></name></person-group><article-title>Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR</article-title><source>Biochem. Pharmacol.</source><year>2017</year><volume>136</volume><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2017.03.020</pub-id><pub-id pub-id-type="pmid">28366727</pub-id></element-citation></ref><ref id="B151-cells-11-01868"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckford</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ramjeesingh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molinski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pasyk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ip</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Du</surname><given-names>K.</given-names></name><etal/></person-group><article-title>VX-809 and Related Corrector Compounds Exhibit Secondary Activity Stabilizing Active F508del-CFTR after Its Partial Rescue to the Cell Surface</article-title><source>Chem. Biol.</source><year>2014</year><volume>21</volume><fpage>666</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2014.02.021</pub-id><pub-id pub-id-type="pmid">24726831</pub-id></element-citation></ref><ref id="B152-cells-11-01868"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Actis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yarlagadda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>K.</given-names></name><name name-style="western"><surname>Woodroofe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ziady</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry</article-title><source>ChemBioChem</source><year>2015</year><volume>16</volume><fpage>2017</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1002/cbic.201500123</pub-id><pub-id pub-id-type="pmid">26227551</pub-id><pub-id pub-id-type="pmcid">PMC4672727</pub-id></element-citation></ref><ref id="B153-cells-11-01868"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Daines</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ringshausen</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Kerem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>N.</given-names></name><name name-style="western"><surname>Simard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ingenito</surname><given-names>E.P.</given-names></name><etal/></person-group><article-title>Tezacaftor&#8211;Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2024</fpage><lpage>2035</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1709847</pub-id><pub-id pub-id-type="pmid">29099333</pub-id><pub-id pub-id-type="pmcid">PMC6472479</pub-id></element-citation></ref><ref id="B154-cells-11-01868"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laselva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Marzaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vaccarin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lampronti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tamanini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gambari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cabrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Chilin</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>719</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.00719</pub-id><pub-id pub-id-type="pmid">30022950</pub-id><pub-id pub-id-type="pmcid">PMC6039571</pub-id></element-citation></ref><ref id="B155-cells-11-01868"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Balut</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manelli</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Swensen</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Neelands</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Vortherms</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2020</year><volume>372</volume><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1124/jpet.119.261800</pub-id><pub-id pub-id-type="pmid">31732698</pub-id><pub-id pub-id-type="pmcid">PMC11047061</pub-id></element-citation></ref><ref id="B156-cells-11-01868"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Drevinek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Elborn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Plant</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Mini&#263;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van Braeckel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Verhulst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>K.</given-names></name><etal/></person-group><article-title>CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials</article-title><source>J. Cyst. Fibros.</source><year>2019</year><volume>18</volume><fpage>700</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2019.04.014</pub-id><pub-id pub-id-type="pmid">31056441</pub-id></element-citation></ref><ref id="B157-cells-11-01868"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bertozzi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Caci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sorana</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fruscia</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Tomati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ferrera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gimeno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eaay9669</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aay9669</pub-id><pub-id pub-id-type="pmid">32128418</pub-id><pub-id pub-id-type="pmcid">PMC7034990</pub-id></element-citation></ref><ref id="B158-cells-11-01868"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keating</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marigowda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Burr</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daines</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>McKone</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Sass</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><etal/></person-group><article-title>VX-445&#8211;Tezacaftor&#8211;Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>1612</fpage><lpage>1620</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1807120</pub-id><pub-id pub-id-type="pmid">30334692</pub-id><pub-id pub-id-type="pmcid">PMC6289290</pub-id></element-citation></ref><ref id="B159-cells-11-01868"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Moskowitz</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C.</given-names></name><name name-style="western"><surname>Horsley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>McKone</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Plant</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Prais</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Taylor-Cousar</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>VX-659&#8211;Tezacaftor&#8211;Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>1599</fpage><lpage>1611</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1807119</pub-id><pub-id pub-id-type="pmid">30334693</pub-id><pub-id pub-id-type="pmcid">PMC6277022</pub-id></element-citation></ref><ref id="B160-cells-11-01868"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baatallah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Elbahnsi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mornon</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Chevalier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pranke</surname><given-names>I.</given-names></name><name name-style="western"><surname>Servel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>D&#233;cout</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sermet-Gaudelus</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR</article-title><source>Cell. Mol. Life Sci.</source><year>2021</year><volume>78</volume><fpage>7813</fpage><lpage>7829</lpage><pub-id pub-id-type="doi">10.1007/s00018-021-03994-5</pub-id><pub-id pub-id-type="pmid">34714360</pub-id><pub-id pub-id-type="pmcid">PMC11071985</pub-id></element-citation></ref><ref id="B161-cells-11-01868"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stratford</surname><given-names>F.L.L.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>M.M.C.</given-names></name><name name-style="western"><surname>Becq</surname><given-names>F.</given-names></name><name name-style="western"><surname>McPherson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dormer</surname><given-names>R.L.</given-names></name></person-group><article-title>Benzo(c)quinolizinium drugs inhibit degradation of &#916;F508-CFTR cytoplasmic domain</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2003</year><volume>300</volume><fpage>524</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(02)02883-8</pub-id><pub-id pub-id-type="pmid">12504115</pub-id></element-citation></ref><ref id="B162-cells-11-01868"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dormer</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>D&#233;Rand</surname><given-names>R.</given-names></name><name name-style="western"><surname>McNeilly</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mettey</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bulteau-Pignoux</surname><given-names>L.</given-names></name><name name-style="western"><surname>M&#233;Tay&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vierfond</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Galietta</surname><given-names>L.J.V.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells</article-title><source>J. Cell Sci.</source><year>2001</year><volume>114</volume><fpage>4073</fpage><lpage>4081</lpage><pub-id pub-id-type="doi">10.1242/jcs.114.22.4073</pub-id><pub-id pub-id-type="pmid">11739639</pub-id></element-citation></ref><ref id="B163-cells-11-01868"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becq</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mettey</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Galietta</surname><given-names>L.J.V.</given-names></name><name name-style="western"><surname>Dormer</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Merten</surname><given-names>M.</given-names></name><name name-style="western"><surname>M&#233;tay&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chappe</surname><given-names>V.</given-names></name><name name-style="western"><surname>Marvingt-Mounir</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zegarra-Moran</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Development of Substituted Benzo[c]quinolizinium Compounds as Novel Activators of the Cystic Fibrosis Chloride Channel</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>27415</fpage><lpage>27425</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.39.27415</pub-id><pub-id pub-id-type="pmid">10488073</pub-id></element-citation></ref><ref id="B164-cells-11-01868"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odolczyk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Norez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Servel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Da Cunha</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Bitam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kupniewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wiszniewski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Colas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tarnowski</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Discovery of novel potent &#916;F 508-CFTR correctors that target the nucleotide binding domain</article-title><source>EMBO Mol. Med.</source><year>2013</year><volume>5</volume><fpage>1484</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1002/emmm.201302699</pub-id><pub-id pub-id-type="pmid">23982976</pub-id><pub-id pub-id-type="pmcid">PMC3799575</pub-id></element-citation></ref><ref id="B165-cells-11-01868"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bitam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elbahnsi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Creste</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pranke</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chevalier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Berhal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Servel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baatalah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tondelier</surname><given-names>D.</given-names></name><etal/></person-group><article-title>New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>6842</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-83240-x</pub-id><pub-id pub-id-type="pmid">33767236</pub-id><pub-id pub-id-type="pmcid">PMC7994384</pub-id></element-citation></ref><ref id="B166-cells-11-01868"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieddu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pollarolo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mazzei</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Anzaldi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schenone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galietta</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Mazzei</surname><given-names>M.</given-names></name></person-group><article-title>Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator</article-title><source>Arch. Der Pharm.</source><year>2016</year><volume>349</volume><fpage>112</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1002/ardp.201500352</pub-id><pub-id pub-id-type="pmid">26701662</pub-id></element-citation></ref><ref id="B167-cells-11-01868"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Matthes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Radinovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name></person-group><article-title>A novel triple combination of pharmacological chaperones improves F508del-CFTR correction</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>11404</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-29276-y</pub-id><pub-id pub-id-type="pmid">30061653</pub-id><pub-id pub-id-type="pmcid">PMC6065411</pub-id></element-citation></ref><ref id="B168-cells-11-01868"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes-Pacheco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bacalhau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ramalho</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>I.A.L.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name></person-group><article-title>Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.3390/cells11010136</pub-id><pub-id pub-id-type="pmid">35011698</pub-id><pub-id pub-id-type="pmcid">PMC8750248</pub-id></element-citation></ref><ref id="B169-cells-11-01868"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubenstein</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Egan</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Zeitlin</surname><given-names>P.L.</given-names></name></person-group><article-title>In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR</article-title><source>J. Clin. Investig.</source><year>1997</year><volume>100</volume><fpage>2457</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1172/JCI119788</pub-id><pub-id pub-id-type="pmid">9366560</pub-id><pub-id pub-id-type="pmcid">PMC508446</pub-id></element-citation></ref><ref id="B170-cells-11-01868"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suaud</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alvey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Robay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kebler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kreindler</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Guttentag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Rubenstein</surname><given-names>R.C.</given-names></name></person-group><article-title>ERp29 Regulates &#916;F508 and Wild-type Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Trafficking to the Plasma Membrane in Cystic Fibrosis (CF) and Non-CF Epithelial Cells</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>21239</fpage><lpage>21253</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.240267</pub-id><pub-id pub-id-type="pmid">21525008</pub-id><pub-id pub-id-type="pmcid">PMC3122184</pub-id></element-citation></ref><ref id="B171-cells-11-01868"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suaud</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Panichelli</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Randell</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Marando</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Rubenstein</surname><given-names>R.C.</given-names></name></person-group><article-title>4-Phenylbutyrate Stimulates Hsp70 Expression through the Elp2 Component of Elongator and STAT-3 in Cystic Fibrosis Epithelial Cells</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>45083</fpage><lpage>45092</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.293282</pub-id><pub-id pub-id-type="pmid">22069317</pub-id><pub-id pub-id-type="pmcid">PMC3247989</pub-id></element-citation></ref><ref id="B172-cells-11-01868"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubenstein</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Zeitlin</surname><given-names>P.L.</given-names></name></person-group><article-title>A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in &#916; F508-Homozygous Cystic Fibrosis Patients</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1998</year><volume>157</volume><fpage>484</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.157.2.9706088</pub-id><pub-id pub-id-type="pmid">9476862</pub-id></element-citation></ref><ref id="B173-cells-11-01868"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Venable</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lapointe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hutt</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Koulov</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Coppinger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurkan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kellner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Plutner</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Hsp90 Cochaperone Aha1 Downregulation Rescues Misfolding of CFTR in Cystic Fibrosis</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>803</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.09.043</pub-id><pub-id pub-id-type="pmid">17110338</pub-id></element-citation></ref><ref id="B174-cells-11-01868"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pankow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bamberger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Calzolari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Bartolom&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lavall&#233;e-Adam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Balch</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>J.R.</given-names></name></person-group><article-title>&#8710;F508 CFTR interactome remodelling promotes rescue of cystic fibrosis</article-title><source>Nature</source><year>2015</year><volume>528</volume><fpage>510</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1038/nature15729</pub-id><pub-id pub-id-type="pmid">26618866</pub-id><pub-id pub-id-type="pmcid">PMC4826614</pub-id></element-citation></ref><ref id="B175-cells-11-01868"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutt</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>A.P.C.</given-names></name><name name-style="western"><surname>Noel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pilewski</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kellner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis</article-title><source>Nat. Chem. Biol.</source><year>2010</year><volume>6</volume><fpage>25</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/nchembio.275</pub-id><pub-id pub-id-type="pmid">19966789</pub-id><pub-id pub-id-type="pmcid">PMC2901172</pub-id></element-citation></ref><ref id="B176-cells-11-01868"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutt</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Vickers</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chalfant</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Montero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leman</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Burkle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maryanoff</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Balch</surname><given-names>W.E.</given-names></name><etal/></person-group><article-title>Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides That Restore Trafficking and Activity of &#916;F508-CFTR</article-title><source>ACS Med. Chem. Lett.</source><year>2011</year><volume>2</volume><fpage>703</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1021/ml200136e</pub-id><pub-id pub-id-type="pmid">21984958</pub-id><pub-id pub-id-type="pmcid">PMC3187562</pub-id></element-citation></ref><ref id="B177-cells-11-01868"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angl&#232;s</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hutt</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Balch</surname><given-names>W.E.</given-names></name></person-group><article-title>HDAC inhibitors rescue multiple disease-causing CFTR variants</article-title><source>Hum. Mol. Genet.</source><year>2019</year><volume>28</volume><fpage>1982</fpage><lpage>2000</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddz026</pub-id><pub-id pub-id-type="pmid">30753450</pub-id><pub-id pub-id-type="pmcid">PMC6548347</pub-id></element-citation></ref><ref id="B178-cells-11-01868"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergougnoux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Knabe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bribes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chiron</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Sario</surname><given-names>A.</given-names></name><name name-style="western"><surname>Claustres</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molinari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vachier</surname><given-names>I.</given-names></name><name name-style="western"><surname>Taulan-Cadars</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2017</year><volume>88</volume><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2017.05.002</pub-id><pub-id pub-id-type="pmid">28478266</pub-id></element-citation></ref><ref id="B179-cells-11-01868"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sondo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tomati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Caci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Pfeffer</surname><given-names>U.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galietta</surname><given-names>L.J.V.</given-names></name></person-group><article-title>Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling</article-title><source>Am. J. Physiol.-Cell Physiol.</source><year>2011</year><volume>301</volume><fpage>C872</fpage><lpage>C885</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00507.2010</pub-id><pub-id pub-id-type="pmid">21753184</pub-id><pub-id pub-id-type="pmcid">PMC3512166</pub-id></element-citation></ref><ref id="B180-cells-11-01868"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pineda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walterfang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>M.C.</given-names></name></person-group><article-title>Miglustat in Niemann-Pick disease type C patients: A review</article-title><source>Orphanet J. Rare Dis.</source><year>2018</year><volume>13</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/s13023-018-0844-0</pub-id><pub-id pub-id-type="pmid">30111334</pub-id><pub-id pub-id-type="pmcid">PMC6094874</pub-id></element-citation></ref><ref id="B181-cells-11-01868"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Noel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bijvelds</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jorna</surname><given-names>H.</given-names></name><name name-style="western"><surname>Melin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dejonge</surname><given-names>H.</given-names></name><name name-style="western"><surname>Becq</surname><given-names>F.</given-names></name></person-group><article-title>Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the &#945;-glucosidase inhibitor miglustat</article-title><source>FEBS Lett.</source><year>2006</year><volume>580</volume><fpage>2081</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2006.03.010</pub-id><pub-id pub-id-type="pmid">16546175</pub-id></element-citation></ref><ref id="B182-cells-11-01868"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lebecque</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dingemanse</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>T.</given-names></name></person-group><article-title>A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference</article-title><source>J. Cyst. Fibros.</source><year>2012</year><volume>11</volume><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2011.12.004</pub-id><pub-id pub-id-type="pmid">22281182</pub-id></element-citation></ref><ref id="B183-cells-11-01868"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egan</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gl&#246;ckner-Pagel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cahill</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Pappoe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Balamuth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>E.</given-names></name><name name-style="western"><surname>Canny</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Geibel</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells</article-title><source>Nat. Med.</source><year>2002</year><volume>8</volume><fpage>485</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nm0502-485</pub-id><pub-id pub-id-type="pmid">11984593</pub-id></element-citation></ref><ref id="B184-cells-11-01868"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vandebrouck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>J.</given-names></name><name name-style="western"><surname>Noel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Durieu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oumata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galons</surname><given-names>H.</given-names></name><name name-style="western"><surname>Antigny</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chatelier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bois</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism</article-title><source>Br. J. Pharmacol.</source><year>2014</year><volume>171</volume><fpage>4831</fpage><lpage>4849</lpage><pub-id pub-id-type="doi">10.1111/bph.12859</pub-id><pub-id pub-id-type="pmid">25065395</pub-id><pub-id pub-id-type="pmcid">PMC4294108</pub-id></element-citation></ref><ref id="B185-cells-11-01868"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrestha</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>B.</given-names></name><name name-style="western"><surname>H&#228;fner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kopp</surname><given-names>B.T.</given-names></name></person-group><article-title>(R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>21700</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-78817-x</pub-id><pub-id pub-id-type="pmid">33303916</pub-id><pub-id pub-id-type="pmcid">PMC7728753</pub-id></element-citation></ref><ref id="B186-cells-11-01868"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meijer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Riazanski</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gabdoulkhakova</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hery-Arnaud</surname><given-names>G.</given-names></name><name name-style="western"><surname>Le Berre</surname><given-names>R.</given-names></name><name name-style="western"><surname>Loa&#235;c</surname><given-names>N.</given-names></name><name name-style="western"><surname>Oumata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galons</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis</article-title><source>J. Innate Immun.</source><year>2016</year><volume>8</volume><fpage>330</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1159/000444256</pub-id><pub-id pub-id-type="pmid">26987072</pub-id><pub-id pub-id-type="pmcid">PMC4800827</pub-id></element-citation></ref><ref id="B187-cells-11-01868"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meijer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hery-Arnaud</surname><given-names>G.</given-names></name><name name-style="western"><surname>Leven</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hillion</surname><given-names>S.</given-names></name><name name-style="western"><surname>Renaudineau</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Durieu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chiron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Prevotat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fajac</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study</article-title><source>J. Cyst. Fibros.</source><year>2021</year><volume>21</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2021.10.013</pub-id><pub-id pub-id-type="pmid">34961705</pub-id></element-citation></ref><ref id="B188-cells-11-01868"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vauthier</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ben Saad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oumata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Durand-Schneider</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Bruneau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Delaunay</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Housset</surname><given-names>C.</given-names></name><name name-style="western"><surname>A&#239;t-Slimane</surname><given-names>T.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Structural analogues of roscovitine rescue the intracellular traffic and the function of ER-retained ABCB4 variants in cell models</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>6653</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-43111-y</pub-id><pub-id pub-id-type="pmid">31040306</pub-id><pub-id pub-id-type="pmcid">PMC6491434</pub-id></element-citation></ref><ref id="B189-cells-11-01868"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egan</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gl&#246;ckner-Pagel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Canny</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Caplan</surname><given-names>M.J.</given-names></name></person-group><article-title>Curcumin, a Major Constituent of Turmeric, Corrects Cystic Fibrosis Defects</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>600</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1126/science.1093941</pub-id><pub-id pub-id-type="pmid">15105504</pub-id></element-citation></ref><ref id="B190-cells-11-01868"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sonawane</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Salinas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galietta</surname><given-names>L.J.V.</given-names></name><name name-style="western"><surname>Verkman</surname><given-names>A.S.</given-names></name></person-group><article-title>Evidence against the Rescue of Defective &#916;F508-CFTR Cellular Processing by Curcumin in Cell Culture and Mouse Models</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>40629</fpage><lpage>40633</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407308200</pub-id><pub-id pub-id-type="pmid">15280357</pub-id></element-citation></ref><ref id="B191-cells-11-01868"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grubb</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Mengos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gentzsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Randell</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Van Heeckeren</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Drumm</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Riordan</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>R.C.</given-names></name></person-group><article-title>SERCA Pump Inhibitors Do Not Correct Biosynthetic Arrest of &#916;F508 CFTR in Cystic Fibrosis</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2006</year><volume>34</volume><fpage>355</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2005-0286OC</pub-id><pub-id pub-id-type="pmid">16284361</pub-id><pub-id pub-id-type="pmcid">PMC2644200</pub-id></element-citation></ref><ref id="B192-cells-11-01868"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berger</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Randak</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Ostedgaard</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Karp</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Vermeer</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>M.J.</given-names></name></person-group><article-title>Curcumin Stimulates Cystic Fibrosis Transmembrane Conductance Regulator Cl<sup>&#8722;</sup> Channel Activity</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>5221</fpage><lpage>5226</lpage><pub-id pub-id-type="doi">10.1074/jbc.M412972200</pub-id><pub-id pub-id-type="pmid">15582996</pub-id></element-citation></ref><ref id="B193-cells-11-01868"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berkers</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Der Meer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Mourik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vonk</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kruisselbrink</surname><given-names>E.</given-names></name><name name-style="western"><surname>Suen</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Heijerman</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Majoor</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Koppelman</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Roukema</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>19</volume><fpage>955</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2020.04.014</pub-id><pub-id pub-id-type="pmid">32499204</pub-id></element-citation></ref><ref id="B194-cells-11-01868"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Keyzers</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Teske</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Linington</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Centko</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Anjos</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Correction of F508del-CFTR Trafficking by the Sponge Alkaloid Latonduine Is Modulated by Interaction with PARP</article-title><source>Chem. Biol.</source><year>2012</year><volume>19</volume><fpage>1288</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2012.08.014</pub-id><pub-id pub-id-type="pmid">23102222</pub-id></element-citation></ref><ref id="B195-cells-11-01868"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Matthes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Solari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hatley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Edge</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name><etal/></person-group><article-title>Latonduine Analogs Restore F508del&#8211;Cystic Fibrosis Transmembrane Conductance Regulator Trafficking through the Modulation of Poly-ADP Ribose Polymerase 3 and Poly-ADP Ribose Polymerase 16 Activity</article-title><source>Mol. Pharmacol.</source><year>2016</year><volume>90</volume><fpage>65</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1124/mol.115.102418</pub-id><pub-id pub-id-type="pmid">27193581</pub-id></element-citation></ref><ref id="B196-cells-11-01868"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Centko</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Barne</surname><given-names>I.</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>B.O.</given-names></name><name name-style="western"><surname>Blagojevic</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>R.J.</given-names></name></person-group><article-title>Combination of Selective PARP3 and PARP16 Inhibitory Analogues of Latonduine A Corrects F508del-CFTR Trafficking</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>25593</fpage><lpage>25604</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c02467</pub-id><pub-id pub-id-type="pmid">33073085</pub-id><pub-id pub-id-type="pmcid">PMC7557227</pub-id></element-citation></ref><ref id="B197-cells-11-01868"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Goeckeler-Fried</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Havasi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Plyler</surname><given-names>Z.E.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Piazza</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Keeton</surname><given-names>A.B.</given-names></name><etal/></person-group><article-title>Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0163615</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0163615</pub-id><pub-id pub-id-type="pmid">27732613</pub-id><pub-id pub-id-type="pmcid">PMC5061379</pub-id></element-citation></ref><ref id="B198-cells-11-01868"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goeckeler-Fried</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Aldrin Denny</surname><given-names>R.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>C.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Frizzell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Wipf</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sorscher</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>J.L.</given-names></name></person-group><article-title>Improved correction of F508del-CFTR biogenesis with a folding facilitator and an inhibitor of protein ubiquitination</article-title><source>Bioorganic Med. Chem. Lett.</source><year>2021</year><volume>48</volume><fpage>128243</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2021.128243</pub-id><pub-id pub-id-type="pmcid">PMC8869796</pub-id><pub-id pub-id-type="pmid">34246753</pub-id></element-citation></ref><ref id="B199-cells-11-01868"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borgo</surname><given-names>C.</given-names></name><name name-style="western"><surname>D&#8217;Amore</surname><given-names>C.</given-names></name><name name-style="western"><surname>Capurro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tomati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sondo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cresta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castellani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Salvi</surname><given-names>M.</given-names></name></person-group><article-title>Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants</article-title><source>Cell. Mol. Life Sci.</source><year>2022</year><volume>79</volume><fpage>192</fpage><pub-id pub-id-type="doi">10.1007/s00018-022-04215-3</pub-id><pub-id pub-id-type="pmid">35292885</pub-id><pub-id pub-id-type="pmcid">PMC8924136</pub-id></element-citation></ref><ref id="B200-cells-11-01868"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sondo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Falchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Caci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferrera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giacomini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tomati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mandrup Bertozzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goldoni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Armirotti</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia</article-title><source>Cell Chem. Biol.</source><year>2018</year><volume>25</volume><fpage>891</fpage><lpage>905.e898</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.04.010</pub-id><pub-id pub-id-type="pmid">29754957</pub-id></element-citation></ref><ref id="B201-cells-11-01868"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henning</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Boike</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spradlin</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Belcher</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Brittain</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hesse</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Dovala</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Deubiquitinase-targeting chimeras for targeted protein stabilization</article-title><source>Nat. Chem. Biol.</source><year>2022</year><volume>18</volume><fpage>412</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/s41589-022-00971-2</pub-id><pub-id pub-id-type="pmid">35210618</pub-id><pub-id pub-id-type="pmcid">PMC10125259</pub-id></element-citation></ref><ref id="B202-cells-11-01868"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Frizzell</surname><given-names>R.A.</given-names></name></person-group><article-title>Divergent signaling via SUMO modification: Potential for CFTR modulation</article-title><source>Am. J. Physiol.-Cell Physiol.</source><year>2016</year><volume>310</volume><fpage>C175</fpage><lpage>C180</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00124.2015</pub-id><pub-id pub-id-type="pmid">26582473</pub-id><pub-id pub-id-type="pmcid">PMC4838058</pub-id></element-citation></ref><ref id="B203-cells-11-01868"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Frizzell</surname><given-names>R.A.</given-names></name></person-group><article-title>Cystic Fibrosis Transmembrane Conductance Regulator Folding Mutations Reveal Differences in Corrector Efficacy Linked to Increases in Immature Cystic Fibrosis Transmembrane Conductance Regulator Expression</article-title><source>Front. Physiol.</source><year>2021</year><volume>12</volume><fpage>695767</fpage><pub-id pub-id-type="doi">10.3389/fphys.2021.695767</pub-id><pub-id pub-id-type="pmid">34764878</pub-id><pub-id pub-id-type="pmcid">PMC8576290</pub-id></element-citation></ref><ref id="B204-cells-11-01868"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ahner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Frizzell</surname><given-names>R.A.</given-names></name></person-group><article-title>Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: Biogenesis versus degradation</article-title><source>Mol. Biol. Cell</source><year>2019</year><volume>30</volume><fpage>4</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1091/mbc.E18-04-0252</pub-id><pub-id pub-id-type="pmid">30403549</pub-id><pub-id pub-id-type="pmcid">PMC6337916</pub-id></element-citation></ref><ref id="B205-cells-11-01868"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Okiyoneda</surname><given-names>T.</given-names></name></person-group><article-title>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis</article-title><source>Pharmaceuticals</source><year>2020</year><volume>13</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.3390/ph13040075</pub-id><pub-id pub-id-type="pmcid">PMC7243099</pub-id><pub-id pub-id-type="pmid">32331485</pub-id></element-citation></ref><ref id="B206-cells-11-01868"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luciani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Villella</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gavina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Silano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guido</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pettoello-Mantovani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carnuccio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scholte</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on &#916;F508 cystic fibrosis transmembrane conductance regulator</article-title><source>Autophagy</source><year>2012</year><volume>8</volume><fpage>1657</fpage><lpage>1672</lpage><pub-id pub-id-type="doi">10.4161/auto.21483</pub-id><pub-id pub-id-type="pmid">22874563</pub-id><pub-id pub-id-type="pmcid">PMC3494594</pub-id></element-citation></ref><ref id="B207-cells-11-01868"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherqui</surname><given-names>S.</given-names></name></person-group><article-title>Cysteamine therapy: A treatment for cystinosis, not a cure</article-title><source>Kidney Int.</source><year>2012</year><volume>81</volume><fpage>127</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.301</pub-id><pub-id pub-id-type="pmid">22205430</pub-id><pub-id pub-id-type="pmcid">PMC3386783</pub-id></element-citation></ref><ref id="B208-cells-11-01868"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefano</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Villella</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tosco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sepe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gregorio</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Salvadori</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grassia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation</article-title><source>Autophagy</source><year>2014</year><volume>10</volume><fpage>2053</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.4161/15548627.2014.973737</pub-id><pub-id pub-id-type="pmid">25350163</pub-id><pub-id pub-id-type="pmcid">PMC4502695</pub-id></element-citation></ref><ref id="B209-cells-11-01868"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tosco</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Stefano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sana</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sepe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salvadori</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buonpensiero</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Pasqua</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A novel treatment of cystic fibrosis acting on-target: Cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR</article-title><source>Cell Death Differ.</source><year>2016</year><volume>23</volume><fpage>1380</fpage><lpage>1393</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.22</pub-id><pub-id pub-id-type="pmid">27035618</pub-id><pub-id pub-id-type="pmcid">PMC4947669</pub-id></element-citation></ref><ref id="B210-cells-11-01868"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Oikonomou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iannitti</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>D'Adamo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Villella</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Pariano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sforna</surname><given-names>L.</given-names></name><name name-style="western"><surname>Borghi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bellet</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Thymosin &#945;1 represents a potential potent single-molecule-based therapy for cystic fibrosis</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>590</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1038/nm.4305</pub-id><pub-id pub-id-type="pmid">28394330</pub-id><pub-id pub-id-type="pmcid">PMC5420451</pub-id></element-citation></ref><ref id="B211-cells-11-01868"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Caci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferrera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sondo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cholon</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Quinney</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Boyles</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Armirotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ravazzolo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Thymosin &#945;-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><fpage>e98699</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.98699</pub-id><pub-id pub-id-type="pmid">29415893</pub-id><pub-id pub-id-type="pmcid">PMC5821210</pub-id></element-citation></ref><ref id="B212-cells-11-01868"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Cantin</surname><given-names>A.M.</given-names></name></person-group><article-title>F508del-CFTR is not corrected by thymosin &#945;1</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>890</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0079-6</pub-id><pub-id pub-id-type="pmid">29942095</pub-id></element-citation></ref><ref id="B213-cells-11-01868"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armirotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tomati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Matthes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cholon</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Phuan</surname><given-names>P.-W.</given-names></name><name name-style="western"><surname>Braccia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guidone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gentzsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lukacs</surname><given-names>G.L.</given-names></name><etal/></person-group><article-title>Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>10310</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-46639-1</pub-id><pub-id pub-id-type="pmid">31311979</pub-id><pub-id pub-id-type="pmcid">PMC6635361</pub-id></element-citation></ref><ref id="B214-cells-11-01868"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>K.E.</given-names></name></person-group><article-title>PDE5 inhibitors&#8212;Pharmacology and clinical applications 20 years after sildenafil discovery</article-title><source>Br. J. Pharmacol.</source><year>2018</year><volume>175</volume><fpage>2554</fpage><lpage>2565</lpage><pub-id pub-id-type="doi">10.1111/bph.14205</pub-id><pub-id pub-id-type="pmid">29667180</pub-id><pub-id pub-id-type="pmcid">PMC6003652</pub-id></element-citation></ref><ref id="B215-cells-11-01868"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dormer</surname><given-names>R.L.</given-names></name></person-group><article-title>Sildenafil (Viagra) corrects F508-CFTR location in nasal epithelial cells from patients with cystic fibrosis</article-title><source>Thorax</source><year>2005</year><volume>60</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1136/thx.2003.019778</pub-id><pub-id pub-id-type="pmid">15618584</pub-id><pub-id pub-id-type="pmcid">PMC1747155</pub-id></element-citation></ref><ref id="B216-cells-11-01868"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubamba</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lecourt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lebacq</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lebecque</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Jonge</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wallemacq</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>T.</given-names></name></person-group><article-title>Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2008</year><volume>177</volume><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1164/rccm.200703-344OC</pub-id><pub-id pub-id-type="pmid">18006891</pub-id></element-citation></ref><ref id="B217-cells-11-01868"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Pavel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anjos</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name></person-group><article-title>Structural Analog of Sildenafil Identified as a Novel Corrector of the F508del-CFTR Trafficking Defect</article-title><source>Mol. Pharmacol.</source><year>2008</year><volume>73</volume><fpage>478</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1124/mol.107.040725</pub-id><pub-id pub-id-type="pmid">17975008</pub-id></element-citation></ref><ref id="B218-cells-11-01868"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loo</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>D.M.</given-names></name></person-group><article-title>Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump</article-title><source>Biochem. Pharmacol.</source><year>2012</year><volume>83</volume><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2011.11.014</pub-id><pub-id pub-id-type="pmid">22138447</pub-id></element-citation></ref><ref id="B219-cells-11-01868"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor-Cousar</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Wiley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Felton</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>St. Clair</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M.</given-names></name><name name-style="western"><surname>Curran-Everett</surname><given-names>D.</given-names></name><name name-style="western"><surname>Poch</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Saavedra</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease</article-title><source>J. Cyst. Fibros.</source><year>2015</year><volume>14</volume><fpage>228</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2014.10.006</pub-id><pub-id pub-id-type="pmid">25466700</pub-id><pub-id pub-id-type="pmcid">PMC4355330</pub-id></element-citation></ref><ref id="B220-cells-11-01868"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garnock-Jones</surname><given-names>K.P.</given-names></name></person-group><article-title>Riociguat: A Review of Its Use in Patients with Chronic Thromboembolic Pulmonary Hypertension or Pulmonary Arterial Hypertension</article-title><source>Drugs</source><year>2014</year><volume>74</volume><fpage>2065</fpage><lpage>2078</lpage><pub-id pub-id-type="doi">10.1007/s40265-014-0317-2</pub-id><pub-id pub-id-type="pmid">25352393</pub-id></element-citation></ref><ref id="B221-cells-11-01868"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derichs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Taylor-Cousar</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Fajac</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nazareth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Rosenbluth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Malfroot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis</article-title><source>J. Cyst. Fibros.</source><year>2021</year><volume>20</volume><fpage>1018</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2021.07.015</pub-id><pub-id pub-id-type="pmid">34419414</pub-id></element-citation></ref><ref id="B222-cells-11-01868"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derichs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Taylor-Cousar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tullis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nazareth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Rosenbluth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fajac</surname><given-names>I.</given-names></name><name name-style="western"><surname>Malfroot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>M.</given-names></name><etal/></person-group><article-title>EPS1.3 Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: Study design and rationale for the Rio-CF study</article-title><source>J. Cyst. Fibros.</source><year>2017</year><volume>16</volume><fpage>S36</fpage><pub-id pub-id-type="doi">10.1016/S1569-1993(17)30276-X</pub-id></element-citation></ref><ref id="B223-cells-11-01868"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sponta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coppolino</surname><given-names>M.F.</given-names></name></person-group><article-title>Clinical pharmacology of non-steroidal anti-inflammatory drugs: A review</article-title><source>Anti-Inflamm. Anti-Allergy Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Inflamm. Anti-Allergy Agents)</source><year>2012</year><volume>11</volume><fpage>52</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.2174/187152312803476255</pub-id><pub-id pub-id-type="pmid">22934743</pub-id></element-citation></ref><ref id="B224-cells-11-01868"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goepp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matthes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Macknight</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Rotin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name></person-group><article-title>Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking</article-title><source>J. Cyst. Fibros.</source><year>2015</year><volume>14</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2014.06.001</pub-id><pub-id pub-id-type="pmid">24974227</pub-id></element-citation></ref><ref id="B225-cells-11-01868"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlile</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Matthes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Birault</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sneddon</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Poole</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hanrahan</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.Y.</given-names></name></person-group><article-title>The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><fpage>4595</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-08661-8</pub-id><pub-id pub-id-type="pmid">35302062</pub-id><pub-id pub-id-type="pmcid">PMC8930988</pub-id></element-citation></ref><ref id="B226-cells-11-01868"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donaldson</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Zeitlin</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Flume</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>A.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zemanick</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Mandagere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Troha</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Shoemaker</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR</article-title><source>J. Cyst. Fibros.</source><year>2017</year><volume>16</volume><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2017.01.009</pub-id><pub-id pub-id-type="pmid">28209466</pub-id></element-citation></ref><ref id="B227-cells-11-01868"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sawczak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.</given-names></name><name name-style="western"><surname>Getsy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zeinomar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Forbes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Augmentation of CFTR maturation by S-nitrosoglutathione reductase</article-title><source>Am. J. Physiol.-Lung Cell. Mol. Physiol.</source><year>2015</year><volume>310</volume><fpage>L263</fpage><lpage>L270</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00269.2014</pub-id><pub-id pub-id-type="pmid">26637637</pub-id><pub-id pub-id-type="pmcid">PMC4838141</pub-id></element-citation></ref><ref id="B228-cells-11-01868"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fraser-Butler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Getsy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sattar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>J.</given-names></name><etal/></person-group><article-title>S-nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2014</year><volume>443</volume><fpage>1257</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2013.12.130</pub-id><pub-id pub-id-type="pmid">24393850</pub-id><pub-id pub-id-type="pmcid">PMC3974270</pub-id></element-citation></ref><ref id="B229-cells-11-01868"><label>229.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Nivalis Therapeutics</collab></person-group><source>Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat for Treatment of Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B230-cells-11-01868"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becq</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mirval</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carrez</surname><given-names>T.</given-names></name><name name-style="western"><surname>L&#233;v&#234;que</surname><given-names>M.</given-names></name><name name-style="western"><surname>Billet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coraux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sage</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cantereau</surname><given-names>A.</given-names></name></person-group><article-title>The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor</article-title><source>Eur. Respir. J.</source><year>2021</year><volume>59</volume><fpage>2100671</fpage><pub-id pub-id-type="doi">10.1183/13993003.00671-2021</pub-id><pub-id pub-id-type="pmid">34266939</pub-id></element-citation></ref><ref id="B231-cells-11-01868"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matos</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>P.</given-names></name></person-group><article-title>Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770</article-title><source>Front. Mol. Biosci.</source><year>2021</year><volume>8</volume><fpage>812101</fpage><pub-id pub-id-type="doi">10.3389/fmolb.2021.812101</pub-id><pub-id pub-id-type="pmid">35004859</pub-id><pub-id pub-id-type="pmcid">PMC8727755</pub-id></element-citation></ref><ref id="B232-cells-11-01868"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matos</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Gomes-Duarte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Faria</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>P.</given-names></name></person-group><article-title>Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>13026</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-31514-2</pub-id><pub-id pub-id-type="pmid">30158635</pub-id><pub-id pub-id-type="pmcid">PMC6115363</pub-id></element-citation></ref><ref id="B233-cells-11-01868"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moniz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Palma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fragata</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>P.</given-names></name></person-group><article-title>HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR</article-title><source>ACS Chem. Biol.</source><year>2013</year><volume>8</volume><fpage>432</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1021/cb300484r</pub-id><pub-id pub-id-type="pmid">23148778</pub-id></element-citation></ref><ref id="B234-cells-11-01868"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshafie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chappe</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anini</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chappe</surname><given-names>V.M.</given-names></name></person-group><article-title>VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKC&#949;-dependent manner</article-title><source>Am. J. Physiol.-Cell Physiol.</source><year>2014</year><volume>307</volume><fpage>C107</fpage><lpage>C119</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00296.2013</pub-id><pub-id pub-id-type="pmid">24788249</pub-id></element-citation></ref><ref id="B235-cells-11-01868"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobo</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Zaccolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name></person-group><article-title>EPAC1 activation by cAMP stabilizes CFTR at the membrane by promoting its interaction with NHERF1</article-title><source>J. Cell Sci.</source><year>2016</year><volume>129</volume><fpage>2599</fpage><lpage>2612</lpage><pub-id pub-id-type="doi">10.1242/jcs.185629</pub-id><pub-id pub-id-type="pmid">27206858</pub-id></element-citation></ref><ref id="B236-cells-11-01868"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Zaccolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name></person-group><article-title>Cytoskeleton regulators CAPZA2 and INF2 associate with CFTR to control its plasma membrane levels under EPAC1 activation</article-title><source>Biochem. J.</source><year>2020</year><volume>477</volume><fpage>2561</fpage><lpage>2580</lpage><pub-id pub-id-type="doi">10.1042/BCJ20200287</pub-id><pub-id pub-id-type="pmid">32573649</pub-id></element-citation></ref><ref id="B237-cells-11-01868"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matos</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>P.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Pepperkok</surname><given-names>R.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>P.</given-names></name></person-group><article-title>Inhibition of calpain 1 restores plasma membrane stability to pharmacologically rescued Phe508del-CFTR variant</article-title><source>J. Biol. Chem.</source><year>2019</year><volume>294</volume><fpage>13396</fpage><lpage>13410</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.008738</pub-id><pub-id pub-id-type="pmid">31324722</pub-id><pub-id pub-id-type="pmcid">PMC6737230</pub-id></element-citation></ref><ref id="B238-cells-11-01868"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Favia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fanelli</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cardone</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Monterisi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Sole</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castellani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seidler</surname><given-names>U.</given-names></name><name name-style="western"><surname>Reshkin</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Na<sup>+</sup>/H<sup>+</sup> Exchanger Regulatory Factor 1 Overexpression-dependent Increase of Cytoskeleton Organization Is Fundamental in the Rescue of F508del Cystic Fibrosis Transmembrane Conductance Regulator in Human Airway CFBE41o-Cells</article-title><source>Mol. Biol. Cell</source><year>2010</year><volume>21</volume><fpage>73</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1091/mbc.e09-03-0185</pub-id><pub-id pub-id-type="pmid">19889841</pub-id><pub-id pub-id-type="pmcid">PMC2801722</pub-id></element-citation></ref><ref id="B239-cells-11-01868"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cushing</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Vouilleme</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boisguerin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Madden</surname><given-names>D.R.</given-names></name></person-group><article-title>A Stabilizing Influence: CAL PDZ Inhibition Extends the Half-Life of &#916;F508-CFTR</article-title><source>Angew. Chem. Int. Ed.</source><year>2010</year><volume>49</volume><fpage>9907</fpage><lpage>9911</lpage><pub-id pub-id-type="doi">10.1002/anie.201005585</pub-id><pub-id pub-id-type="pmcid">PMC3033200</pub-id><pub-id pub-id-type="pmid">21105033</pub-id></element-citation></ref><ref id="B240-cells-11-01868"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Bebok</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bartoszewski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Collawn</surname><given-names>J.F.</given-names></name></person-group><article-title>&#916;F508 CFTR Surface Stability Is Regulated by DAB2 and CHIP-Mediated Ubiquitination in Post-Endocytic Compartments</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0123131</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0123131</pub-id><pub-id pub-id-type="pmid">25879443</pub-id><pub-id pub-id-type="pmcid">PMC4399842</pub-id></element-citation></ref><ref id="B241-cells-11-01868"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rajagopalan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouhamdan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zaman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><etal/></person-group><article-title>CK19 stabilizes CFTR at the cell surface by limiting its endocytic pathway degradation</article-title><source>FASEB J.</source><year>2019</year><volume>33</volume><fpage>12602</fpage><lpage>12615</lpage><pub-id pub-id-type="doi">10.1096/fj.201901050R</pub-id><pub-id pub-id-type="pmid">31450978</pub-id><pub-id pub-id-type="pmcid">PMC9292138</pub-id></element-citation></ref><ref id="B242-cells-11-01868"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>P.</given-names></name></person-group><article-title>Rab GTPases regulate the trafficking of channels and transporters&#8212;A focus on cystic fibrosis</article-title><source>Small GTPases</source><year>2018</year><volume>9</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1080/21541248.2017.1317700</pub-id><pub-id pub-id-type="pmid">28463591</pub-id><pub-id pub-id-type="pmcid">PMC5902203</pub-id></element-citation></ref><ref id="B243-cells-11-01868"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendes</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moniz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Farinha</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>P.</given-names></name></person-group><article-title>Antagonistic Regulation of Cystic Fibrosis Transmembrane Conductance Regulator Cell Surface Expression by Protein Kinases WNK4 and Spleen Tyrosine Kinase</article-title><source>Mol. Cell. Biol.</source><year>2011</year><volume>31</volume><fpage>4076</fpage><lpage>4086</lpage><pub-id pub-id-type="doi">10.1128/MCB.05152-11</pub-id><pub-id pub-id-type="pmid">21807898</pub-id><pub-id pub-id-type="pmcid">PMC3187369</pub-id></element-citation></ref><ref id="B244-cells-11-01868"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loureiro</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Barros</surname><given-names>P.</given-names></name><name name-style="western"><surname>Matos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>P.</given-names></name></person-group><article-title>A SYK/SHC1 pathway regulates the amount of CFTR in the plasma membrane</article-title><source>Cell. Mol. Life Sci.</source><year>2020</year><volume>77</volume><fpage>4997</fpage><lpage>5015</lpage><pub-id pub-id-type="doi">10.1007/s00018-020-03448-4</pub-id><pub-id pub-id-type="pmid">31974654</pub-id><pub-id pub-id-type="pmcid">PMC11105000</pub-id></element-citation></ref><ref id="B245-cells-11-01868"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliver</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Rauscher</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mijnders</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wolpert</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Maya</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sabusap</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kesterson</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Rab</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Slowing ribosome velocity restores folding and function of mutant CFTR</article-title><source>J. Clin. Investig.</source><year>2019</year><volume>129</volume><fpage>5236</fpage><lpage>5253</lpage><pub-id pub-id-type="doi">10.1172/JCI124282</pub-id><pub-id pub-id-type="pmid">31657788</pub-id><pub-id pub-id-type="pmcid">PMC6877332</pub-id></element-citation></ref><ref id="B246-cells-11-01868"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veit</surname><given-names>G.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>K.</given-names></name><name name-style="western"><surname>Apaja</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Perdomo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bidaud-Meynard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.-T.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Icyuz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sorscher</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Ribosomal Stalk Protein Silencing Partially Corrects the &#916;F508-CFTR Functional Expression Defect</article-title><source>PLoS Biol.</source><year>2016</year><volume>14</volume><elocation-id>e1002462</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1002462</pub-id><pub-id pub-id-type="pmid">27168400</pub-id><pub-id pub-id-type="pmcid">PMC4864299</pub-id></element-citation></ref><ref id="B247-cells-11-01868"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Drew</surname><given-names>L.</given-names></name><name name-style="western"><surname>Green</surname><given-names>O.</given-names></name><name name-style="western"><surname>Villella</surname><given-names>A.</given-names></name><name name-style="western"><surname>McEwan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bhalla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parks</surname><given-names>D.</given-names></name><etal/></person-group><article-title>CFTR Amplifiers: A New Class of CFTR Modulator that Complements the Substrate Limitations of Other CF Therapeutic Modalities</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2016</year><volume>193</volume><fpage>A5574</fpage></element-citation></ref><ref id="B248-cells-11-01868"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giuliano</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Wachi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Drew</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dukovski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Green</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Hauck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tait</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors</article-title><source>SLAS Discov. Adv. Sci. Drug Discov.</source><year>2018</year><volume>23</volume><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1177/2472555217729790</pub-id><pub-id pub-id-type="pmcid">PMC5784457</pub-id><pub-id pub-id-type="pmid">28898585</pub-id></element-citation></ref><ref id="B249-cells-11-01868"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dukovski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Villella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>C.</given-names></name><name name-style="western"><surname>King</surname><given-names>R.</given-names></name><name name-style="western"><surname>Finley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>F.U.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.S.</given-names></name><etal/></person-group><article-title>Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>19</volume><fpage>733</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2020.02.006</pub-id><pub-id pub-id-type="pmid">32067958</pub-id></element-citation></ref><ref id="B250-cells-11-01868"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molinski</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ip</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Villella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Kulleperuma</surname><given-names>K.</given-names></name><name name-style="western"><surname>Du</surname><given-names>K.</given-names></name><name name-style="western"><surname>Di Paola</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Orkambi<sup>&#174;</sup> and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue</article-title><source>EMBO Mol. Med.</source><year>2017</year><volume>9</volume><fpage>1224</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.15252/emmm.201607137</pub-id><pub-id pub-id-type="pmid">28667089</pub-id><pub-id pub-id-type="pmcid">PMC5582412</pub-id></element-citation></ref><ref id="B251-cells-11-01868"><label>251.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Proteostasis Therapeutics</collab></person-group><source>Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B252-cells-11-01868"><label>252.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>HIT-CF</collab></person-group><article-title>HIT-CF Newsletter November 2021</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ecfs.eu/sites/default/files/general-content-files/news/HIT-CF%20Newsletter%20November%202021.pdf" ext-link-type="uri">https://www.ecfs.eu/sites/default/files/general-content-files/news/HIT-CF%20Newsletter%20November%202021.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-10">(accessed on 10 May 2022)</date-in-citation></element-citation></ref><ref id="B253-cells-11-01868"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glasgow</surname><given-names>A.M.A.</given-names></name><name name-style="western"><surname>De Santi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>C.M.</given-names></name></person-group><article-title>Non-coding RNA in cystic fibrosis</article-title><source>Biochem. Soc. Trans.</source><year>2018</year><volume>46</volume><fpage>619</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1042/BST20170469</pub-id><pub-id pub-id-type="pmid">29743276</pub-id></element-citation></ref><ref id="B254-cells-11-01868"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Palma</surname><given-names>F.D.E.</given-names></name><name name-style="western"><surname>Raia</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maiuri</surname><given-names>M.C.</given-names></name></person-group><article-title>The Multifaceted Roles of MicroRNAs in Cystic Fibrosis</article-title><source>Diagnostics</source><year>2020</year><volume>10</volume><elocation-id>1102</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics10121102</pub-id><pub-id pub-id-type="pmid">33348555</pub-id><pub-id pub-id-type="pmcid">PMC7765910</pub-id></element-citation></ref><ref id="B255-cells-11-01868"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viart</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bergougnoux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Varilh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chiron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tabary</surname><given-names>O.</given-names></name><name name-style="western"><surname>Molinari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Claustres</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taulan-Cadars</surname><given-names>M.</given-names></name></person-group><article-title>Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis</article-title><source>Eur. Respir. J.</source><year>2015</year><volume>45</volume><fpage>116</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1183/09031936.00113214</pub-id><pub-id pub-id-type="pmid">25186262</pub-id></element-citation></ref><ref id="B256-cells-11-01868"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karp</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lennox</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Jacobi</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Praekh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Behlke</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2013</year><volume>49</volume><fpage>544</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2012-0430OC</pub-id><pub-id pub-id-type="pmid">23646886</pub-id><pub-id pub-id-type="pmcid">PMC3824042</pub-id></element-citation></ref><ref id="B257-cells-11-01868"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutful Kabir</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ambalavanan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halloran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Szul</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gerthoffer</surname><given-names>W.T.</given-names></name><etal/></person-group><article-title>MicroRNA-145 Antagonism Reverses TGF-beta Inhibition of F508del CFTR Correction in Airway Epithelia</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2018</year><volume>197</volume><fpage>632</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1164/rccm.201704-0732OC</pub-id><pub-id pub-id-type="pmid">29232160</pub-id><pub-id pub-id-type="pmcid">PMC6005236</pub-id></element-citation></ref><ref id="B258-cells-11-01868"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabbri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tamanini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jakova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gasparello</surname><given-names>J.</given-names></name><name name-style="western"><surname>Manicardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corradini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sabbioni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Finotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borgatti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lampronti</surname><given-names>I.</given-names></name><etal/></person-group><article-title>A Peptide Nucleic Acid against MicroRNA miR-145-5p Enhances the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Calu-3 Cells</article-title><source>Molecules</source><year>2017</year><volume>23</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23010071</pub-id><pub-id pub-id-type="pmcid">PMC6017273</pub-id><pub-id pub-id-type="pmid">29286300</pub-id></element-citation></ref><ref id="B259-cells-11-01868"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tomaiuolo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nici</surname><given-names>F.</given-names></name><name name-style="western"><surname>Borbone</surname><given-names>N.</given-names></name><name name-style="western"><surname>Elce</surname><given-names>A.</given-names></name><name name-style="western"><surname>Catalanotti</surname><given-names>B.</given-names></name><name name-style="western"><surname>D'Errico</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morgillo</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mayol</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression</article-title><source>Biomed Res. Int.</source><year>2014</year><volume>2014</volume><fpage>610718</fpage><pub-id pub-id-type="doi">10.1155/2014/610718</pub-id><pub-id pub-id-type="pmid">24829907</pub-id><pub-id pub-id-type="pmcid">PMC4009323</pub-id></element-citation></ref><ref id="B260-cells-11-01868"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Santi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fernandez Fernandez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gaul</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vencken</surname><given-names>S.</given-names></name><name name-style="western"><surname>Glasgow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oglesby</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mitash</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Precise Targeting of miRNA Sites Restores CFTR Activity in CF Bronchial Epithelial Cells</article-title><source>Mol. Ther.</source><year>2020</year><volume>28</volume><fpage>1190</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.02.001</pub-id><pub-id pub-id-type="pmid">32059764</pub-id><pub-id pub-id-type="pmcid">PMC7132615</pub-id></element-citation></ref><ref id="B261-cells-11-01868"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurosaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maquat</surname><given-names>L.E.</given-names></name></person-group><article-title>Nonsense-mediated mRNA decay in humans at a glance</article-title><source>J. Cell Sci.</source><year>2016</year><volume>129</volume><fpage>461</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1242/jcs.181008</pub-id><pub-id pub-id-type="pmid">26787741</pub-id><pub-id pub-id-type="pmcid">PMC4760306</pub-id></element-citation></ref><ref id="B262-cells-11-01868"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linde</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boelz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nissim-Rafinia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oren</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Wilschanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yaacov</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Virgilis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neu-Yilik</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kulozik</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Kerem</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin</article-title><source>J. Clin. Invest.</source><year>2007</year><volume>117</volume><fpage>683</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1172/JCI28523</pub-id><pub-id pub-id-type="pmid">17290305</pub-id><pub-id pub-id-type="pmcid">PMC1783999</pub-id></element-citation></ref><ref id="B263-cells-11-01868"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aksit</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bowling</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Joynt</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>West</surname><given-names>N.</given-names></name><name name-style="western"><surname>Merlo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sosnay</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Cutting</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>Decreased mRNA and protein stability of W1282X limits response to modulator therapy</article-title><source>J. Cyst. Fibros.</source><year>2019</year><volume>18</volume><fpage>606</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2019.02.009</pub-id><pub-id pub-id-type="pmid">30803905</pub-id><pub-id pub-id-type="pmcid">PMC6706327</pub-id></element-citation></ref><ref id="B264-cells-11-01868"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Awatade</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Fel&#237;cio</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Calucho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cavaco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bertuzzo</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: A basis for read-through therapies in cystic fibrosis</article-title><source>Hum. Mutat.</source><year>2018</year><volume>40</volume><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1002/humu.23692</pub-id><pub-id pub-id-type="pmid">30488522</pub-id></element-citation></ref><ref id="B265-cells-11-01868"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linde</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boelz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neu-Yilik</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kulozik</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Kerem</surname><given-names>B.</given-names></name></person-group><article-title>The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells</article-title><source>Eur. J. Hum. Genet.</source><year>2007</year><volume>15</volume><fpage>1156</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201889</pub-id><pub-id pub-id-type="pmid">17625509</pub-id></element-citation></ref><ref id="B266-cells-11-01868"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keeling</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name></person-group><article-title>Pharmacological approaches for targeting cystic fibrosis nonsense mutations</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>200</volume><fpage>112436</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112436</pub-id><pub-id pub-id-type="pmid">32512483</pub-id><pub-id pub-id-type="pmcid">PMC7384597</pub-id></element-citation></ref><ref id="B267-cells-11-01868"><label>267.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Maule</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ensinck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bulcaen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlon</surname><given-names>M.S.</given-names></name></person-group><article-title>Rewriting CFTR to cure cystic fibrosis</article-title><source>Progress in Molecular Biology and Translational Science</source><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2021</year><pub-id pub-id-type="doi">10.1016/bs.pmbts.2020.12.018</pub-id><pub-id pub-id-type="pmid">34175042</pub-id></element-citation></ref><ref id="B268-cells-11-01868"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venturini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borrelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Musante</surname><given-names>I.</given-names></name><name name-style="western"><surname>Scudieri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Capurro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Renda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pedemonte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galietta</surname><given-names>L.J.V.</given-names></name></person-group><article-title>Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>11972</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222111972</pub-id><pub-id pub-id-type="pmid">34769402</pub-id><pub-id pub-id-type="pmcid">PMC8584557</pub-id></element-citation></ref><ref id="B269-cells-11-01868"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valley</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Bukis</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Allaire</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Sivachenko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bihler</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells</article-title><source>J. Cyst. Fibros.</source><year>2019</year><volume>18</volume><fpage>476</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2018.12.001</pub-id><pub-id pub-id-type="pmid">30563749</pub-id></element-citation></ref><ref id="B270-cells-11-01868"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keenan</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Valley</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Mahiou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bihler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mense</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2019</year><volume>61</volume><fpage>290</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2018-0316OC</pub-id><pub-id pub-id-type="pmid">30836009</pub-id></element-citation></ref><ref id="B271-cells-11-01868"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lentini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Melfi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cancemi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pibiri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Di Leonardo</surname><given-names>A.</given-names></name></person-group><article-title>Caffeine boosts Ataluren&#8217;s readthrough activity</article-title><source>Heliyon</source><year>2019</year><volume>5</volume><fpage>e01963</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2019.e01963</pub-id><pub-id pub-id-type="pmid">31294114</pub-id><pub-id pub-id-type="pmcid">PMC6595402</pub-id></element-citation></ref><ref id="B272-cells-11-01868"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McHugh</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>C.A.</given-names></name></person-group><article-title>Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>22</volume><elocation-id>344</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22010344</pub-id><pub-id pub-id-type="pmcid">PMC7794695</pub-id><pub-id pub-id-type="pmid">33396210</pub-id></element-citation></ref><ref id="B273-cells-11-01868"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viotti Perisse</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Van Wettere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leir</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Keim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Regouski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Cholewa</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Mansbach</surname><given-names>S.N.</given-names></name><etal/></person-group><article-title>Sheep models of F508del and G542X cystic fibrosis mutations show cellular responses to human therapeutics</article-title><source>FASEB BioAdvances</source><year>2021</year><volume>3</volume><fpage>841</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1096/fba.2021-00043</pub-id><pub-id pub-id-type="pmid">34632318</pub-id><pub-id pub-id-type="pmcid">PMC8493969</pub-id></element-citation></ref><ref id="B274-cells-11-01868"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Poel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spelier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suen</surname><given-names>S.W.F.</given-names></name><name name-style="western"><surname>Kruisselbrink</surname><given-names>E.</given-names></name><name name-style="western"><surname>Graeber</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Mall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Weersink</surname><given-names>E.J.M.</given-names></name><name name-style="western"><surname>Van Der Eerden</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Koppelman</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Van Der Ent</surname><given-names>C.K.</given-names></name><etal/></person-group><article-title>Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids</article-title><source>J. Cyst. Fibros.</source><year>2021</year><volume>21</volume><fpage>246</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2021.09.020</pub-id><pub-id pub-id-type="pmid">34666947</pub-id></element-citation></ref><ref id="B275-cells-11-01868"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gewandter</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Bambara</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>O'Reilly</surname><given-names>M.A.</given-names></name></person-group><article-title>The RNA surveillance protein SMG1 activates p53 in response to DNA double-strand breaks but not exogenously oxidized mRNA</article-title><source>Cell Cycle</source><year>2011</year><volume>10</volume><fpage>2561</fpage><lpage>2567</lpage><pub-id pub-id-type="doi">10.4161/cc.10.15.16347</pub-id><pub-id pub-id-type="pmid">21701263</pub-id><pub-id pub-id-type="pmcid">PMC3180194</pub-id></element-citation></ref><ref id="B276-cells-11-01868"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>A.</given-names></name></person-group><article-title>Role of SMG-1-mediated Upf1 phosphorylation in mammalian nonsense-mediated mRNA decay</article-title><source>Genes Cells</source><year>2013</year><volume>18</volume><fpage>161</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1111/gtc.12033</pub-id><pub-id pub-id-type="pmid">23356578</pub-id></element-citation></ref><ref id="B277-cells-11-01868"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Pellicore</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aksit</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>McCague</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Joynt</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Anzmann</surname><given-names>A.F.</given-names></name><etal/></person-group><article-title>Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis</article-title><source>PLoS Genet.</source><year>2018</year><volume>14</volume><elocation-id>e1007723</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007723</pub-id><pub-id pub-id-type="pmid">30444886</pub-id><pub-id pub-id-type="pmcid">PMC6267994</pub-id></element-citation></ref><ref id="B278-cells-11-01868"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutyam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Keeling</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>White</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Bostwick</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2016</year><volume>194</volume><fpage>1092</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1164/rccm.201601-0154OC</pub-id><pub-id pub-id-type="pmid">27104944</pub-id><pub-id pub-id-type="pmcid">PMC5114449</pub-id></element-citation></ref><ref id="B279-cells-11-01868"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Hilarion</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beghyn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Debreuck</surname><given-names>N.</given-names></name><name name-style="western"><surname>Berte</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mamchaoui</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mouly</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gruenert</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>D&#233;prez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lejeune</surname><given-names>F.</given-names></name></person-group><article-title>Rescue of nonsense mutations by amlexanox in human cells</article-title><source>Orphanet J. Rare Dis.</source><year>2012</year><volume>7</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-7-58</pub-id><pub-id pub-id-type="pmid">22938201</pub-id><pub-id pub-id-type="pmcid">PMC3562214</pub-id></element-citation></ref><ref id="B280-cells-11-01868"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nomakuchi</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Rigo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aznarez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Krainer</surname><given-names>A.R.</given-names></name></person-group><article-title>Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay</article-title><source>Nat. Biotechnol.</source><year>2016</year><volume>34</volume><fpage>164</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/nbt.3427</pub-id><pub-id pub-id-type="pmid">26655495</pub-id><pub-id pub-id-type="pmcid">PMC4744113</pub-id></element-citation></ref><ref id="B281-cells-11-01868"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erwood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Laselva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bily</surname><given-names>T.M.I.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Rutherford</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Ivakine</surname><given-names>E.A.</given-names></name></person-group><article-title>Allele-Specific Prevention of Nonsense-Mediated Decay in Cystic Fibrosis Using Homology-Independent Genome Editing</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2020</year><volume>17</volume><fpage>1118</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2020.05.002</pub-id><pub-id pub-id-type="pmid">32490033</pub-id><pub-id pub-id-type="pmcid">PMC7256445</pub-id></element-citation></ref><ref id="B282-cells-11-01868"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oren</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Avizur-Barchad</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ozeri-Galai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Elgrabli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schirelman</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Blinder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Stampfer</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Ordan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laselva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cohen-Cymberknoh</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation</article-title><source>J. Cyst. Fibros.</source><year>2021</year><comment>in press</comment><pub-id pub-id-type="doi">10.1016/j.jcf.2021.12.012</pub-id><pub-id pub-id-type="pmid">34972649</pub-id></element-citation></ref><ref id="B283-cells-11-01868"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michaels</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Pena-Rasgado</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kotaria</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bridges</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>M.L.</given-names></name></person-group><article-title>Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2114886119</fpage><pub-id pub-id-type="doi">10.1073/pnas.2114886119</pub-id><pub-id pub-id-type="pmid">35017302</pub-id><pub-id pub-id-type="pmcid">PMC8784102</pub-id></element-citation></ref><ref id="B284-cells-11-01868"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Sivetz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Layne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Krainer</surname><given-names>A.R.</given-names></name></person-group><article-title>Exon-skipping antisense oligonucleotides for cystic fibrosis therapy</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2022</year><volume>119</volume><fpage>e2114858118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2114858118</pub-id><pub-id pub-id-type="pmid">35017301</pub-id><pub-id pub-id-type="pmcid">PMC8784140</pub-id></element-citation></ref><ref id="B285-cells-11-01868"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frizzell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Bedwell</surname><given-names>D.M.</given-names></name></person-group><article-title>Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations</article-title><source>Nat. Med.</source><year>1996</year><volume>2</volume><fpage>467</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/nm0496-467</pub-id><pub-id pub-id-type="pmid">8597960</pub-id></element-citation></ref><ref id="B286-cells-11-01868"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedwell</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Kaenjak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benos</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Bebok</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bubien</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tousson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Sorscher</surname><given-names>E.J.</given-names></name></person-group><article-title>Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line</article-title><source>Nat. Med.</source><year>1997</year><volume>3</volume><fpage>1280</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1038/nm1197-1280</pub-id><pub-id pub-id-type="pmid">9359706</pub-id></element-citation></ref><ref id="B287-cells-11-01868"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Lanier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keeling</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lindsey</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Tousson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beb&#246;k</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Whitsett</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Colledge</surname><given-names>W.H.</given-names></name><etal/></person-group><article-title>Aminoglycoside suppression of a premature stop mutation in a Cftr&#8211;/&#8211; mouse carrying a human CFTR-G542X transgene</article-title><source>J. Mol. Med.</source><year>2002</year><volume>80</volume><fpage>595</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1007/s00109-002-0363-1</pub-id><pub-id pub-id-type="pmid">12226741</pub-id></element-citation></ref><ref id="B288-cells-11-01868"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sermet-Gaudelus</surname><given-names>I.</given-names></name><name name-style="western"><surname>Renouil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fajac</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bidou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Parbaille</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pierrot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bismuth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reinert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lenoir</surname><given-names>G.</given-names></name><etal/></person-group><article-title>In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: A pilot study</article-title><source>BMC Med.</source><year>2007</year><volume>5</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7015-5-5</pub-id><pub-id pub-id-type="pmid">17394637</pub-id><pub-id pub-id-type="pmcid">PMC1852113</pub-id></element-citation></ref><ref id="B289-cells-11-01868"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilschanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yahav</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yaacov</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Blau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bentur</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rivlin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aviram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bdolah-Abram</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bebok</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shushi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis andCFTRStop Mutations</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>349</volume><fpage>1433</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa022170</pub-id><pub-id pub-id-type="pmid">14534336</pub-id></element-citation></ref><ref id="B290-cells-11-01868"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clancy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bebok</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zeitlin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Berclaz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>R.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Oster</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>No Detectable Improvements in Cystic Fibrosis Transmembrane Conductance Regulator by Nasal Aminoglycosides in Patients with Cystic Fibrosis with Stop Mutations</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2007</year><volume>37</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2006-0173OC</pub-id><pub-id pub-id-type="pmid">17347447</pub-id><pub-id pub-id-type="pmcid">PMC1899350</pub-id></element-citation></ref><ref id="B291-cells-11-01868"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keeling</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kova&#231;s</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sorscher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bedwell</surname><given-names>D.M.</given-names></name></person-group><article-title>Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model</article-title><source>J. Mol. Med.</source><year>2006</year><volume>84</volume><fpage>573</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1007/s00109-006-0045-5</pub-id><pub-id pub-id-type="pmid">16541275</pub-id></element-citation></ref><ref id="B292-cells-11-01868"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altamura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Castaldo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Finotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Breveglieri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salvatori</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zuccato</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gambari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Panin</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Borgatti</surname><given-names>M.</given-names></name></person-group><article-title>Tobramycin is a suppressor of premature termination codons</article-title><source>J. Cyst. Fibros.</source><year>2013</year><volume>12</volume><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2013.02.007</pub-id><pub-id pub-id-type="pmid">23540394</pub-id></element-citation></ref><ref id="B293-cells-11-01868"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Barton</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tomizawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Friesen</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Trifillis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Paushkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trotta</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>PTC124 targets genetic disorders caused by nonsense mutations</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/nature05756</pub-id><pub-id pub-id-type="pmid">17450125</pub-id></element-citation></ref><ref id="B294-cells-11-01868"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McDonald</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Torricelli</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Flanigan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Goemans</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heydemann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaminska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muntoni</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>1489</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31611-2</pub-id><pub-id pub-id-type="pmid">28728956</pub-id></element-citation></ref><ref id="B295-cells-11-01868"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Hirawat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peltz</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Bedwell</surname><given-names>D.M.</given-names></name></person-group><article-title>PTC124 is an orally bioavailable compound that promotes suppression of the human <italic toggle="yes">CFTR</italic> -G542X nonsense allele in a CF mouse model</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>2064</fpage><lpage>2069</lpage><pub-id pub-id-type="doi">10.1073/pnas.0711795105</pub-id><pub-id pub-id-type="pmid">18272502</pub-id><pub-id pub-id-type="pmcid">PMC2538881</pub-id></element-citation></ref><ref id="B296-cells-11-01868"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hirawat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Armoni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yaakov</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shoseyov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nissim-Rafinia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rivlin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aviram</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>719</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61168-X</pub-id><pub-id pub-id-type="pmid">18722008</pub-id></element-citation></ref><ref id="B297-cells-11-01868"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilschanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Shoseyov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rivlin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aviram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armoni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yaakov</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pugatch</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis</article-title><source>Eur. Respir. J.</source><year>2011</year><volume>38</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1183/09031936.00120910</pub-id><pub-id pub-id-type="pmid">21233271</pub-id></element-citation></ref><ref id="B298-cells-11-01868"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sermet-Gaudelus</surname><given-names>I.</given-names></name><name name-style="western"><surname>Boeck</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Casimir</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mogenet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roussel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanssens</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hirawat</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2010</year><volume>182</volume><fpage>1262</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1164/rccm.201001-0137OC</pub-id><pub-id pub-id-type="pmid">20622033</pub-id></element-citation></ref><ref id="B299-cells-11-01868"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Konstan</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Accurso</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Sermet-Gaudelus</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wilschanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elborn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Melotti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bronsveld</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fajac</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial</article-title><source>Lancet Respir. Med.</source><year>2014</year><volume>2</volume><fpage>539</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(14)70100-6</pub-id><pub-id pub-id-type="pmid">24836205</pub-id><pub-id pub-id-type="pmcid">PMC4154311</pub-id></element-citation></ref><ref id="B300-cells-11-01868"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zomer-Van Ommen</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Vijftigschild</surname><given-names>L.A.W.</given-names></name><name name-style="western"><surname>Kruisselbrink</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vonk</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>De Winter-De Groot</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Van Der Ent</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Beekman</surname><given-names>J.M.</given-names></name></person-group><article-title>Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids</article-title><source>J. Cyst. Fibros.</source><year>2016</year><volume>15</volume><fpage>158</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2015.07.007</pub-id><pub-id pub-id-type="pmid">26255232</pub-id></element-citation></ref><ref id="B301-cells-11-01868"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McHugh</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Valerio</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Miron</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>LePage</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Conlon</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Drumm</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>C.A.</given-names></name></person-group><article-title>A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0199573</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0199573</pub-id><pub-id pub-id-type="pmid">29924856</pub-id><pub-id pub-id-type="pmcid">PMC6010256</pub-id></element-citation></ref><ref id="B302-cells-11-01868"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pibiri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lentini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Melfi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tutone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baldassano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ricco Galluzzo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Leonardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pace</surname><given-names>A.</given-names></name></person-group><article-title>Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>159</volume><fpage>126</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.09.057</pub-id><pub-id pub-id-type="pmid">30278331</pub-id></element-citation></ref><ref id="B303-cells-11-01868"><label>303.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pibiri</surname><given-names>I.</given-names></name><name name-style="western"><surname>Melfi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tutone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Leonardo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pace</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lentini</surname><given-names>L.</given-names></name></person-group><article-title>Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>6420</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21176420</pub-id><pub-id pub-id-type="pmcid">PMC7504161</pub-id><pub-id pub-id-type="pmid">32899265</pub-id></element-citation></ref><ref id="B304-cells-11-01868"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Sloane</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Backer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Buckley-Lanier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nudelman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Belakhov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bebok</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Schwiebert</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54</article-title><source>J. Mol. Med.</source><year>2011</year><volume>89</volume><fpage>1149</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1007/s00109-011-0787-6</pub-id><pub-id pub-id-type="pmid">21779978</pub-id><pub-id pub-id-type="pmcid">PMC3204584</pub-id></element-citation></ref><ref id="B305-cells-11-01868"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mutyam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Belakhov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shalev</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by Ivacaftor</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2014</year><volume>50</volume><fpage>805</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2013-0282OC</pub-id><pub-id pub-id-type="pmid">24251786</pub-id><pub-id pub-id-type="pmcid">PMC4068923</pub-id></element-citation></ref><ref id="B306-cells-11-01868"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandasamy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Atia-Glikin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shapira</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shavit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Belakhov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Baasov</surname><given-names>T.</given-names></name></person-group><article-title>Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations</article-title><source>J. Med. Chem.</source><year>2012</year><volume>55</volume><fpage>10630</fpage><lpage>10643</lpage><pub-id pub-id-type="doi">10.1021/jm3012992</pub-id><pub-id pub-id-type="pmid">23148581</pub-id><pub-id pub-id-type="pmcid">PMC3542475</pub-id></element-citation></ref><ref id="B307-cells-11-01868"><label>307.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerem</surname><given-names>E.</given-names></name></person-group><article-title>ELX-02: An investigational read-through agent for the treatment of nonsense mutation-related genetic disease</article-title><source>Expert Opin Investig Drugs</source><year>2020</year><volume>29</volume><fpage>1347</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1080/13543784.2020.1828862</pub-id><pub-id pub-id-type="pmid">32972261</pub-id></element-citation></ref><ref id="B308-cells-11-01868"><label>308.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leubitz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frydman-Marom</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Van Duzer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>K.C.M.</given-names></name><name name-style="western"><surname>Vanhoutte</surname><given-names>F.</given-names></name></person-group><article-title>Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2019</year><volume>8</volume><fpage>984</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1002/cpdd.647</pub-id><pub-id pub-id-type="pmid">30650260</pub-id></element-citation></ref><ref id="B309-cells-11-01868"><label>309.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawford</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Mullenders</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pott</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boj</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Landskroner-Eiger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goddeeris</surname><given-names>M.M.</given-names></name></person-group><article-title>Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids</article-title><source>J. Cyst. Fibros.</source><year>2021</year><volume>20</volume><fpage>436</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2021.01.009</pub-id><pub-id pub-id-type="pmid">33558100</pub-id></element-citation></ref><ref id="B310-cells-11-01868"><label>310.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mutyam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thakerar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bridges</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Keeling</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Bedwell</surname><given-names>D.M.</given-names></name></person-group><article-title>Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>3116</fpage><lpage>3129</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx196</pub-id><pub-id pub-id-type="pmid">28575328</pub-id><pub-id pub-id-type="pmcid">PMC5886253</pub-id></element-citation></ref><ref id="B311-cells-11-01868"><label>311.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keeling</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Conard</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Bedwell</surname><given-names>D.M.</given-names></name></person-group><article-title>Suppression of premature termination codons as a therapeutic approach</article-title><source>Crit. Rev. Biochem. Mol. Biol.</source><year>2012</year><volume>47</volume><fpage>444</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.3109/10409238.2012.694846</pub-id><pub-id pub-id-type="pmid">22672057</pub-id><pub-id pub-id-type="pmcid">PMC3432268</pub-id></element-citation></ref><ref id="B312-cells-11-01868"><label>312.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mutyam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wangen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thrasher</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>4358</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24575-x</pub-id><pub-id pub-id-type="pmid">34272367</pub-id><pub-id pub-id-type="pmcid">PMC8285393</pub-id></element-citation></ref><ref id="B313-cells-11-01868"><label>313.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dukovski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shumate</surname><given-names>J.</given-names></name><name name-style="western"><surname>Scampavia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Spicer</surname><given-names>T.P.</given-names></name></person-group><article-title>Identification of Compounds That Promote Readthrough of Premature Termination Codons in the CFTR</article-title><source>SLAS Discov.</source><year>2021</year><volume>26</volume><fpage>205</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1177/2472555220962001</pub-id><pub-id pub-id-type="pmid">33016182</pub-id><pub-id pub-id-type="pmcid">PMC7838340</pub-id></element-citation></ref><ref id="B314-cells-11-01868"><label>314.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lueck</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Perales-Puchalt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Infield</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Behlke</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pope</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Skach</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>McCray</surname><given-names>P.B.</given-names></name><etal/></person-group><article-title>Engineered transfer RNAs for suppression of premature termination codons</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>822</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-08329-4</pub-id><pub-id pub-id-type="pmid">30778053</pub-id><pub-id pub-id-type="pmcid">PMC6379413</pub-id></element-citation></ref><ref id="B315-cells-11-01868"><label>315.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>W.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Sipple</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lueck</surname><given-names>J.D.</given-names></name></person-group><article-title>Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs</article-title><source>Mol. Ther.-Nucleic Acids</source><year>2022</year><volume>28</volume><fpage>685</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2022.04.033</pub-id><pub-id pub-id-type="pmid">35664697</pub-id><pub-id pub-id-type="pmcid">PMC9126842</pub-id></element-citation></ref><ref id="B316-cells-11-01868"><label>316.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mansfield</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Puttaraju</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>J.F.</given-names></name></person-group><article-title>Partial correction of endogenous &#916;F508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing</article-title><source>Nat. Biotechnol.</source><year>2002</year><volume>20</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1038/nbt0102-47</pub-id><pub-id pub-id-type="pmid">11753361</pub-id></element-citation></ref><ref id="B317-cells-11-01868"><label>317.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansfield</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Kole</surname><given-names>J.</given-names></name><name name-style="western"><surname>Puttaraju</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Garcia-Blanco</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>L.G.</given-names></name></person-group><article-title>Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing</article-title><source>Gene Ther.</source><year>2000</year><volume>7</volume><fpage>1885</fpage><lpage>1895</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301307</pub-id><pub-id pub-id-type="pmid">11127576</pub-id></element-citation></ref><ref id="B318-cells-11-01868"><label>318.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamecnik</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Raychowdhury</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Tabatadze</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Cantiello</surname><given-names>H.F.</given-names></name></person-group><article-title>Reversal of cystic fibrosis phenotype in a cultured &#916;508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>8150</fpage><lpage>8155</lpage><pub-id pub-id-type="doi">10.1073/pnas.0401933101</pub-id><pub-id pub-id-type="pmid">15148387</pub-id><pub-id pub-id-type="pmcid">PMC419572</pub-id></element-citation></ref><ref id="B319-cells-11-01868"><label>319.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beumer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Swildens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Noel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anthonijsz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Van Der Horst</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kuiperij-Boersma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Potman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Putten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Biasutto</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0219182</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0219182</pub-id><pub-id pub-id-type="pmid">31251792</pub-id><pub-id pub-id-type="pmcid">PMC6599119</pub-id></element-citation></ref><ref id="B320-cells-11-01868"><label>320.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drevinek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pressler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cipolli</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouisset</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henig</surname><given-names>N.</given-names></name><name name-style="western"><surname>Paquette-Lamontagne</surname><given-names>N.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>19</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2019.05.014</pub-id><pub-id pub-id-type="pmid">31182369</pub-id></element-citation></ref><ref id="B321-cells-11-01868"><label>321.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sermet-Gaudelus</surname><given-names>I.</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Nick</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Mall</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bolognese</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bouisset</surname><given-names>F.</given-names></name><name name-style="western"><surname>Den Hollander</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis</article-title><source>J. Cyst. Fibros.</source><year>2019</year><volume>18</volume><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2018.10.015</pub-id><pub-id pub-id-type="pmid">30467074</pub-id><pub-id pub-id-type="pmcid">PMC7227803</pub-id></element-citation></ref><ref id="B322-cells-11-01868"><label>322.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montiel-Gonzalez</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Vallecillo-Viejo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yudowski</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>J.J.C.</given-names></name></person-group><article-title>Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>18285</fpage><lpage>18290</lpage><pub-id pub-id-type="doi">10.1073/pnas.1306243110</pub-id><pub-id pub-id-type="pmid">24108353</pub-id><pub-id pub-id-type="pmcid">PMC3831439</pub-id></element-citation></ref><ref id="B323-cells-11-01868"><label>323.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melfi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cancemi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chiavetta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lentini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Leonardo</surname><given-names>A.</given-names></name></person-group><article-title>Investigating REPAIRv2 as a Tool to Edit CFTR mRNA with Premature Stop Codons</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>4781</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21134781</pub-id><pub-id pub-id-type="pmcid">PMC7369808</pub-id><pub-id pub-id-type="pmid">32640650</pub-id></element-citation></ref><ref id="B324-cells-11-01868"><label>324.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aartsma-Rus</surname><given-names>A.</given-names></name></person-group><article-title>FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides</article-title><source>Nucleic Acid. Ther.</source><year>2017</year><volume>27</volume><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1089/nat.2017.0665</pub-id><pub-id pub-id-type="pmid">28346110</pub-id></element-citation></ref><ref id="B325-cells-11-01868"><label>325.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igreja</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Botelho</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>L.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name></person-group><article-title>Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides</article-title><source>Hum. Mutat.</source><year>2016</year><volume>37</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1002/humu.22931</pub-id><pub-id pub-id-type="pmid">26553470</pub-id></element-citation></ref><ref id="B326-cells-11-01868"><label>326.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Kole</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kole</surname><given-names>R.</given-names></name></person-group><article-title>Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>36193</fpage><lpage>36199</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.51.36193</pub-id><pub-id pub-id-type="pmid">10593905</pub-id></element-citation></ref><ref id="B327-cells-11-01868"><label>327.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michaels</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Bridges</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>M.L.</given-names></name></person-group><article-title>Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>7454</fpage><lpage>7467</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa490</pub-id><pub-id pub-id-type="pmid">32520327</pub-id><pub-id pub-id-type="pmcid">PMC7367209</pub-id></element-citation></ref><ref id="B328-cells-11-01868"><label>328.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oren</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Irony-Tur Sinai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Golec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barchad-Avitzur</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mutyam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ozeri-Galai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hatton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leibson</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation</article-title><source>J. Cyst. Fibros.</source><year>2021</year><volume>20</volume><fpage>865</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2021.06.003</pub-id><pub-id pub-id-type="pmid">34226157</pub-id><pub-id pub-id-type="pmcid">PMC8464507</pub-id></element-citation></ref><ref id="B329-cells-11-01868"><label>329.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>SpliSense</collab></person-group><source>SpliSense Announces FDA and EMA Grant Orphan Drug Designation to SPL84-23-1 for the Treatment of Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2022</year></element-citation></ref><ref id="B330-cells-11-01868"><label>330.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Rudra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.G.</given-names></name></person-group><article-title>Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery</article-title><source>Mol. Ther.</source><year>2019</year><volume>27</volume><fpage>710</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.02.012</pub-id><pub-id pub-id-type="pmid">30846391</pub-id><pub-id pub-id-type="pmcid">PMC6453548</pub-id></element-citation></ref><ref id="B331-cells-11-01868"><label>331.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name></person-group><article-title>Lipid nanoparticles for mRNA delivery</article-title><source>Nat. Rev. Mater.</source><year>2021</year><volume>6</volume><fpage>1078</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00358-0</pub-id><pub-id pub-id-type="pmid">34394960</pub-id><pub-id pub-id-type="pmcid">PMC8353930</pub-id></element-citation></ref><ref id="B332-cells-11-01868"><label>332.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>K.A.</given-names></name></person-group><article-title>mRNA vaccines for infectious diseases: Principles, delivery and clinical translation</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>817</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmid">34433919</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id></element-citation></ref><ref id="B333-cells-11-01868"><label>333.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Translate Bio</collab></person-group><source>Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF)</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2021</year></element-citation></ref><ref id="B334-cells-11-01868"><label>334.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Translate Bio</collab></person-group><source>Translate Bio Announces Interim Results from Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2019</year></element-citation></ref><ref id="B335-cells-11-01868"><label>335.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Arcturus Therapeutics</collab></person-group><article-title>LUNAR-CF</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://arcturusrx.com/mrna-medicines-pipeline/#lunarCf" ext-link-type="uri">https://arcturusrx.com/mrna-medicines-pipeline/#lunarCf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-10">(accessed on 10 May 2022)</date-in-citation></element-citation></ref><ref id="B336-cells-11-01868"><label>336.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolonko</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Efing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Espinosa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bangel-Ruland</surname><given-names>N.</given-names></name><name name-style="western"><surname>Van Driessche</surname><given-names>W.</given-names></name><name name-style="western"><surname>Goycoolea</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>W.-M.</given-names></name></person-group><article-title>Capsaicin-Loaded Chitosan Nanocapsules for wtCFTR-mRNA Delivery to a Cystic Fibrosis Cell Line</article-title><source>Biomedicines</source><year>2020</year><volume>8</volume><elocation-id>364</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines8090364</pub-id><pub-id pub-id-type="pmcid">PMC7554911</pub-id><pub-id pub-id-type="pmid">32962254</pub-id></element-citation></ref><ref id="B337-cells-11-01868"><label>337.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trimble</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>S.H.</given-names></name></person-group><article-title>Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation</article-title><source>J. Cyst. Fibros.</source><year>2018</year><volume>17</volume><fpage>e13</fpage><lpage>e16</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2017.09.006</pub-id><pub-id pub-id-type="pmid">29079142</pub-id></element-citation></ref><ref id="B338-cells-11-01868"><label>338.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>CFF</collab></person-group><article-title>Path to a Cure: Many Routes, One Mission|CF Foundation</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cff.org/Research/About-Our-Research/Path-to-a-Cure-Many-Routes-One-Mission/" ext-link-type="uri">https://www.cff.org/Research/About-Our-Research/Path-to-a-Cure-Many-Routes-One-Mission/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-17">(accessed on 17 October 2020)</date-in-citation></element-citation></ref><ref id="B339-cells-11-01868"><label>339.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooney</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Sinn</surname><given-names>P.L.</given-names></name></person-group><article-title>Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward</article-title><source>Genes</source><year>2018</year><volume>9</volume><elocation-id>538</elocation-id><pub-id pub-id-type="doi">10.3390/genes9110538</pub-id><pub-id pub-id-type="pmid">30405068</pub-id><pub-id pub-id-type="pmcid">PMC6266271</pub-id></element-citation></ref><ref id="B340-cells-11-01868"><label>340.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sondhi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stiles</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>De</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>R.G.</given-names></name></person-group><article-title>Genetic Modification of the Lung Directed Toward Treatment of Human Disease</article-title><source>Hum. Gene Ther.</source><year>2017</year><volume>28</volume><fpage>3</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1089/hum.2016.152</pub-id><pub-id pub-id-type="pmid">27927014</pub-id></element-citation></ref><ref id="B341-cells-11-01868"><label>341.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alton</surname><given-names>E.W.F.W.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Griesenbach</surname><given-names>U.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Henig</surname><given-names>N.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Innes</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Genetic medicines for CF: Hype versus reality</article-title><source>Pediatric Pulmonol.</source><year>2016</year><volume>51</volume><fpage>S5</fpage><lpage>S17</lpage><pub-id pub-id-type="doi">10.1002/ppul.23543</pub-id><pub-id pub-id-type="pmid">27662105</pub-id></element-citation></ref><ref id="B342-cells-11-01868"><label>342.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidovi&#263;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carlon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Da Cunha</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Hollenhorst</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Bijvelds</surname><given-names>M.J.C.</given-names></name><name name-style="western"><surname>Ramalho</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Van Den Haute</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferrante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baekelandt</surname><given-names>V.</given-names></name><etal/></person-group><article-title>rAAV-CFTR&#916;R Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2016</year><volume>193</volume><fpage>288</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1164/rccm.201505-0914OC</pub-id><pub-id pub-id-type="pmid">26509335</pub-id></element-citation></ref><ref id="B343-cells-11-01868"><label>343.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooney</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Abou Alaiwa</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Bouzek</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Stroik</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Gansemer</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Stoltz</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Lentiviral-mediated phenotypic correction of cystic fibrosis pigs</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><fpage>e88730</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.88730</pub-id><pub-id pub-id-type="pmid">27656681</pub-id><pub-id pub-id-type="pmcid">PMC5027966</pub-id></element-citation></ref><ref id="B344-cells-11-01868"><label>344.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alton</surname><given-names>E.W.F.W.</given-names></name><name name-style="western"><surname>Beekman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Brand</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carlon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conlon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis</article-title><source>Thorax</source><year>2017</year><volume>72</volume><fpage>137</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2016-208406</pub-id><pub-id pub-id-type="pmid">27852956</pub-id><pub-id pub-id-type="pmcid">PMC5284333</pub-id></element-citation></ref><ref id="B345-cells-11-01868"><label>345.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steines</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Bergen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Excoffon</surname><given-names>K.J.D.A.</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Alaiwa</surname><given-names>M.H.A.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Bouzek</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><fpage>e88728</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.88728</pub-id><pub-id pub-id-type="pmid">27699238</pub-id><pub-id pub-id-type="pmcid">PMC5033908</pub-id></element-citation></ref><ref id="B346-cells-11-01868"><label>346.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alton</surname><given-names>E.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Ashby</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bayfield</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Bilton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bloomfield</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Brand</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buchan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Calcedo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial</article-title><source>Lancet Respir. Med.</source><year>2015</year><volume>3</volume><fpage>684</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(15)00245-3</pub-id><pub-id pub-id-type="pmid">26149841</pub-id><pub-id pub-id-type="pmcid">PMC4673100</pub-id></element-citation></ref><ref id="B347-cells-11-01868"><label>347.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Spirovant Sciences</collab></person-group><source>FDA Grants Spirovant Sciences Orphan Drug and Rare Pediatric Disease Designations for SPIRO-2101 for Treatment of Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B348-cells-11-01868"><label>348.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Krystal Biotech</collab></person-group><source>Krystal Biotech&#8217;s KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B349-cells-11-01868"><label>349.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Boehringer Ingelheim</collab></person-group><source>Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2021</year></element-citation></ref><ref id="B350-cells-11-01868"><label>350.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ledford</surname><given-names>H.</given-names></name><name name-style="western"><surname>Callaway</surname><given-names>E.</given-names></name></person-group><article-title>Pioneers of revolutionary CRISPR gene editing win chemistry Nobel</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>346</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/d41586-020-02765-9</pub-id><pub-id pub-id-type="pmid">33028993</pub-id></element-citation></ref><ref id="B351-cells-11-01868"><label>351.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jinek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chylinski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fonfara</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doudna</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Charpentier</surname><given-names>E.</given-names></name></person-group><article-title>A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1126/science.1225829</pub-id><pub-id pub-id-type="pmid">22745249</pub-id><pub-id pub-id-type="pmcid">PMC6286148</pub-id></element-citation></ref><ref id="B352-cells-11-01868"><label>352.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maule</surname><given-names>G.</given-names></name><name name-style="western"><surname>Casini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Montagna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramalho</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>De Boeck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Debyser</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Carlon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Petris</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cereseto</surname><given-names>A.</given-names></name></person-group><article-title>Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>3556</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11454-9</pub-id><pub-id pub-id-type="pmid">31391465</pub-id><pub-id pub-id-type="pmcid">PMC6685978</pub-id></element-citation></ref><ref id="B353-cells-11-01868"><label>353.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geurts</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>De Poel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pleguezuelos-Manzano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Andersson-Rolf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boretto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brunsveld</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Van Boxtel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beekman</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids</article-title><source>Life Sci. Alliance</source><year>2021</year><volume>4</volume><fpage>e202000940</fpage><pub-id pub-id-type="doi">10.26508/lsa.202000940</pub-id><pub-id pub-id-type="pmid">34373320</pub-id><pub-id pub-id-type="pmcid">PMC8356249</pub-id></element-citation></ref><ref id="B354-cells-11-01868"><label>354.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geurts</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>de Poel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Amatngalim</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meijers</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Kruisselbrink</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Mourik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Berkers</surname><given-names>G.</given-names></name><name name-style="western"><surname>de Winter-de Groot</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Michel</surname><given-names>S.</given-names></name><etal/></person-group><article-title>CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank</article-title><source>Cell Stem Cell</source><year>2020</year><volume>26</volume><fpage>503</fpage><lpage>510 e507</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2020.01.019</pub-id><pub-id pub-id-type="pmid">32084388</pub-id></element-citation></ref><ref id="B355-cells-11-01868"><label>355.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaidyanathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salahudeen</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sellers</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Bravo</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Batish</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le</surname><given-names>W.</given-names></name><name name-style="western"><surname>Baik</surname><given-names>R.</given-names></name><name name-style="western"><surname>de la</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>M.P.</given-names></name><etal/></person-group><article-title>High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia</article-title><source>Cell Stem Cell</source><year>2020</year><volume>26</volume><fpage>161</fpage><lpage>171 e14</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.11.002</pub-id><pub-id pub-id-type="pmid">31839569</pub-id><pub-id pub-id-type="pmcid">PMC10908575</pub-id></element-citation></ref><ref id="B356-cells-11-01868"><label>356.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crane</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Anirudhan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barilla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Matthias</surname><given-names>N.</given-names></name><name name-style="western"><surname>Randell</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Rab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sorscher</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kerschner</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Highly Efficient Gene Editing of Cystic Fibrosis Patient-Derived Airway Basal Cells Results in Functional CFTR Correction</article-title><source>Mol. Ther.</source><year>2020</year><volume>28</volume><fpage>1684</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2020.04.021</pub-id><pub-id pub-id-type="pmid">32402246</pub-id><pub-id pub-id-type="pmcid">PMC7335734</pub-id></element-citation></ref><ref id="B357-cells-11-01868"><label>357.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensinck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mottais</surname><given-names>A.</given-names></name><name name-style="western"><surname>Detry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Carlon</surname><given-names>M.S.</given-names></name></person-group><article-title>On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><fpage>662110</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.662110</pub-id><pub-id pub-id-type="pmid">33986686</pub-id><pub-id pub-id-type="pmcid">PMC8111007</pub-id></element-citation></ref><ref id="B358-cells-11-01868"><label>358.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Flume</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Elborn</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>McColley</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rubenstein</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial</article-title><source>Lancet Respir. Med.</source><year>2015</year><volume>3</volume><fpage>524</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(15)00201-5</pub-id><pub-id pub-id-type="pmid">26070913</pub-id><pub-id pub-id-type="pmcid">PMC4641035</pub-id></element-citation></ref><ref id="B359-cells-11-01868"><label>359.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fidler</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Statia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boj</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Vries</surname><given-names>R.G.J.</given-names></name><name name-style="western"><surname>Munck</surname><given-names>A.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moretto Zita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Negulescu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>G970R-CFTR Mutation (c.2908G&gt;C) Results Predominantly in a Splicing Defect</article-title><source>Clin. Transl. Sci.</source><year>2020</year><volume>14</volume><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1111/cts.12927</pub-id><pub-id pub-id-type="pmid">33278322</pub-id><pub-id pub-id-type="pmcid">PMC7993255</pub-id></element-citation></ref><ref id="B360-cells-11-01868"><label>360.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sosnay</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Siklosi</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Van Goor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kaniecki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ramalho</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Dorfman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zielenski</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene</article-title><source>Nat. Genet.</source><year>2013</year><volume>45</volume><fpage>1160</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1038/ng.2745</pub-id><pub-id pub-id-type="pmid">23974870</pub-id><pub-id pub-id-type="pmcid">PMC3874936</pub-id></element-citation></ref><ref id="B361-cells-11-01868"><label>361.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clancy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Vandevanter</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Gentzsch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nick</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Illek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wallenburg</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>CFTR modulator theratyping: Current status, gaps and future directions</article-title><source>J. Cyst. Fibros.</source><year>2019</year><volume>18</volume><fpage>22</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2018.05.004</pub-id><pub-id pub-id-type="pmid">29934203</pub-id><pub-id pub-id-type="pmcid">PMC6301143</pub-id></element-citation></ref><ref id="B362-cells-11-01868"><label>362.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Mourik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Michel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vonk</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Beekman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Van Der Ent</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>De Keyser</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lammertyn</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Koningsbruggen-Rietschel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Naehrlich</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pool</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Rationale and design of the HIT-CF organoid study: Stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators</article-title><source>Transl. Med. Commun.</source><year>2020</year><volume>5</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s41231-020-00060-3</pub-id></element-citation></ref><ref id="B363-cells-11-01868"><label>363.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dekkers</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Wiegerinck</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>De Jonge</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Bronsveld</surname><given-names>I.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>De Winter-De Groot</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Brandsma</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>N.W.M.</given-names></name><name name-style="western"><surname>Bijvelds</surname><given-names>M.J.C.</given-names></name><name name-style="western"><surname>Scholte</surname><given-names>B.J.</given-names></name><etal/></person-group><article-title>A functional CFTR assay using primary cystic fibrosis intestinal organoids</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>939</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/nm.3201</pub-id><pub-id pub-id-type="pmid">23727931</pub-id></element-citation></ref><ref id="B364-cells-11-01868"><label>364.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dekkers</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Berkers</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kruisselbrink</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vonk</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Jonge</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Bronsveld</surname><given-names>I.</given-names></name><name name-style="western"><surname>Van De Graaf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Nieuwenhuis</surname><given-names>E.E.S.</given-names></name><name name-style="western"><surname>Houwen</surname><given-names>R.H.J.</given-names></name><etal/></person-group><article-title>Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis</article-title><source>Sci. Transl. Med.</source><year>2016</year><volume>8</volume><fpage>344ra84</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aad8278</pub-id><pub-id pub-id-type="pmid">27334259</pub-id></element-citation></ref><ref id="B365-cells-11-01868"><label>365.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramalho</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>F&#252;rstov&#225;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vonk</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ferrante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verfaillie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Proesmans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beekman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sarouk</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis</article-title><source>Eur. Respir. J.</source><year>2021</year><volume>57</volume><fpage>1902426</fpage><pub-id pub-id-type="doi">10.1183/13993003.02426-2019</pub-id><pub-id pub-id-type="pmid">32747394</pub-id></element-citation></ref><ref id="B366-cells-11-01868"><label>366.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sachs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Papaspyropoulos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zomer-Van Ommen</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>I.</given-names></name><name name-style="western"><surname>B&#246;ttinger</surname><given-names>L.</given-names></name><name name-style="western"><surname>Klay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weeber</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huelsz-Prince</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iakobachvili</surname><given-names>N.</given-names></name><name name-style="western"><surname>Amatngalim</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>Long-term expanding human airway organoids for disease modeling</article-title><source>EMBO J.</source><year>2019</year><volume>38</volume><fpage>e100300</fpage><pub-id pub-id-type="doi">10.15252/embj.2018100300</pub-id><pub-id pub-id-type="pmid">30643021</pub-id><pub-id pub-id-type="pmcid">PMC6376275</pub-id></element-citation></ref><ref id="B367-cells-11-01868"><label>367.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Neuberger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>H.</given-names></name><name name-style="western"><surname>Van Goor</surname><given-names>F.</given-names></name></person-group><article-title>Use of Primary Cultures of Human Bronchial Epithelial Cells Isolated from Cystic Fibrosis Patients for the Pre-clinical Testing of CFTR Modulators</article-title><source>Cystic Fibrosis</source><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2011</year><fpage>39</fpage><lpage>54</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-61779-117-8_4</pub-id><pub-id pub-id-type="pmid">21594777</pub-id></element-citation></ref><ref id="B368-cells-11-01868"><label>368.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pranke</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Hatton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simonin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jais</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Le Pimpec-Barthes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carsin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonnette</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fayon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stremler-Le Bel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grenet</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>7375</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-07504-1</pub-id><pub-id pub-id-type="pmid">28785019</pub-id><pub-id pub-id-type="pmcid">PMC5547155</pub-id></element-citation></ref><ref id="B369-cells-11-01868"><label>369.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sette</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lo Cicero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blacon&#224;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pierandrei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Salvati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Castelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Falchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fabrizzi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cimino</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells</article-title><source>Eur. Respir. J.</source><year>2021</year><volume>58</volume><fpage>2100908</fpage><pub-id pub-id-type="doi">10.1183/13993003.00908-2021</pub-id><pub-id pub-id-type="pmid">34413153</pub-id><pub-id pub-id-type="pmcid">PMC8675295</pub-id></element-citation></ref><ref id="B370-cells-11-01868"><label>370.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Vertex</collab></person-group><article-title>Who Symdeko Is for</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.symdeko.com/who-symdeko-is-for" ext-link-type="uri">https://www.symdeko.com/who-symdeko-is-for</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-10">(accessed on 10 May 2022)</date-in-citation></element-citation></ref><ref id="B371-cells-11-01868"><label>371.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Vertex</collab></person-group><article-title>Who Trikafta Is for</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.trikafta.com/who-trikafta-is-for" ext-link-type="uri">https://www.trikafta.com/who-trikafta-is-for</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-13">(accessed on 13 September 2021)</date-in-citation></element-citation></ref><ref id="B372-cells-11-01868"><label>372.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shishido</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Skach</surname><given-names>W.R.</given-names></name></person-group><article-title>CFTR trafficking mutations disrupt cotranslational protein folding by targeting biosynthetic intermediates</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>4258</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-18101-8</pub-id><pub-id pub-id-type="pmid">32848127</pub-id><pub-id pub-id-type="pmcid">PMC7450043</pub-id></element-citation></ref><ref id="B373-cells-11-01868"><label>373.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sermet-Gaudelus</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>D.N.</given-names></name></person-group><article-title>N1303K: Leaving no stone unturned in the search for transformational therapeutics</article-title><source>J. Cyst. Fibros.</source><year>2018</year><volume>17</volume><fpage>555</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2018.07.009</pub-id><pub-id pub-id-type="pmid">30126793</pub-id></element-citation></ref><ref id="B374-cells-11-01868"><label>374.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laselva</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Popa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gunawardena</surname><given-names>T.N.A.</given-names></name><name name-style="western"><surname>Gonska</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Bear</surname><given-names>C.E.</given-names></name></person-group><article-title>Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>20</volume><fpage>106</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2020.07.015</pub-id><pub-id pub-id-type="pmid">32741662</pub-id></element-citation></ref><ref id="B375-cells-11-01868"><label>375.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yarlagadda</surname><given-names>S.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Naren</surname><given-names>A.P.</given-names></name></person-group><article-title>Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in an N1303K-CFTR Patient Based on in vitro Experimental Evidence</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2021</year><volume>204</volume><fpage>1231</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1164/rccm.202101-0090LE</pub-id><pub-id pub-id-type="pmid">34379998</pub-id><pub-id pub-id-type="pmcid">PMC8759307</pub-id></element-citation></ref><ref id="B376-cells-11-01868"><label>376.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hull</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shackleton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>A.</given-names></name></person-group><article-title>Abnormal mRNA splicing resulting from three different mutations in the CFTR gene</article-title><source>Hum. Mol. Genet.</source><year>1993</year><volume>2</volume><fpage>689</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1093/hmg/2.6.689</pub-id><pub-id pub-id-type="pmid">7689009</pub-id></element-citation></ref><ref id="B377-cells-11-01868"><label>377.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>SpliSense</collab></person-group><article-title>SPL84-23-1 Treatment for 3849+10 kb C-to-T CF mutation</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://splisense.com/pipeline/spl84-23-1-program/" ext-link-type="uri">https://splisense.com/pipeline/spl84-23-1-program/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-04-10">(accessed on 10 April 2022)</date-in-citation></element-citation></ref><ref id="B378-cells-11-01868"><label>378.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanz</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hollywood</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Scallan</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>P.T.</given-names></name></person-group><article-title>Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0184009</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0184009</pub-id><pub-id pub-id-type="pmid">28863137</pub-id><pub-id pub-id-type="pmcid">PMC5581164</pub-id></element-citation></ref><ref id="B379-cells-11-01868"><label>379.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamurthy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Traore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cooney</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Brommel</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kulhankova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sinn</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Newby</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>McCray</surname><given-names>P.B.</given-names></name></person-group><article-title>Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>10558</fpage><lpage>10572</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab788</pub-id><pub-id pub-id-type="pmid">34520545</pub-id><pub-id pub-id-type="pmcid">PMC8501978</pub-id></element-citation></ref><ref id="B380-cells-11-01868"><label>380.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bednarski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tomczak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vom Hovel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Cathomen</surname><given-names>T.</given-names></name></person-group><article-title>Targeted Integration of a Super-Exon into the CFTR Locus Leads to Functional Correction of a Cystic Fibrosis Cell Line Model</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0161072</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0161072</pub-id><pub-id pub-id-type="pmid">27526025</pub-id><pub-id pub-id-type="pmcid">PMC4985144</pub-id></element-citation></ref><ref id="B381-cells-11-01868"><label>381.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mall</surname><given-names>M.A.</given-names></name></person-group><article-title>ENaC inhibition in cystic fibrosis: Potential role in the new era of CFTR modulator therapies</article-title><source>Eur. Respir. J.</source><year>2020</year><volume>56</volume><fpage>2000946</fpage><pub-id pub-id-type="doi">10.1183/13993003.00946-2020</pub-id><pub-id pub-id-type="pmid">32732328</pub-id><pub-id pub-id-type="pmcid">PMC7758539</pub-id></element-citation></ref><ref id="B382-cells-11-01868"><label>382.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quesada</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dutzler</surname><given-names>R.</given-names></name></person-group><article-title>Alternative chloride transport pathways as pharmacological targets for the treatment of cystic fibrosis</article-title><source>J. Cyst. Fibros.</source><year>2020</year><volume>19</volume><issue>(Suppl. 1)</issue><fpage>S37</fpage><lpage>S41</lpage><pub-id pub-id-type="doi">10.1016/j.jcf.2019.10.020</pub-id><pub-id pub-id-type="pmid">31662238</pub-id></element-citation></ref><ref id="B383-cells-11-01868"><label>383.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hampton</surname><given-names>T.</given-names></name></person-group><article-title>With First CRISPR Trials, Gene Editing Moves Toward the Clinic</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1537</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.3438</pub-id><pub-id pub-id-type="pmid">32267478</pub-id></element-citation></ref><ref id="B384-cells-11-01868"><label>384.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirakawa</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Krishnakumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Timlin</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Carney</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>K.S.</given-names></name></person-group><article-title>Gene editing and CRISPR in the clinic: Current and future perspectives</article-title><source>Biosci. Rep.</source><year>2020</year><volume>40</volume><fpage>BSR20200127</fpage><pub-id pub-id-type="doi">10.1042/BSR20200127</pub-id><pub-id pub-id-type="pmid">32207531</pub-id><pub-id pub-id-type="pmcid">PMC7146048</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="cells-11-01868-f001" orientation="portrait"><label>Figure 1</label><caption><p>CFTR mutations can cause different defects and are grouped accordingly. Green arrows: normal CFTR biogenesis and function. Red arrows/crosses: defects caused by the mentioned mutation classes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-11-01868-g001.jpg"/></fig><fig position="float" id="cells-11-01868-f002" orientation="portrait"><label>Figure 2</label><caption><p>Global overview of therapeutic strategies for causal treatment of CF and their current progress in clinical development. On the right, strategies are represented by dots, and lines connecting them indicate combination therapies, either market-approved (green), or in clinical development (red). WT: wild-type. PM: plasma membrane.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-11-01868-g002.jpg"/></fig><fig position="float" id="cells-11-01868-f003" orientation="portrait"><label>Figure 3</label><caption><p>Strategies to improve CFTR function. Left: Activators (red) improve CFTR function by altering its normal regulation, for example by promoting phosphorylation of CFTR or via ATP analogues which lock CFTR in an open state. Right: CFTR potentiators (orange) interact directly with CFTR to promote function, in a phosphorylation-dependent, but ATP-independent manner. Co-potentiators (blue) also interact with CFTR, to further stimulate function but only in the presence of CFTR potentiators.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-11-01868-g003.jpg"/></fig><fig position="float" id="cells-11-01868-f004" orientation="portrait"><label>Figure 4</label><caption><p>Strategies to improve the amount of CFTR channels at the plasma membrane (PM). CFTR correctors (red) interact directly with CFTR to improve its folding and subsequent trafficking. Targeting CFTR interactors through proteostasis modulation (orange) allows mutant CFTR to escape early degradation and traffic to the PM. Stabilizers (blue) prolong the duration of CFTR&#8217;s residence at the PM by slowing down its turn-over and peripheral degradation. ERQC: Endoplasmic Reticulum Quality Control; PQC: Peripheral Quality Control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-11-01868-g004.jpg"/></fig><fig position="float" id="cells-11-01868-f005" orientation="portrait"><label>Figure 5</label><caption><p>Different types of CFTR correctors. Left: The F508del-CFTR protein is misfolded and does not achieve the native conformation of wild-type (WT)-CFTR. Schematic overview of folding defects associated with the F508del mutation. Right: Type I, II, and III correctors tackle different folding defects, which alone or in combination (partially) rescue F508del to a more WT-like state.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-11-01868-g005.jpg"/></fig><fig position="float" id="cells-11-01868-f006" orientation="portrait"><label>Figure 6</label><caption><p>Amplifiers stabilize the <italic toggle="yes">CFTR</italic> mRNA and thereby increase translation, enlarging the pool of immature CFTR protein. Amplifiers (red) are of particular interest for the treatment of Class II and V mutations. Top: Class II mutations are misfolded and only a fraction reaches the plasma membrane, even in the presence of CFTR correctors (blue). Amplifiers provide more immature protein that can subsequently be rescued with CFTR modulators. Bottom: Class V mutations introduce cryptic splice sites, resulting in a mix of normal and alternatively spliced (yellow) <italic toggle="yes">CFTR</italic> mRNA. The fraction of normal mRNA gives rise to wild-type CFTR, but the number of channels is severely reduced. Enhancing the number of correct mRNA transcripts results in more CFTR protein at the PM.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-11-01868-g006.jpg"/></fig><fig position="float" id="cells-11-01868-f007" orientation="portrait"><label>Figure 7</label><caption><p><italic toggle="yes">CFTR</italic> with premature termination codon (PTC) mutations: defects and therapeutic strategies. Left: PTC <italic toggle="yes">CFTR</italic> mutations present two specific defects: the mRNA is often degraded via nonsense mediated mRNA decay (NMD), and the resulting protein is truncated. Right: To overcome these challenges, NMD inhibitors (NMDi) and Translational Readthrough Inducing Drugs (TRIDs) are investigated. As TRID treatment does not necessarily result in incorporation of the native amino-acid, these treatments can further be complemented with CFTR modulators.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-11-01868-g007.jpg"/></fig><fig position="float" id="cells-11-01868-f008" orientation="portrait"><label>Figure 8</label><caption><p>Strategies to produce wild-type (WT) CFTR by introducing the correct gene or mRNA sequence. The principles for the strategies for mRNA and DNA are identical, either the existing, mutated version is edited to the WT sequence, or a new correct exogenous copy is introduced into cells. Red star: sequence with mutation; green star: corrected sequence.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-11-01868-g008.jpg"/></fig><table-wrap position="float" id="cells-11-01868-t001" orientation="portrait"><object-id pub-id-type="pii">cells-11-01868-t001_Table 1</object-id><label>Table 1</label><caption><p>Overview of <italic toggle="yes">CFTR</italic> mutations in this review, their frequency and approved treatments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">cDNA Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Allele<break/>Frequency (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CFTR2<break/>Alleles</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approved Treatment</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CFTRdele2,3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.54-5940_273 + 10250del21kb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">417</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P67L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.200C&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">239</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G85E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.254G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">616</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E92K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.274G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R117H *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.350G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1854</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y122X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.366T&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">621+1G&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.489+1G&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1323</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G178R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.532G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R334W</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1000C&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">429</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">W496X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1487G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I507del</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1519-1521delACT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">651</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F508del</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1521-1523delCTT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">69.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99061</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1717-1G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1585-1G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1216</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G542X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1624G&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3610</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S549R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1645A&gt;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S549N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1646G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">203</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G551S</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1651G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G551D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1652G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2986</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R553X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.1657C&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1323</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2789+5G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.2657+5G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1027</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G970R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.2908G&gt;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R1162X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3484C&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">651</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I1234V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3700A&gt;G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3849+10kbC&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3718-2477C&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1158</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G1244E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3731G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S1251N</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3752G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S1255P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3763T&gt;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">W1282X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3846G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1726</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N1303K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3909C&gt;G</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2246</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Q1313X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.3937C&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G1349D</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.4046G&gt;A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">K/S/T</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Q1412X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c.4234C&gt;T</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn><p>NA: no treatment available; K: Kalydeco&#8482;; O: Orkambi&#8482;; S: Symdeko&#8482;; T: Trikafta&#8482;. * mutation with varying clinical significance. Frequency/allele numbers: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.CFTR2.org">www.CFTR2.org</uri> (accessed on 10 May 2022); Approved treatments: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.kalydeco.com">www.kalydeco.com</uri> (accessed on 10 May 2022)/<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.orkambi.com">www.orkambi.com</uri> (accessed on 10 May 2022)/<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.symdeko.com">www.symdeko.com</uri> (accessed on 10 May 2022)/<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.trikafta.com">www.trikafta.com</uri> (accessed on 10 May 2022).</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>